{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "gpuType": "T4"
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    },
    "accelerator": "GPU",
    "widgets": {
      "application/vnd.jupyter.widget-state+json": {
        "84fd5b4906974d0a90b78c82b41cc4b6": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_01af1c7d3bc245b784c3c0575527cbf8",
              "IPY_MODEL_b9c01d68c44b405ab80b33ee94dece03",
              "IPY_MODEL_4e5c8aa233b3434b860e6b987468dc4e"
            ],
            "layout": "IPY_MODEL_0216da2c5b624fb29785a58e1abfc0b3"
          }
        },
        "01af1c7d3bc245b784c3c0575527cbf8": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_9d68ca698a1940b980f86ba70530a9c4",
            "placeholder": "​",
            "style": "IPY_MODEL_91f4ca0e6c294af7836885c5fc8463c0",
            "value": "config.json: 100%"
          }
        },
        "b9c01d68c44b405ab80b33ee94dece03": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_2d0ba0f3a0db4b01b88d1db268c23dcd",
            "max": 595,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_7840aa8525eb47599cf6ef138729df99",
            "value": 595
          }
        },
        "4e5c8aa233b3434b860e6b987468dc4e": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_9b931684f3f848afa2128d3ae64c1546",
            "placeholder": "​",
            "style": "IPY_MODEL_048de3e1dd074f638f199d3c46ea210c",
            "value": " 595/595 [00:00&lt;00:00, 6.28kB/s]"
          }
        },
        "0216da2c5b624fb29785a58e1abfc0b3": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "9d68ca698a1940b980f86ba70530a9c4": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "91f4ca0e6c294af7836885c5fc8463c0": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "2d0ba0f3a0db4b01b88d1db268c23dcd": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "7840aa8525eb47599cf6ef138729df99": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "9b931684f3f848afa2128d3ae64c1546": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "048de3e1dd074f638f199d3c46ea210c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "cca22fba350844bfa856eded865e7ecf": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_747933cde16d4cc2a3a476dc81157e30",
              "IPY_MODEL_a7fdb287cab145c29a44d68f1f7e7319",
              "IPY_MODEL_1d609c99c9b74a6b85d6364202004a8a"
            ],
            "layout": "IPY_MODEL_19329acedcee4fc3ad1c582b9edb0cd7"
          }
        },
        "747933cde16d4cc2a3a476dc81157e30": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_0a101039d3014799b984b733201eb32d",
            "placeholder": "​",
            "style": "IPY_MODEL_1bd5138e2970452aaf2514d8507f1b57",
            "value": "pytorch_model.bin: 100%"
          }
        },
        "a7fdb287cab145c29a44d68f1f7e7319": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_0db6c37c09b245c9b033c6473ce4c4da",
            "max": 1560781537,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_44de376ced4141ddbc803f7eceb9ae2c",
            "value": 1560781537
          }
        },
        "1d609c99c9b74a6b85d6364202004a8a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_810f41d8f4554bef948ce55cafe31149",
            "placeholder": "​",
            "style": "IPY_MODEL_1da52901822e4d93a4cf814a16fdc720",
            "value": " 1.56G/1.56G [00:28&lt;00:00, 64.0MB/s]"
          }
        },
        "19329acedcee4fc3ad1c582b9edb0cd7": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "0a101039d3014799b984b733201eb32d": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "1bd5138e2970452aaf2514d8507f1b57": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "0db6c37c09b245c9b033c6473ce4c4da": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "44de376ced4141ddbc803f7eceb9ae2c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "810f41d8f4554bef948ce55cafe31149": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "1da52901822e4d93a4cf814a16fdc720": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "a52becad12b7462882799b3e9c3a9a4b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_72b6c3f24b394d6ca1221715d2b16962",
              "IPY_MODEL_53d0dcc59f3a4407812bafd4d6a32581",
              "IPY_MODEL_9a6c3ee0660145e6b260a30218838e28"
            ],
            "layout": "IPY_MODEL_4f55b67ac34c4ebf9a134e6b8db455cf"
          }
        },
        "72b6c3f24b394d6ca1221715d2b16962": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_7bfea427f3534e5ab8c39a3c9e51bce7",
            "placeholder": "​",
            "style": "IPY_MODEL_a6fa3b18b4024bb38679c86833531150",
            "value": "vocab.json: 100%"
          }
        },
        "53d0dcc59f3a4407812bafd4d6a32581": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_9a94aa7e947f4be78afee689d84eb45e",
            "max": 927059,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_f7baa1f054764b86955f2ae42722869b",
            "value": 927059
          }
        },
        "9a6c3ee0660145e6b260a30218838e28": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_1236e8a8776c4a4e9dfca07db060ef78",
            "placeholder": "​",
            "style": "IPY_MODEL_32244eeabdbc42139b05c30d1c0034a6",
            "value": " 927k/927k [00:00&lt;00:00, 2.77MB/s]"
          }
        },
        "4f55b67ac34c4ebf9a134e6b8db455cf": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "7bfea427f3534e5ab8c39a3c9e51bce7": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "a6fa3b18b4024bb38679c86833531150": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "9a94aa7e947f4be78afee689d84eb45e": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "f7baa1f054764b86955f2ae42722869b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "1236e8a8776c4a4e9dfca07db060ef78": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "32244eeabdbc42139b05c30d1c0034a6": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "b6100a9d7d094dbba135b1fda10348ad": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_186e1d045e974e4bbf9519b35b835568",
              "IPY_MODEL_073920105c3f4fc19368f97b1d3ada6e",
              "IPY_MODEL_6efcd23eaa34420e8fb67915aa1cacf7"
            ],
            "layout": "IPY_MODEL_fd9a7e73e93444509ebb5f68f88ae000"
          }
        },
        "186e1d045e974e4bbf9519b35b835568": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_0f61fd96658f496c9955843116dd7b00",
            "placeholder": "​",
            "style": "IPY_MODEL_978d1e6e322e434180b5bfda45559046",
            "value": "merges.txt: 100%"
          }
        },
        "073920105c3f4fc19368f97b1d3ada6e": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_0b9b6f890f804f6fb5ad2b65ed9a4714",
            "max": 696298,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_092ca74784ca4d05bd3bebb4af258203",
            "value": 696298
          }
        },
        "6efcd23eaa34420e8fb67915aa1cacf7": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_fcf32c7c10aa4470ad8d616bb7f6b26d",
            "placeholder": "​",
            "style": "IPY_MODEL_fd08453629d3415abdb8e0bcce0d9ab2",
            "value": " 696k/696k [00:00&lt;00:00, 2.15MB/s]"
          }
        },
        "fd9a7e73e93444509ebb5f68f88ae000": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "0f61fd96658f496c9955843116dd7b00": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "978d1e6e322e434180b5bfda45559046": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "0b9b6f890f804f6fb5ad2b65ed9a4714": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "092ca74784ca4d05bd3bebb4af258203": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "fcf32c7c10aa4470ad8d616bb7f6b26d": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "fd08453629d3415abdb8e0bcce0d9ab2": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "6b669abe6f53410b9621203c65b4c187": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_a9849b1aa9aa4bfb8c9515ce300a7391",
              "IPY_MODEL_651d4013196e41daaf44610fe22ed47c",
              "IPY_MODEL_31699bfb0f2146218ed0cda0bf4f1ca0"
            ],
            "layout": "IPY_MODEL_698fcf6eed324e84ae9dd4eacd3f5524"
          }
        },
        "a9849b1aa9aa4bfb8c9515ce300a7391": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_715af07769904483888086f38d73fcb6",
            "placeholder": "​",
            "style": "IPY_MODEL_1b3aa5aa800941cca01f3bd00c8f926d",
            "value": "model.safetensors: 100%"
          }
        },
        "651d4013196e41daaf44610fe22ed47c": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_5813a2f913834ef6899820f9b62cf56c",
            "max": 1560700544,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_2564dc7cb50c4dd8bcb98b6c41e009b5",
            "value": 1560700544
          }
        },
        "31699bfb0f2146218ed0cda0bf4f1ca0": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_bcd889240d84410dad87f8d2ef2087ef",
            "placeholder": "​",
            "style": "IPY_MODEL_b6881dfcf4a14c34a9596bd4c6f06050",
            "value": " 1.56G/1.56G [00:28&lt;00:00, 40.6MB/s]"
          }
        },
        "698fcf6eed324e84ae9dd4eacd3f5524": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "715af07769904483888086f38d73fcb6": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "1b3aa5aa800941cca01f3bd00c8f926d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "5813a2f913834ef6899820f9b62cf56c": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "2564dc7cb50c4dd8bcb98b6c41e009b5": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "bcd889240d84410dad87f8d2ef2087ef": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "b6881dfcf4a14c34a9596bd4c6f06050": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        }
      }
    }
  },
  "cells": [
    {
      "cell_type": "code",
      "execution_count": 2,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "sbWNRYN2Z5Py",
        "outputId": "5cb197da-9c6c-4b68-f8cc-71e681948dc9",
        "collapsed": true
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Requirement already satisfied: transformers in /usr/local/lib/python3.10/dist-packages (4.46.2)\n",
            "Requirement already satisfied: filelock in /usr/local/lib/python3.10/dist-packages (from transformers) (3.16.1)\n",
            "Requirement already satisfied: huggingface-hub<1.0,>=0.23.2 in /usr/local/lib/python3.10/dist-packages (from transformers) (0.26.2)\n",
            "Requirement already satisfied: numpy>=1.17 in /usr/local/lib/python3.10/dist-packages (from transformers) (1.26.4)\n",
            "Requirement already satisfied: packaging>=20.0 in /usr/local/lib/python3.10/dist-packages (from transformers) (24.2)\n",
            "Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.10/dist-packages (from transformers) (6.0.2)\n",
            "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.10/dist-packages (from transformers) (2024.9.11)\n",
            "Requirement already satisfied: requests in /usr/local/lib/python3.10/dist-packages (from transformers) (2.32.3)\n",
            "Requirement already satisfied: safetensors>=0.4.1 in /usr/local/lib/python3.10/dist-packages (from transformers) (0.4.5)\n",
            "Requirement already satisfied: tokenizers<0.21,>=0.20 in /usr/local/lib/python3.10/dist-packages (from transformers) (0.20.3)\n",
            "Requirement already satisfied: tqdm>=4.27 in /usr/local/lib/python3.10/dist-packages (from transformers) (4.66.6)\n",
            "Requirement already satisfied: fsspec>=2023.5.0 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub<1.0,>=0.23.2->transformers) (2024.10.0)\n",
            "Requirement already satisfied: typing-extensions>=3.7.4.3 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub<1.0,>=0.23.2->transformers) (4.12.2)\n",
            "Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests->transformers) (3.4.0)\n",
            "Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests->transformers) (3.10)\n",
            "Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests->transformers) (2.2.3)\n",
            "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests->transformers) (2024.8.30)\n",
            "Collecting sacremoses\n",
            "  Downloading sacremoses-0.1.1-py3-none-any.whl.metadata (8.3 kB)\n",
            "Requirement already satisfied: regex in /usr/local/lib/python3.10/dist-packages (from sacremoses) (2024.9.11)\n",
            "Requirement already satisfied: click in /usr/local/lib/python3.10/dist-packages (from sacremoses) (8.1.7)\n",
            "Requirement already satisfied: joblib in /usr/local/lib/python3.10/dist-packages (from sacremoses) (1.4.2)\n",
            "Requirement already satisfied: tqdm in /usr/local/lib/python3.10/dist-packages (from sacremoses) (4.66.6)\n",
            "Downloading sacremoses-0.1.1-py3-none-any.whl (897 kB)\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m897.5/897.5 kB\u001b[0m \u001b[31m22.9 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25hInstalling collected packages: sacremoses\n",
            "Successfully installed sacremoses-0.1.1\n"
          ]
        }
      ],
      "source": [
        "!pip install transformers\n",
        "!pip install sacremoses"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from transformers import pipeline\n",
        "import sacremoses"
      ],
      "metadata": {
        "id": "hEkJaMcvaIxz"
      },
      "execution_count": 3,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "pipe = pipeline(\"text-generation\", model=\"microsoft/biogpt\", max_length=1000, truncation=False)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 281,
          "referenced_widgets": [
            "84fd5b4906974d0a90b78c82b41cc4b6",
            "01af1c7d3bc245b784c3c0575527cbf8",
            "b9c01d68c44b405ab80b33ee94dece03",
            "4e5c8aa233b3434b860e6b987468dc4e",
            "0216da2c5b624fb29785a58e1abfc0b3",
            "9d68ca698a1940b980f86ba70530a9c4",
            "91f4ca0e6c294af7836885c5fc8463c0",
            "2d0ba0f3a0db4b01b88d1db268c23dcd",
            "7840aa8525eb47599cf6ef138729df99",
            "9b931684f3f848afa2128d3ae64c1546",
            "048de3e1dd074f638f199d3c46ea210c",
            "cca22fba350844bfa856eded865e7ecf",
            "747933cde16d4cc2a3a476dc81157e30",
            "a7fdb287cab145c29a44d68f1f7e7319",
            "1d609c99c9b74a6b85d6364202004a8a",
            "19329acedcee4fc3ad1c582b9edb0cd7",
            "0a101039d3014799b984b733201eb32d",
            "1bd5138e2970452aaf2514d8507f1b57",
            "0db6c37c09b245c9b033c6473ce4c4da",
            "44de376ced4141ddbc803f7eceb9ae2c",
            "810f41d8f4554bef948ce55cafe31149",
            "1da52901822e4d93a4cf814a16fdc720",
            "a52becad12b7462882799b3e9c3a9a4b",
            "72b6c3f24b394d6ca1221715d2b16962",
            "53d0dcc59f3a4407812bafd4d6a32581",
            "9a6c3ee0660145e6b260a30218838e28",
            "4f55b67ac34c4ebf9a134e6b8db455cf",
            "7bfea427f3534e5ab8c39a3c9e51bce7",
            "a6fa3b18b4024bb38679c86833531150",
            "9a94aa7e947f4be78afee689d84eb45e",
            "f7baa1f054764b86955f2ae42722869b",
            "1236e8a8776c4a4e9dfca07db060ef78",
            "32244eeabdbc42139b05c30d1c0034a6",
            "b6100a9d7d094dbba135b1fda10348ad",
            "186e1d045e974e4bbf9519b35b835568",
            "073920105c3f4fc19368f97b1d3ada6e",
            "6efcd23eaa34420e8fb67915aa1cacf7",
            "fd9a7e73e93444509ebb5f68f88ae000",
            "0f61fd96658f496c9955843116dd7b00",
            "978d1e6e322e434180b5bfda45559046",
            "0b9b6f890f804f6fb5ad2b65ed9a4714",
            "092ca74784ca4d05bd3bebb4af258203",
            "fcf32c7c10aa4470ad8d616bb7f6b26d",
            "fd08453629d3415abdb8e0bcce0d9ab2",
            "6b669abe6f53410b9621203c65b4c187",
            "a9849b1aa9aa4bfb8c9515ce300a7391",
            "651d4013196e41daaf44610fe22ed47c",
            "31699bfb0f2146218ed0cda0bf4f1ca0",
            "698fcf6eed324e84ae9dd4eacd3f5524",
            "715af07769904483888086f38d73fcb6",
            "1b3aa5aa800941cca01f3bd00c8f926d",
            "5813a2f913834ef6899820f9b62cf56c",
            "2564dc7cb50c4dd8bcb98b6c41e009b5",
            "bcd889240d84410dad87f8d2ef2087ef",
            "b6881dfcf4a14c34a9596bd4c6f06050"
          ]
        },
        "id": "mqjJ0FeBaTbf",
        "outputId": "34a703c2-86a0-4e78-96a6-cf5cd5998d9a",
        "collapsed": true
      },
      "execution_count": 4,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stderr",
          "text": [
            "/usr/local/lib/python3.10/dist-packages/huggingface_hub/utils/_auth.py:94: UserWarning: \n",
            "The secret `HF_TOKEN` does not exist in your Colab secrets.\n",
            "To authenticate with the Hugging Face Hub, create a token in your settings tab (https://huggingface.co/settings/tokens), set it as secret in your Google Colab and restart your session.\n",
            "You will be able to reuse this secret in all of your notebooks.\n",
            "Please note that authentication is recommended but still optional to access public models or datasets.\n",
            "  warnings.warn(\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "config.json:   0%|          | 0.00/595 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "84fd5b4906974d0a90b78c82b41cc4b6"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "pytorch_model.bin:   0%|          | 0.00/1.56G [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "cca22fba350844bfa856eded865e7ecf"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "vocab.json:   0%|          | 0.00/927k [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "a52becad12b7462882799b3e9c3a9a4b"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "merges.txt:   0%|          | 0.00/696k [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "b6100a9d7d094dbba135b1fda10348ad"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "model.safetensors:   0%|          | 0.00/1.56G [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "6b669abe6f53410b9621203c65b4c187"
            }
          },
          "metadata": {}
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "generation_tag = \"The important background information needed to understand this text is \""
      ],
      "metadata": {
        "id": "sSRIhjnvow21"
      },
      "execution_count": 5,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "import json\n",
        "from pprint import pprint\n",
        "\n",
        "# Open the JSON file for reading\n",
        "with open('/content/test.json', 'r') as file:\n",
        "  # Load JSON data from the file\n",
        "  test = json.load(file)\n",
        "\n",
        "keys = list(test.keys())\n",
        "data = {}\n",
        "i = 0\n",
        "# Iterate through the loaded JSON data\n",
        "while i < len(keys):\n",
        "  #for line in test:\n",
        "    line = test[keys[i]]\n",
        "    line['abstract'] = (pipe(line['abstract']+generation_tag)[0]['generated_text'])\n",
        "    i += 1\n",
        "    print(f\"Lines completed:{i}\")\n",
        "\n",
        "pprint(test)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "2zZ-1MlmFxmS",
        "outputId": "fa4f6035-4e31-441b-c62a-4f5f5eb83a3e"
      },
      "execution_count": 14,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[1;30;43mStreaming output truncated to the last 5000 lines.\u001b[0m\n",
            "                           'codeine': 'D003061',\n",
            "                           'codine': 'D003061',\n",
            "                           'fentanyl': 'D005283',\n",
            "                           'monoamines': 'D015306',\n",
            "                           'morphine': 'D009020',\n",
            "                           'na': 'D009638',\n",
            "                           'naphazoline': 'D009278',\n",
            "                           'noradrenaline': 'D009638',\n",
            "                           'pentazocine': 'D010423',\n",
            "                           'xylometazoline': 'C009695'},\n",
            "           'disease2id': {'catalepsy': 'D002375', 'cataleptic': 'D002375'},\n",
            "           'relations': [{'chemical': 'D003000', 'disease': 'D002375'},\n",
            "                         {'chemical': 'D005283', 'disease': 'D002375'},\n",
            "                         {'chemical': 'D009278', 'disease': 'D002375'},\n",
            "                         {'chemical': 'D003061', 'disease': 'D002375'},\n",
            "                         {'chemical': 'C009695', 'disease': 'D002375'},\n",
            "                         {'chemical': 'D009020', 'disease': 'D002375'}],\n",
            "           'title': 'Central action of narcotic analgesics. Part IV. '\n",
            "                    'Noradrenergic influences on the activity of analgesics in '\n",
            "                    'rats.'},\n",
            " '3685052': {'abstract': 'Monosodium glutamate (MSG) administration to '\n",
            "                         'neonatal rodents produces convulsions and results in '\n",
            "                         'numerous biochemical and behavioral deficits. These '\n",
            "                         'studies were undertaken to determine if neonatal '\n",
            "                         'administration of MSG produced permanent alterations '\n",
            "                         'in seizure susceptibility, since previous '\n",
            "                         'investigations were inconclusive. A flurothyl ether '\n",
            "                         'seizure screening technique was used to evaluate '\n",
            "                         'seizure susceptibility in adult mice that received '\n",
            "                         'neonatal injections of MSG (4 mg/g and 1 mg/g). MSG '\n",
            "                         'treatment resulted in significant reductions in '\n",
            "                         'whole brain weight but did not alter seizure '\n",
            "                         'threshold. A naloxone (5 mg/kg) challenge was also '\n",
            "                         'ineffective in altering the seizure thresholds of '\n",
            "                         'either control of MSG-treated mice. Flurothyl ether '\n",
            "                         'produced hypothermia which was correlated with the '\n",
            "                         'duration of flurothyl exposure; however, the '\n",
            "                         'relationship of hypothermia to seizure induction was '\n",
            "                         'unclear. Flurothyl seizure testing proved to be a '\n",
            "                         'rapid and reliable technique with which to evaluate '\n",
            "                         'seizure susceptibility.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that the seizure threshold of adult mice is not '\n",
            "                         'altered by neonatal MSG treatment.',\n",
            "             'chemical2id': {'ether': 'D004986',\n",
            "                             'flurothyl': 'D005481',\n",
            "                             'monosodium glutamate': 'D012970',\n",
            "                             'msg': 'D012970',\n",
            "                             'naloxone': 'D009270'},\n",
            "             'disease2id': {'convulsions': 'D012640',\n",
            "                            'hypothermia': 'D007035',\n",
            "                            'seizure': 'D012640'},\n",
            "             'relations': [{'chemical': 'D005481', 'disease': 'D007035'}],\n",
            "             'title': 'Flurothyl seizure thresholds in mice treated neonatally '\n",
            "                      'with a single injection of monosodium glutamate (MSG): '\n",
            "                      'evaluation of experimental parameters in flurothyl '\n",
            "                      'seizure testing.'},\n",
            " '3708328': {'abstract': 'Pilocarpine, given intraperitoneally to rats, '\n",
            "                         'reproduces the neuropathological sequelae of '\n",
            "                         'temporal lobe epilepsy and provides a relevant '\n",
            "                         'animal model for studying mechanisms of buildup of '\n",
            "                         'convulsive activity and pathways operative in the '\n",
            "                         'generalization and propagation of seizures within '\n",
            "                         'the forebrain. In the present study, the effects of '\n",
            "                         'manipulating the activity of the gamma-aminobutyric '\n",
            "                         'acid (GABA)-mediated synaptic inhibition within the '\n",
            "                         'substantia nigra on seizures produced by pilocarpine '\n",
            "                         'in rats, were investigated. In animals pretreated '\n",
            "                         'with microinjections of isoniazid, 150 micrograms, '\n",
            "                         'an inhibitor of activity of the GABA-synthesizing '\n",
            "                         'enzyme, L-glutamic acid decarboxylase, into the '\n",
            "                         'substantia nigra pars reticulata (SNR), bilaterally, '\n",
            "                         'non-convulsant doses of pilocarpine, 100 and 200 '\n",
            "                         'mg/kg, resulted in severe motor limbic seizures and '\n",
            "                         'status epilepticus. Electroencephalographic and '\n",
            "                         'behavioral monitoring revealed a profound reduction '\n",
            "                         'of the threshold for pilocarpine-induced '\n",
            "                         'convulsions. Morphological analysis of frontal '\n",
            "                         'forebrain sections with light microscopy revealed '\n",
            "                         'seizure-related damage to the hippocampal formation, '\n",
            "                         'thalamus, amygdala, olfactory cortex, substantia '\n",
            "                         'nigra and neocortex, which is typically observed '\n",
            "                         'with pilocarpine in doses exceeding 350 mg/kg. '\n",
            "                         'Bilateral intrastriatal injections of isoniazid did '\n",
            "                         'not augment seizures produced by pilocarpine, 200 '\n",
            "                         'mg/kg. Application of an irreversible inhibitor of '\n",
            "                         'GABA transaminase, gamma-vinyl-GABA '\n",
            "                         '(D,L-4-amino-hex-5-enoic acid), 5 micrograms, into '\n",
            "                         'the SNR, bilaterally, suppressed the appearance of '\n",
            "                         'electrographic and behavioral seizures produced by '\n",
            "                         'pilocarpine, 380 mg/kg. This treatment was also '\n",
            "                         'sufficient to protect animals from the occurrence of '\n",
            "                         'brain damage. Microinjections of gamma-vinyl-GABA, 5 '\n",
            "                         'micrograms, into the dorsal striatum, bilaterally, '\n",
            "                         'failed to prevent the development of convulsions '\n",
            "                         'produced by pilocarpine, 380 mg/kg. The results '\n",
            "                         'demonstrate that the threshold for '\n",
            "                         'pilocarpine-induced seizures in rats is subjected to '\n",
            "                         'the regulation of the GABA-mediated synaptic '\n",
            "                         'inhibition within the substantia nigra.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the substantia nigra pars '\n",
            "                         'reticulata is a major site of action of pilocarpine, '\n",
            "                         'and that the substantia nigra pars reticulata is a '\n",
            "                         'major site of action of gamma-vinyl-GABA.',\n",
            "             'chemical2id': {'d,l-4-amino-hex-5-enoic acid': 'D020888',\n",
            "                             'gaba': 'D005680',\n",
            "                             'gamma-aminobutyric acid': 'D005680',\n",
            "                             'gamma-vinyl-gaba': 'D020888',\n",
            "                             'isoniazid': 'D007538',\n",
            "                             'l-glutamic acid': 'D018698',\n",
            "                             'pilocarpine': 'D010862'},\n",
            "             'disease2id': {'brain damage': 'D001930',\n",
            "                            'convulsions': 'D012640',\n",
            "                            'convulsive': 'D012640',\n",
            "                            'seizure': 'D012640',\n",
            "                            'seizures': 'D012640',\n",
            "                            'status epilepticus': 'D013226',\n",
            "                            'temporal lobe epilepsy': 'D004833'},\n",
            "             'relations': [{'chemical': 'D010862', 'disease': 'D012640'}],\n",
            "             'title': 'Susceptibility to seizures produced by pilocarpine in '\n",
            "                      'rats after microinjection of isoniazid or '\n",
            "                      'gamma-vinyl-GABA into the substantia nigra.'},\n",
            " '3711722': {'abstract': 'Vasoactive intestinal polypeptide (VIP) is a '\n",
            "                         'systemic and coronary vasodilator that may have '\n",
            "                         'positive inotropic properties. Myocardial levels of '\n",
            "                         'VIP were assayed before and after the development of '\n",
            "                         'heart failure in two canine models. In the first, '\n",
            "                         'cobalt cardiomyopathy was induced in eight dogs; VIP '\n",
            "                         '(by radioimmunoassay) decreased from 35 +/- 11 pg/mg '\n",
            "                         'protein (mean +/- SD) to 5 +/- 4 pg/mg protein (P '\n",
            "                         'less than 0.05). In six dogs with '\n",
            "                         'doxorubicin-induced heart failure, VIP decreased '\n",
            "                         'from 31 +/- 7 to 11 +/- 4 pg/mg protein (P less than '\n",
            "                         '0.05). In addition, VIP content of left ventricular '\n",
            "                         'muscle of resected failing hearts in 10 patients '\n",
            "                         'receiving a heart transplant was compared with the '\n",
            "                         'papillary muscles in 14 patients (five with '\n",
            "                         'rheumatic disease, nine with myxomatous '\n",
            "                         'degeneration) receiving mitral valve prostheses. The '\n",
            "                         'lowest myocardial VIP concentration was found in the '\n",
            "                         'hearts of patients with coronary disease (one '\n",
            "                         'patient receiving a transplant and three receiving '\n",
            "                         'mitral prostheses) (6.3 +/- 1.9 pg/mg protein). The '\n",
            "                         'other patients undergoing transplantation had an '\n",
            "                         'average ejection fraction of 17% +/- 6% and a VIP '\n",
            "                         'level of 8.8 +/- 3.9 pg/mg protein. The hearts '\n",
            "                         'without coronary artery disease (average ejection '\n",
            "                         'fraction of this group 62% +/- 10%) had a VIP '\n",
            "                         'concentration of 14.1 +/- 7.9 pg/mg protein, and '\n",
            "                         'this was greater than in hearts of the patients with '\n",
            "                         'coronary disease and the hearts of patients '\n",
            "                         'receiving a transplant (P less than 0.05). '\n",
            "                         'Myocardial catecholamines were also determined in 14 '\n",
            "                         'subjects; a weak correlation (r = 0.57, P less than '\n",
            "                         '0.05) between the tissue concentrations of VIP and '\n",
            "                         'norepinephrine was noted.(ABSTRACT TRUNCATED AT 250 '\n",
            "                         'WORDS)The important background information needed to '\n",
            "                         'understand this text is  the fact that VIP is a '\n",
            "                         'potent coronary vasodilator and that it is present '\n",
            "                         'in the myocardium.',\n",
            "             'chemical2id': {'catecholamines': 'D002395',\n",
            "                             'cobalt': 'D003035',\n",
            "                             'doxorubicin': 'D004317',\n",
            "                             'norepinephrine': 'D009638'},\n",
            "             'disease2id': {'cardiomyopathy': 'D009202',\n",
            "                            'coronary artery disease': 'D003324',\n",
            "                            'coronary disease': 'D003327',\n",
            "                            'heart failure': 'D006333',\n",
            "                            'myxomatous degeneration': '-1',\n",
            "                            'rheumatic disease': 'D012216'},\n",
            "             'relations': [{'chemical': 'D004317', 'disease': 'D006333'},\n",
            "                           {'chemical': 'D003035', 'disease': 'D009202'}],\n",
            "             'title': 'Human and canine ventricular vasoactive intestinal '\n",
            "                      'polypeptide: decrease with heart failure.'},\n",
            " '3746148': {'abstract': 'Electrocardiographic changes after dipyridamole '\n",
            "                         'infusion (0.568 mg/kg/4 min) were studied in 41 '\n",
            "                         'patients with coronary artery disease and compared '\n",
            "                         'with those after submaximal treadmill exercise by '\n",
            "                         'use of the body surface mapping technique. Patients '\n",
            "                         'were divided into three groups; 19 patients without '\n",
            "                         'myocardial infarction (non-MI group), 14 with '\n",
            "                         'anterior infarction (ANT-MI) and eight with inferior '\n",
            "                         'infarction (INF-MI). Eighty-seven unipolar '\n",
            "                         'electrocardiograms (ECGs) distributed over the '\n",
            "                         'entire thoracic surface were simultaneously '\n",
            "                         'recorded. After dipyridamole, ischemic ST-segment '\n",
            "                         'depression (0.05 mV or more) was observed in 84% of '\n",
            "                         'the non-MI group, 29% of the ANT-MI group, 63% of '\n",
            "                         'the INF-MI group and 61% of the total population. '\n",
            "                         'Exercise-induced ST depression was observed in 84% '\n",
            "                         'of the non-MI group, 43% of the ANT-MI group, 38% of '\n",
            "                         'the INF-MI group and 61% of the total. For '\n",
            "                         'individual patients, there were no obvious '\n",
            "                         'differences between the body surface distribution of '\n",
            "                         'ST depression in both tests. The increase in '\n",
            "                         'pressure rate product after dipyridamole was '\n",
            "                         'significantly less than that during the treadmill '\n",
            "                         'exercise. The data suggest that the '\n",
            "                         'dipyridamole-induced myocardial ischemia is caused '\n",
            "                         'by the inhomogenous distribution of myocardial blood '\n",
            "                         'flow. We conclude that the dipyridamole ECG test is '\n",
            "                         'as useful as the exercise ECG test for the '\n",
            "                         'assessment of coronary artery disease.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the dipyridamole ECG test is '\n",
            "                         'a non-invasive method and is not influenced by the '\n",
            "                         'presence of myocardial ischemia.',\n",
            "             'chemical2id': {'dipyridamole': 'D004176'},\n",
            "             'disease2id': {'ant-mi': 'D056988',\n",
            "                            'anterior infarction': 'D056988',\n",
            "                            'coronary artery disease': 'D003324',\n",
            "                            'depression': 'D003866',\n",
            "                            'inf-mi': 'D056989',\n",
            "                            'inferior infarction': 'D056989',\n",
            "                            'ischemic': 'D007511',\n",
            "                            'mi': 'D009203',\n",
            "                            'myocardial infarction': 'D009203',\n",
            "                            'myocardial ischemia': 'D017202'},\n",
            "             'relations': [{'chemical': 'D004176', 'disease': 'D017202'}],\n",
            "             'title': 'Non-invasive detection of coronary artery disease by '\n",
            "                      'body surface electrocardiographic mapping after '\n",
            "                      'dipyridamole infusion.'},\n",
            " '3798047': {'abstract': 'In 5 consecutive patients with rheumatoid arthritis '\n",
            "                         'who received intravenous high-dose '\n",
            "                         'methylprednisolone (MP) therapy (1 g daily for 2 or '\n",
            "                         '3 consecutive days), a decline in pulse rate was '\n",
            "                         'observed, most pronounced on day 4. In one of the 5 '\n",
            "                         'patients the bradycardia was associated with '\n",
            "                         'complaints of substernal pressure. Reversal to '\n",
            "                         'normal heart rate was found on day 7. '\n",
            "                         'Electrocardiographic registrations showed sinus '\n",
            "                         'bradycardia in all cases. No significant changes in '\n",
            "                         'plasma concentrations of electrolytes were found. '\n",
            "                         'Careful observation of patients receiving high-dose '\n",
            "                         'MP is recommended. High-dose MP may be '\n",
            "                         'contraindicated in patients with known heart '\n",
            "                         'disease.The important background information needed '\n",
            "                         'to understand this text is  the fact that the heart '\n",
            "                         'rate is a function of the autonomic nervous system '\n",
            "                         'and that the heart rate is influenced by the '\n",
            "                         'autonomic nervous system.',\n",
            "             'chemical2id': {'methylprednisolone': 'D008775', 'mp': 'D008775'},\n",
            "             'disease2id': {'bradycardia': 'D001919',\n",
            "                            'heart disease': 'D006331',\n",
            "                            'rheumatoid arthritis': 'D001172',\n",
            "                            'sinus bradycardia': 'D012804'},\n",
            "             'relations': [{'chemical': 'D008775', 'disease': 'D001919'}],\n",
            "             'title': 'Bradycardia after high-dose intravenous '\n",
            "                      'methylprednisolone therapy.'},\n",
            " '3812624': {'abstract': 'Downbeat nystagmus is often associated with '\n",
            "                         'structural lesions at the craniocervical junction, '\n",
            "                         'but has occasionally been reported as a '\n",
            "                         'manifestation of metabolic imbalance or drug '\n",
            "                         'intoxication. We recorded the eye movements of two '\n",
            "                         'patients with reversible downbeat nystagmus related '\n",
            "                         'to carbamazepine therapy. The nystagmus of both '\n",
            "                         'patients resolved after reduction of the serum '\n",
            "                         'carbamazepine levels. Neuroradiologic investigations '\n",
            "                         'including magnetic resonance imaging scans in both '\n",
            "                         'patients showed no evidence of intracranial '\n",
            "                         'abnormality. In patients with downbeat nystagmus who '\n",
            "                         'are taking anticonvulsant medications, consideration '\n",
            "                         'should be given to reduction in dose before further '\n",
            "                         'investigation is undertaken.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that the nystagmus is not a sign of a '\n",
            "                         'structural lesion at the craniocervical junction.',\n",
            "             'chemical2id': {'carbamazepine': 'D002220'},\n",
            "             'disease2id': {'downbeat nystagmus': 'D009759',\n",
            "                            'nystagmus': 'D009759',\n",
            "                            'oscillopsia': 'D015835'},\n",
            "             'relations': [{'chemical': 'D002220', 'disease': 'D015835'}],\n",
            "             'title': 'Two cases of downbeat nystagmus and oscillopsia '\n",
            "                      'associated with carbamazepine.'},\n",
            " '3831029': {'abstract': 'The efficacy of denopamine, an orally active beta '\n",
            "                         '1-adrenoceptor agonist, in improving cardiac failure '\n",
            "                         'was assessed in dog heart-lung preparations. Cardiac '\n",
            "                         'functions depressed by pentobarbital (118 +/- 28 mg; '\n",
            "                         'mean value +/- SD) such that cardiac output and '\n",
            "                         'maximum rate of rise of left ventricular pressure '\n",
            "                         '(LV dP/dt max) had been reduced by about 35% and 26% '\n",
            "                         'of the respective controls were improved by '\n",
            "                         'denopamine (10-300 micrograms) in a dose-dependent '\n",
            "                         'manner. With 100 micrograms denopamine, almost '\n",
            "                         'complete restoration of cardiac performance was '\n",
            "                         'attained, associated with a slight increase in heart '\n",
            "                         'rate. No arrhythmias were induced by these doses of '\n",
            "                         'denopamine. The results warrant clinical trials of '\n",
            "                         'denopamine in the treatment of cardiac failure.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  that the effects of '\n",
            "                         'denopamine on cardiac function are not mediated by '\n",
            "                         'beta-adrenoceptors, but by other mechanisms.',\n",
            "             'chemical2id': {'denopamine': 'C037293',\n",
            "                             'pentobarbital': 'D010424',\n",
            "                             'ta-064': 'C037293'},\n",
            "             'disease2id': {'arrhythmias': 'D001145',\n",
            "                            'cardiac failure': 'D006333'},\n",
            "             'relations': [{'chemical': 'D010424', 'disease': 'D006333'}],\n",
            "             'title': 'Improvement by denopamine (TA-064) of '\n",
            "                      'pentobarbital-induced cardiac failure in the dog '\n",
            "                      'heart-lung preparation.'},\n",
            " '3832950': {'abstract': 'Sixty patients (age-range one month to 14 years) '\n",
            "                         'with other types of epilepsy than infantile spasms '\n",
            "                         'were treated with clonazepam. Disappearance of '\n",
            "                         'seizures and normalization of abnormal EEG with '\n",
            "                         'disappearance of seizures were recognized in 77% and '\n",
            "                         '50%, respectively. Seizures disappeared in 71% of '\n",
            "                         'the patients with generalized seizures and 89% of '\n",
            "                         'partial seizures. Improvement of abnormal EEG was '\n",
            "                         'noticed in 76% of diffuse paroxysms and in 67% of '\n",
            "                         'focal paroxysms. In excellent cases, mean effective '\n",
            "                         'dosages were 0.086 +/- 0.021 mg/kg/day in infants '\n",
            "                         'and 0.057 +/- 0.022 mg/kg/day in schoolchildren, '\n",
            "                         'this difference was statistically significant (p '\n",
            "                         'less than 0.005). The incidence of side effects such '\n",
            "                         'as drowsiness and ataxia was only 5%.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  that the drug is effective in generalized '\n",
            "                         'seizures and that it is effective in generalized and '\n",
            "                         'focal seizures, and that it is safe and well '\n",
            "                         'tolerated.',\n",
            "             'chemical2id': {'clonazepam': 'D002998'},\n",
            "             'disease2id': {'ataxia': 'D001259',\n",
            "                            'drowsiness': 'D006970',\n",
            "                            'epilepsy': 'D004827',\n",
            "                            'infantile spasms': 'D013036',\n",
            "                            'seizures': 'D012640'},\n",
            "             'relations': [{'chemical': 'D002998', 'disease': 'D006970'},\n",
            "                           {'chemical': 'D002998', 'disease': 'D001259'}],\n",
            "             'title': 'Clonazepam monotherapy for epilepsy in childhood.'},\n",
            " '3833372': {'abstract': 'A postmarketing surveillance study was conducted to '\n",
            "                         'determine the safety and efficacy of a fixed-ratio '\n",
            "                         'combination containing 10 mg of timolol maleate and '\n",
            "                         '25 mg of hydrochlorothiazide, administered twice '\n",
            "                         'daily for one month to hypertensive patients. Data '\n",
            "                         'on 9,037 patients were collected by 1,455 '\n",
            "                         'participating physicians. Mean systolic blood '\n",
            "                         'pressure decreased 25 mmHg and mean diastolic blood '\n",
            "                         'pressure declined 15 mmHg after one month of '\n",
            "                         'timolol-hydrochlorothiazide therapy (P less than '\n",
            "                         '0.01, both comparisons). Age, race, and sex appeared '\n",
            "                         'to have no influence on the decrease in blood '\n",
            "                         'pressure. The antihypertensive effect of the drug '\n",
            "                         'was greater in patients with more severe '\n",
            "                         'hypertension. Overall, 1,453 patients experienced a '\n",
            "                         'total of 2,658 adverse events, the most common being '\n",
            "                         'fatigue, dizziness, and weakness. Treatment in 590 '\n",
            "                         'patients was discontinued because of adverse '\n",
            "                         'events.The important background information needed '\n",
            "                         'to understand this text is  the results of this '\n",
            "                         'postmarketing surveillance study.',\n",
            "             'chemical2id': {'hydrochlorothiazide': 'D006852',\n",
            "                             'timolol': 'D013999',\n",
            "                             'timolol maleate': 'D013999'},\n",
            "             'disease2id': {'dizziness': 'D004244',\n",
            "                            'fatigue': 'D005221',\n",
            "                            'hypertension': 'D006973',\n",
            "                            'hypertensive': 'D006973',\n",
            "                            'weakness': 'D018908'},\n",
            "             'relations': [{'chemical': 'D013999', 'disease': 'D005221'},\n",
            "                           {'chemical': 'D013999', 'disease': 'D004244'},\n",
            "                           {'chemical': 'D006852', 'disease': 'D005221'},\n",
            "                           {'chemical': 'D006852', 'disease': 'D004244'},\n",
            "                           {'chemical': 'D006852', 'disease': 'D018908'},\n",
            "                           {'chemical': 'D013999', 'disease': 'D018908'}],\n",
            "             'title': 'Postmarketing study of timolol-hydrochlorothiazide '\n",
            "                      'antihypertensive therapy.'},\n",
            " '3864191': {'abstract': 'We examined the potential role of prostaglandins in '\n",
            "                         'the development of analgesic nephropathy in the Gunn '\n",
            "                         'strain of rat. The homozygous Gunn rats have '\n",
            "                         'unconjugated hyperbilirubinemia due to the absence '\n",
            "                         'of glucuronyl transferase, leading to marked '\n",
            "                         'bilirubin deposition in renal medulla and papilla. '\n",
            "                         'These rats are also highly susceptible to develop '\n",
            "                         'papillary necrosis with analgesic administration. We '\n",
            "                         'used homozygous (jj) and phenotypically normal '\n",
            "                         'heterozygous (jJ) animals. Four groups of rats (n = '\n",
            "                         '7) were studied: jj and jJ rats treated either with '\n",
            "                         'aspirin 300 mg/kg every other day or sham-treated. '\n",
            "                         'After one week, slices of cortex, outer and inner '\n",
            "                         'medulla from one kidney were incubated in buffer and '\n",
            "                         'prostaglandin synthesis was determined by '\n",
            "                         'radioimmunoassay. The other kidney was examined '\n",
            "                         'histologically. A marked corticomedullary gradient '\n",
            "                         'of prostaglandin synthesis was observed in all '\n",
            "                         'groups. PGE2 synthesis was significantly higher in '\n",
            "                         'outer medulla, but not cortex or inner medulla, of '\n",
            "                         'jj (38 +/- 6 ng/mg prot) than jJ rats (15 +/- 3) (p '\n",
            "                         'less than 0.01). Aspirin treatment reduced PGE2 '\n",
            "                         'synthesis in all regions, but outer medullary PGE2 '\n",
            "                         'remained higher in jj (18 +/- 3) than jJ rats (9 +/- '\n",
            "                         '2) (p less than 0.05). PGF2 alpha was also '\n",
            "                         'significantly higher in the outer medulla of jj rats '\n",
            "                         'with and without aspirin administration (p less than '\n",
            "                         '0.05). The changes in renal prostaglandin synthesis '\n",
            "                         'were accompanied by evidence of renal damage in '\n",
            "                         'aspirin-treated jj but not jJ rats as evidenced by: '\n",
            "                         'increased incidence and severity of hematuria (p '\n",
            "                         'less than 0.01); increased serum creatinine (p less '\n",
            "                         'than 0.05); and increase in outer medullary '\n",
            "                         'histopathologic lesions (p less than 0.005 compared '\n",
            "                         'to either sham-treated jj or aspirin-treated jJ). '\n",
            "                         'These results suggest that enhanced prostaglandin '\n",
            "                         'synthesis contributes to maintenance of renal '\n",
            "                         'function and morphological integrity, and that '\n",
            "                         'inhibition of prostaglandin synthesis may lead to '\n",
            "                         'pathological renal medullary lesions and '\n",
            "                         'deterioration of renal function.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the Gunn rat is a model of '\n",
            "                         'analgesic nephropathy.',\n",
            "             'chemical2id': {'aspirin': 'D001241',\n",
            "                             'bilirubin': 'D001663',\n",
            "                             'creatinine': 'D003404',\n",
            "                             'glucuronyl': '-1',\n",
            "                             'pge2': 'D015232',\n",
            "                             'pgf2 alpha': 'D015237',\n",
            "                             'prostaglandin': 'D011453',\n",
            "                             'prostaglandins': 'D011453',\n",
            "                             'salicylate': 'D012459'},\n",
            "             'disease2id': {'deterioration of renal function': 'D007674',\n",
            "                            'hematuria': 'D006417',\n",
            "                            'hyperbilirubinemia': 'D006932',\n",
            "                            'nephropathy': 'D007674',\n",
            "                            'papillary necrosis': 'D007681',\n",
            "                            'pathological renal medullary lesions': 'D058186',\n",
            "                            'renal damage': 'D007674'},\n",
            "             'relations': [{'chemical': 'D001241', 'disease': 'D007674'}],\n",
            "             'title': 'Salicylate nephropathy in the Gunn rat: potential role '\n",
            "                      'of prostaglandins.'},\n",
            " '3895875': {'abstract': 'Four hundred two patients with suspected myocardial '\n",
            "                         'infarction seen within 6 hours of the onset of '\n",
            "                         'symptoms entered a double-blind randomized trial of '\n",
            "                         'lidocaine vs placebo. During the 1 hour after '\n",
            "                         'administration of the drug the incidence of '\n",
            "                         'ventricular fibrillation or sustained ventricular '\n",
            "                         'tachycardia among the 204 patients with acute '\n",
            "                         'myocardial infarction was low, 1.5%. Lidocaine, '\n",
            "                         'given in a 300 mg dose intramuscularly followed by '\n",
            "                         '100 mg intravenously, did not prevent sustained '\n",
            "                         'ventricular tachycardia, although there was a '\n",
            "                         'significant reduction in the number of patients with '\n",
            "                         'warning arrhythmias between 15 and 45 minutes after '\n",
            "                         'the administration of lidocaine (p less than 0.05). '\n",
            "                         'The average plasma lidocaine level 10 minutes after '\n",
            "                         'administration for patients without a myocardial '\n",
            "                         'infarction was significantly higher than that for '\n",
            "                         'patients with an acute infarction. The mean plasma '\n",
            "                         'lidocaine level of patients on beta-blocking agents '\n",
            "                         'was no different from that in patients not on beta '\n",
            "                         'blocking agents. During the 1-hour study period, the '\n",
            "                         'incidence of central nervous system side effects was '\n",
            "                         'significantly greater in the lidocaine group, '\n",
            "                         'hypotension occurred in 11 patients, nine of whom '\n",
            "                         'had received lidocaine, and four patients died from '\n",
            "                         'asystole, three of whom had had lidocaine. We cannot '\n",
            "                         'advocate the administration of lidocaine '\n",
            "                         'prophylactically in the early hours of suspected '\n",
            "                         'myocardial infarction.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that the incidence of ventricular fibrillation '\n",
            "                         'or sustained ventricular tachycardia in patients '\n",
            "                         'with acute myocardial infarction is low and that the '\n",
            "                         'incidence of sudden death is low.',\n",
            "             'chemical2id': {'lidocaine': 'D008012'},\n",
            "             'disease2id': {'arrhythmias': 'D001145',\n",
            "                            'asystole': 'D006323',\n",
            "                            'hypotension': 'D007022',\n",
            "                            'infarction': 'D007238',\n",
            "                            'myocardial infarction': 'D009203',\n",
            "                            'ventricular fibrillation': 'D014693',\n",
            "                            'ventricular tachycardia': 'D017180'},\n",
            "             'relations': [{'chemical': 'D008012', 'disease': 'D007022'}],\n",
            "             'title': 'Prophylactic lidocaine in the early phase of suspected '\n",
            "                      'myocardial infarction.'},\n",
            " '3925479': {'abstract': 'Experiments in mice tested previous evidence that '\n",
            "                         'activation of cholinergic systems promotes catalepsy '\n",
            "                         'and that cholinergic mechanisms need to be intact '\n",
            "                         'for full expression of neuroleptic-induced '\n",
            "                         'catalepsy. Large doses of the cholinomimetic, '\n",
            "                         'pilocarpine, could induce catalepsy when peripheral '\n",
            "                         'cholinergic receptors were blocked. Low doses of '\n",
            "                         'pilocarpine caused a pronounced enhancement of the '\n",
            "                         'catalepsy that was induced by the dopaminergic '\n",
            "                         'blocker, haloperidol. A muscarinic receptor blocker, '\n",
            "                         'atropine, disrupted haloperidol-induced catalepsy. '\n",
            "                         'Intracranial injection of an acetylcholine-synthesis '\n",
            "                         'inhibitor, hemicholinium, prevented the catalepsy '\n",
            "                         'that is usually induced by haloperidol. These '\n",
            "                         'findings suggest the hypothesis that the catalepsy '\n",
            "                         'that is produced by neuroleptics such as haloperidol '\n",
            "                         'is actually mediated by intrinsic central '\n",
            "                         'cholinergic systems. Alternatively, activation of '\n",
            "                         'central cholinergic systems could promote catalepsy '\n",
            "                         'by suppression of dopaminergic systems.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  that the catalepsy produced by pilocarpine '\n",
            "                         'is not a direct result of cholinergic activation, '\n",
            "                         'but rather is a result of the activation of central '\n",
            "                         'cholinergic systems.',\n",
            "             'chemical2id': {'acetylcholine': 'D000109',\n",
            "                             'atropine': 'D001285',\n",
            "                             'haloperidol': 'D006220',\n",
            "                             'hemicholinium': 'D006426',\n",
            "                             'neuroleptic': 'D014150',\n",
            "                             'neuroleptics': 'D014150',\n",
            "                             'pilocarpine': 'D010862'},\n",
            "             'disease2id': {'catalepsy': 'D002375'},\n",
            "             'relations': [{'chemical': 'D010862', 'disease': 'D002375'},\n",
            "                           {'chemical': 'D006220', 'disease': 'D002375'}],\n",
            "             'title': 'Evidence for a cholinergic role in haloperidol-induced '\n",
            "                      'catalepsy.'},\n",
            " '3975902': {'abstract': 'Barium-supplemented Long-Evans hooded rats were '\n",
            "                         'characterized by a persistent hypertension that was '\n",
            "                         'evident after 1 month of barium (100 micrograms/ml '\n",
            "                         'mineral fortified water) treatment. Analysis of in '\n",
            "                         'vivo myocardial excitability, contractility, and '\n",
            "                         'metabolic characteristics at 16 months revealed '\n",
            "                         'other significant barium-induced disturbances within '\n",
            "                         'the cardiovascular system. The most distinctive '\n",
            "                         'aspect of the barium effect was a demonstrated '\n",
            "                         'hypersensitivity of the cardiovascular system to '\n",
            "                         'sodium pentobarbital. Under barbiturate anesthesia, '\n",
            "                         'virtually all of the myocardial contractile indices '\n",
            "                         'were depressed significantly in barium-exposed rats '\n",
            "                         'relative to the corresponding control-fed rats. The '\n",
            "                         'lack of a similar response to ketamine and xylazine '\n",
            "                         'anesthesia revealed that the cardiovascular actions '\n",
            "                         'of sodium pentobarbital in barium-treated rats were '\n",
            "                         'linked specifically to this anesthetic, and were not '\n",
            "                         'representative of a generalized anesthetic response. '\n",
            "                         'Other myocardial pathophysiologic and metabolic '\n",
            "                         'changes induced by barium were manifest, '\n",
            "                         'irrespective of the anesthetic employed. The '\n",
            "                         'contractile element shortening velocity of the '\n",
            "                         'cardiac muscle fibers was significantly slower in '\n",
            "                         'both groups of barium-treated rats relative to the '\n",
            "                         'control groups, irrespective of the anesthetic '\n",
            "                         'regimen. Similarly, significant disturbances in '\n",
            "                         'myocardial energy metabolism were detected in the '\n",
            "                         'barium-exposed rats which were consistent with the '\n",
            "                         'reduced contractile element shortening velocity. In '\n",
            "                         'addition, the excitability of the cardiac conduction '\n",
            "                         'system was depressed preferentially in the '\n",
            "                         'atrioventricular nodal region of hearts from '\n",
            "                         'barium-exposed rats. Overall, the altered cardiac '\n",
            "                         'contractility and excitability characteristics, the '\n",
            "                         'myocardial metabolic disturbances, and the '\n",
            "                         'hypersensitivity of the cardiovascular system to '\n",
            "                         'sodium pentobarbital suggest the existence of a '\n",
            "                         'heretofore undescribed cardiomyopathic disorder '\n",
            "                         'induced by chronic barium exposure. These '\n",
            "                         'experimental findings represent the first indication '\n",
            "                         'that life-long barium ingestion may have significant '\n",
            "                         'adverse effects on the mammalian cardiovascular '\n",
            "                         'system.The important background information needed '\n",
            "                         'to understand this text is  the fact that the '\n",
            "                         'barium-induced cardiovascular effects are not unique '\n",
            "                         'to the rat, and that the barium-induced '\n",
            "                         'cardiovascular effects are not unique to the rat.',\n",
            "             'chemical2id': {'barbiturate': 'C032232',\n",
            "                             'barium': 'D001464',\n",
            "                             'barium chloride': 'C024986',\n",
            "                             'ketamine': 'D007649',\n",
            "                             'sodium pentobarbital': 'D010424',\n",
            "                             'xylazine': 'D014991'},\n",
            "             'disease2id': {'cardiomyopathic disorder': 'D009202',\n",
            "                            'cardiovascular dysfunction': 'D002318',\n",
            "                            'disturbances within the cardiovascular system': 'D002318',\n",
            "                            'hypersensitivity': 'D004342',\n",
            "                            'hypertension': 'D006973',\n",
            "                            'metabolic disturbances': 'D008659'},\n",
            "             'relations': [{'chemical': 'C024986', 'disease': 'D009202'},\n",
            "                           {'chemical': 'C024986', 'disease': 'D006973'}],\n",
            "             'title': 'Cardiovascular dysfunction and hypersensitivity to '\n",
            "                      'sodium pentobarbital induced by chronic barium chloride '\n",
            "                      'ingestion.'},\n",
            " '3987172': {'abstract': 'Phenylpropanolamine (PPA) overdose can cause severe '\n",
            "                         'hypertension, intracerebral hemorrhage, and death. '\n",
            "                         'We studied the efficacy and safety of propranolol in '\n",
            "                         'the treatment of PPA-induced hypertension. Subjects '\n",
            "                         'received propranolol either by mouth for 48 hours '\n",
            "                         'before PPA or as a rapid intravenous infusion after '\n",
            "                         'PPA. PPA, 75 mg alone, increased blood pressure (31 '\n",
            "                         '+/- 14 mm Hg systolic, 20 +/- 5 mm Hg diastolic), '\n",
            "                         'and propranolol pretreatment antagonized this '\n",
            "                         'increase (12 +/- 10 mm Hg systolic, 10 +/- 7 mm Hg '\n",
            "                         'diastolic). Intravenous propranolol after PPA also '\n",
            "                         'decreased blood pressure. Left ventricular function '\n",
            "                         '(assessed by echocardiography) showed that PPA '\n",
            "                         'increased the stroke volume 30% (from 62.5 +/- 20.9 '\n",
            "                         'to 80.8 +/- 22.4 ml), the ejection fraction 9% (from '\n",
            "                         '64% +/- 10% to 70% +/- 7%), and cardiac output 14% '\n",
            "                         '(from 3.6 +/- 0.6 to 4.1 +/- 1.0 L/min). Intravenous '\n",
            "                         'propranolol reversed these effects. Systemic '\n",
            "                         'vascular resistance was increased by PPA 28% (from '\n",
            "                         '1710 +/- 200 to 2190 +/- 700 dyne X sec/cm5) and was '\n",
            "                         'further increased by propranolol 22% (to 2660 +/- '\n",
            "                         '1200 dyne X sec/cm5). We conclude that PPA increases '\n",
            "                         'blood pressure by increasing systemic vascular '\n",
            "                         'resistance and cardiac output, and that propranolol '\n",
            "                         'antagonizes this increase by reversing the effect of '\n",
            "                         'PPA on cardiac output. That propranolol antagonizes '\n",
            "                         'the pressor effect of PPA is in contrast to the '\n",
            "                         'interaction in which propranolol enhances the '\n",
            "                         'pressor effect of norepinephrine. This is probably '\n",
            "                         'because PPA has less beta 2 activity than does '\n",
            "                         'norepinephrine.The important background information '\n",
            "                         'needed to understand this text is  the fact that PPA '\n",
            "                         'is a beta-adrenergic agonist and that propranolol is '\n",
            "                         'a beta-adrenergic antagonist.',\n",
            "             'chemical2id': {'norepinephrine': 'D009638',\n",
            "                             'phenylpropanolamine': 'D010665',\n",
            "                             'ppa': 'D010665',\n",
            "                             'propranolol': 'D011433'},\n",
            "             'disease2id': {'hypertension': 'D006973',\n",
            "                            'intracerebral hemorrhage': 'D002543',\n",
            "                            'overdose': 'D062787',\n",
            "                            'stroke': 'D020521'},\n",
            "             'relations': [{'chemical': 'D010665', 'disease': 'D006973'}],\n",
            "             'title': 'Propranolol antagonism of phenylpropanolamine-induced '\n",
            "                      'hypertension.'},\n",
            " '3990093': {'abstract': 'The possible relationship between mesangial '\n",
            "                         'dysfunction and development of glomerular sclerosis '\n",
            "                         'was studied in the puromycin aminonucleoside (PAN) '\n",
            "                         'model. Five male Wistar rats received repeated '\n",
            "                         'subcutaneous PAN injections; five controls received '\n",
            "                         'saline only. After 4 weeks the PAN rats were '\n",
            "                         'severely proteinuric (190 +/- 80 mg/24 hr), and all '\n",
            "                         'rats were given colloidal carbon (CC) intravenously. '\n",
            "                         'At 5 months glomerular sclerosis was found in 7.6 '\n",
            "                         '+/- 3.4% of the glomeruli of PAN rats; glomeruli of '\n",
            "                         'the controls were normal. Glomeruli of PAN rats '\n",
            "                         'contained significantly more CC than glomeruli of '\n",
            "                         'controls. Glomeruli with sclerosis contained '\n",
            "                         'significantly more CC than non-sclerotic glomeruli '\n",
            "                         'in the same kidneys. CC was preferentially localized '\n",
            "                         'within the sclerotic areas of the affected '\n",
            "                         'glomeruli. Since mesangial CC clearance from the '\n",
            "                         'mesangium did not change during chronic PAN '\n",
            "                         'treatment, we conclude that this preferential CC '\n",
            "                         'localization within the lesions is caused by an '\n",
            "                         'increased CC uptake shortly after injection in '\n",
            "                         'apparent vulnerable areas where sclerosis will '\n",
            "                         'develop subsequently. Cluster analysis showed a '\n",
            "                         'random distribution of lesions in the PAN glomeruli '\n",
            "                         'in concordance with the random localization of '\n",
            "                         'mesangial areas with dysfunction in this model. '\n",
            "                         'Similar to the remnant kidney model in PAN nephrosis '\n",
            "                         'the development of glomerular sclerosis may be '\n",
            "                         'related to \"mesangial overloading.\"The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the glomerular lesions in '\n",
            "                         'this model are not due to a generalized mesangial '\n",
            "                         'dysfunction.',\n",
            "             'chemical2id': {'aminonucleoside': 'D011692',\n",
            "                             'carbon': 'D002244',\n",
            "                             'pan': 'D011692',\n",
            "                             'puromycin aminonucleoside': 'D011692'},\n",
            "             'disease2id': {'glomerular sclerosis': 'D007674',\n",
            "                            'mesangial dysfunction': 'D007674',\n",
            "                            'nephrosis': 'D009401',\n",
            "                            'proteinuric': 'D011507',\n",
            "                            'sclerosis': 'D012598'},\n",
            "             'relations': [{'chemical': 'D011692', 'disease': 'D011507'}],\n",
            "             'title': 'Mesangial function and glomerular sclerosis in rats '\n",
            "                      'with aminonucleoside nephrosis.'},\n",
            " '4010471': {'abstract': 'A controversy has existed for several years '\n",
            "                         'concerning the physiological relevance of the '\n",
            "                         'nicotinic receptor measured by alpha-bungarotoxin '\n",
            "                         'binding. Using mice derived from a classical F2 and '\n",
            "                         'backcross genetic design, a relationship between '\n",
            "                         'nicotine-induced seizures and alpha-bungarotoxin '\n",
            "                         'nicotinic receptor concentration was found. Mice '\n",
            "                         'sensitive to the convulsant effects of nicotine had '\n",
            "                         'greater alpha-bungarotoxin binding in the '\n",
            "                         'hippocampus than seizure insensitive mice. The '\n",
            "                         'binding sites from seizure sensitive and resistant '\n",
            "                         'mice were equally affected by treatment with '\n",
            "                         'dithiothreitol, trypsin or heat. Thus it appears '\n",
            "                         'that the difference between seizure sensitive and '\n",
            "                         'insensitive animals may be due to a difference in '\n",
            "                         'hippocampal nicotinic receptor concentration as '\n",
            "                         'measured with alpha-bungarotoxin binding.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that the '\n",
            "                         'alpha-bungarotoxin binding site is a member of the '\n",
            "                         'nicotinic receptor family.',\n",
            "             'chemical2id': {'dithiothreitol': 'D004229',\n",
            "                             'nicotine': 'D009538'},\n",
            "             'disease2id': {'seizure': 'D012640', 'seizures': 'D012640'},\n",
            "             'relations': [{'chemical': 'D009538', 'disease': 'D012640'}],\n",
            "             'title': 'Relationship between nicotine-induced seizures and '\n",
            "                      'hippocampal nicotinic receptors.'},\n",
            " '4082192': {'abstract': 'Acetaminophen (APAP) produces proximal tubular '\n",
            "                         'necrosis in Fischer 344 (F344) rats. Recently, '\n",
            "                         'p-aminophenol (PAP), a known potent nephrotoxicant, '\n",
            "                         'was identified as a metabolite of APAP in F344 rats. '\n",
            "                         'The purpose of this study was to determine if PAP '\n",
            "                         'formation is a requisite step in APAP-induced '\n",
            "                         'nephrotoxicity. Therefore, the effect of '\n",
            "                         'bis(p-nitrophenyl) phosphate (BNPP), an acylamidase '\n",
            "                         'inhibitor, on APAP and PAP nephrotoxicity and '\n",
            "                         'metabolism was determined. BNPP (1 to 8 mM) reduced '\n",
            "                         'APAP deacetylation and covalent binding in F344 '\n",
            "                         'renal cortical homogenates in a '\n",
            "                         'concentration-dependent manner. Pretreatment of '\n",
            "                         'animals with BNPP prior to APAP or PAP '\n",
            "                         'administration resulted in marked reduction of APAP '\n",
            "                         '(900 mg/kg) nephrotoxicity but not PAP '\n",
            "                         'nephrotoxicity. This result was not due to altered '\n",
            "                         'disposition of either APAP or acetylated metabolites '\n",
            "                         'in plasma or renal cortical and hepatic tissue. '\n",
            "                         'Rather, BNPP pretreatment reduced the fraction of '\n",
            "                         'APAP excreted as PAP by 64 and 75% after APAP doses '\n",
            "                         'of 750 and 900 mg/kg. BNPP did not alter the '\n",
            "                         'excretion of APAP or any of its non-deacetylated '\n",
            "                         'metabolites nor did BNPP alter excretion of PAP or '\n",
            "                         'its metabolites after PAP doses of 150 and 300 '\n",
            "                         'mg/kg. Therefore, the BNPP-induced reduction in '\n",
            "                         'APAP-induced nephrotoxicity appears to be due to '\n",
            "                         'inhibition of APAP deacetylation. It is concluded '\n",
            "                         'that PAP formation, in vivo, accounts, at least in '\n",
            "                         'part, for APAP-induced renal tubular necrosis.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the lack of a direct '\n",
            "                         'relationship between the formation of PAP and '\n",
            "                         'APAP-induced nephrotoxicity.',\n",
            "             'chemical2id': {'acetaminophen': 'D000082',\n",
            "                             'apap': 'D000082',\n",
            "                             'bis(p-nitrophenyl) phosphate': 'C002887',\n",
            "                             'bnpp': 'C002887',\n",
            "                             'p-aminophenol': 'C026729',\n",
            "                             'pap': 'C026729'},\n",
            "             'disease2id': {'nephrotoxicity': 'D007674',\n",
            "                            'renal tubular necrosis': 'D007683',\n",
            "                            'tubular necrosis': 'D007683'},\n",
            "             'relations': [{'chemical': 'C026729', 'disease': 'D007683'},\n",
            "                           {'chemical': 'D000082', 'disease': 'D007683'}],\n",
            "             'title': 'The role of p-aminophenol in acetaminophen-induced '\n",
            "                      'nephrotoxicity: effect of bis(p-nitrophenyl) phosphate '\n",
            "                      'on acetaminophen and p-aminophenol nephrotoxicity and '\n",
            "                      'metabolism in Fischer 344 rats.'},\n",
            " '4082466': {'abstract': 'Two neonates suffered from generalized seizures '\n",
            "                         'during the course of intravenous morphine sulfate '\n",
            "                         'for post-operative analgesia. They received morphine '\n",
            "                         'in doses of 32 micrograms/kg/hr and 40 '\n",
            "                         'micrograms/kg/hr larger than a group of 10 neonates '\n",
            "                         'who received 6-24 micrograms/kg/hr and had no '\n",
            "                         'seizures. Plasma concentrations of morphine in these '\n",
            "                         'neonates was excessive (60 and 90 mg/ml). Other '\n",
            "                         'known reasons for seizures were ruled out and the '\n",
            "                         'convulsions stopped a few hours after cessation of '\n",
            "                         'morphine and did not reoccur in the subsequent 8 '\n",
            "                         'months. It is suggested that post-operative '\n",
            "                         'intravenous morphine should not exceed 20 '\n",
            "                         'micrograms/kg/ml in neonates.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the seizures in these '\n",
            "                         'neonates were not associated with any other known '\n",
            "                         'cause of seizures.',\n",
            "             'chemical2id': {'morphine': 'D009020',\n",
            "                             'morphine sulfate': 'D009020'},\n",
            "             'disease2id': {'convulsions': 'D012640', 'seizures': 'D012640'},\n",
            "             'relations': [{'chemical': 'D009020', 'disease': 'D012640'}],\n",
            "             'title': 'Morphine-induced seizures in newborn infants.'},\n",
            " '439781': {'abstract': 'After a single oral dose of 4 mg/kg indomethacin '\n",
            "                        '(IDM) to sodium and volume depleted rats plasma renin '\n",
            "                        'activity (PRA) and systolic blood pressure fell '\n",
            "                        'significantly within four hours. In sodium repleted '\n",
            "                        'animals indomethacin did not change systolic blood '\n",
            "                        'pressure (BP) although plasma renin activity was '\n",
            "                        'decreased. Thus, indomethacin by inhibition of '\n",
            "                        'prostaglandin synthesis may diminish the blood '\n",
            "                        'pressure maintaining effect of the stimulated '\n",
            "                        'renin-angiotensin system in sodium and volume '\n",
            "                        'depletion.The important background information needed '\n",
            "                        'to understand this text is  the fact that '\n",
            "                        'indomethacin is a potent inhibitor of prostaglandin '\n",
            "                        'synthesis.',\n",
            "            'chemical2id': {'angiotensin': 'D000809',\n",
            "                            'idm': 'D007213',\n",
            "                            'indomethacin': 'D007213',\n",
            "                            'prostaglandin': 'D011453',\n",
            "                            'sodium': 'D012964'},\n",
            "            'disease2id': {'hypotension': 'D007022'},\n",
            "            'relations': [{'chemical': 'D007213', 'disease': 'D007022'}],\n",
            "            'title': 'Indomethacin induced hypotension in sodium and volume '\n",
            "                     'depleted rats.'},\n",
            " '44072': {'abstract': 'The antiarrhythmic activity of the compound '\n",
            "                       'N-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-N-(3-oxo-3-phenyl-2-methylpropyl)-piperazine '\n",
            "                       'hydrochloride, referred to as P11, is studied on '\n",
            "                       'anaesthesized cats and Wistar albino rats, as well as '\n",
            "                       'on non-anaesthesized rabbits. Four types of '\n",
            "                       'experimental arrhythmia are used--with BaCl2, with '\n",
            "                       'chloroform-adrenaline, with strophantine G and with '\n",
            "                       'aconitine. The compound P11 is introduced in doses of '\n",
            "                       '0.25 and 0.50 mg/kg intravenously and 10 mg/kg orally. '\n",
            "                       'The compound manifests antiarrhythmic activity in all '\n",
            "                       'models of experimental arrhythmia used, causing '\n",
            "                       'greatest inhibition on the arrhythmia induced by '\n",
            "                       'chloroform-adrenaline (in 90 per cent) and with BaCl2 '\n",
            "                       '(in 84 per cent). The results obtained are associated '\n",
            "                       'with the beta-adrenoblocking and with the '\n",
            "                       'membrane-stabilizing action of the compound.The '\n",
            "                       'important background information needed to understand '\n",
            "                       'this text is  the fact that the antiarrhythmic '\n",
            "                       'activity of the compound P11 is not related to the '\n",
            "                       'central nervous system.',\n",
            "           'chemical2id': {'aconitine': 'D000157',\n",
            "                           'adrenaline': 'D004837',\n",
            "                           'bacl2': 'C024986',\n",
            "                           'chloroform': 'D002725',\n",
            "                           'n-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-n-(3-oxo-3-phenyl-2-methylpropyl)-piperazine hydrochloride': 'C013741',\n",
            "                           'p11': 'C013741',\n",
            "                           'piperazine': 'C034930',\n",
            "                           'strophantine g': 'D010042',\n",
            "                           'trans-2-amino-3-hydroxy-1, 2, 3, 4-tetrahydroanaphthalene': '-1'},\n",
            "           'disease2id': {'arrhythmia': 'D001145'},\n",
            "           'relations': [{'chemical': 'D002725', 'disease': 'D001145'},\n",
            "                         {'chemical': 'C024986', 'disease': 'D001145'},\n",
            "                         {'chemical': 'D000157', 'disease': 'D001145'},\n",
            "                         {'chemical': 'D004837', 'disease': 'D001145'},\n",
            "                         {'chemical': 'D010042', 'disease': 'D001145'}],\n",
            "           'title': 'On the antiarrhythmic activity of one N-substituted '\n",
            "                    'piperazine derivative of trans-2-amino-3-hydroxy-1, 2, 3, '\n",
            "                    '4-tetrahydroanaphthalene.'},\n",
            " '448423': {'abstract': 'Epsilon aminocaproic acid (EACA) has been used to '\n",
            "                        'prevent rebleeding in patients with subarachnoid '\n",
            "                        'hemorrhage (SAH). Although this agent does decrease '\n",
            "                        'the frequency of rebleeding, several reports have '\n",
            "                        'described thrombotic complications of EACA therapy. '\n",
            "                        'These complications have included clinical '\n",
            "                        'deterioration and intracranial vascular thrombosis in '\n",
            "                        'patients with SAH, arteriolar and capillary fibrin '\n",
            "                        'thrombi in patients with fibrinolytic syndromes '\n",
            "                        'treated with EACA, or other thromboembolic phenomena. '\n",
            "                        'Since intravascular fibrin thrombi are often observed '\n",
            "                        'in patients with fibrinolytic disorders, EACA should '\n",
            "                        'not be implicated in the pathogenesis of fibrin '\n",
            "                        'thrombi in patients with disseminated intravascular '\n",
            "                        'coagulation or other \"consumption coagulopathies.\" '\n",
            "                        'This report describes subtotal infarction of the '\n",
            "                        'kidney due to thrombosis of a normal renal artery. '\n",
            "                        'This occlusion occurred after EACA therapy in a '\n",
            "                        'patient with SAH and histopathological documentation '\n",
            "                        'of recurrent SAH. The corresponding clinical event '\n",
            "                        'was characterized by marked hypertension and abrupt '\n",
            "                        'neurological deterioration.The important background '\n",
            "                        'information needed to understand this text is  the '\n",
            "                        'fact that the patient had a history of hypertension '\n",
            "                        'and had been treated with EACA for a prolonged period '\n",
            "                        'of time.',\n",
            "            'chemical2id': {'aminocaproic acid': 'D000614',\n",
            "                            'eaca': 'D015119',\n",
            "                            'epsilon aminocaproic acid': 'D015119'},\n",
            "            'disease2id': {'acute renal artery thrombosis': 'D007674',\n",
            "                           'consumption coagulopathies': 'D004211',\n",
            "                           'disseminated intravascular coagulation': 'D004211',\n",
            "                           'hypertension': 'D006973',\n",
            "                           'infarction': 'D007238',\n",
            "                           'intracranial vascular thrombosis': 'D020767',\n",
            "                           'sah': 'D013345',\n",
            "                           'subarachnoid hemorrhage': 'D013345',\n",
            "                           'thrombi': 'D013927',\n",
            "                           'thromboembolic phenomena': 'D013923',\n",
            "                           'thrombosis of a normal renal artery': 'D007674',\n",
            "                           'thrombotic': 'D013927'},\n",
            "            'relations': [{'chemical': 'D015119', 'disease': 'D013345'},\n",
            "                          {'chemical': 'D015119', 'disease': 'D007674'},\n",
            "                          {'chemical': 'D015119', 'disease': 'D013927'},\n",
            "                          {'chemical': 'D015119', 'disease': 'D020767'},\n",
            "                          {'chemical': 'D015119', 'disease': 'D006973'}],\n",
            "            'title': 'Recurrent subarachnoid hemorrhage associated with '\n",
            "                     'aminocaproic acid therapy and acute renal artery '\n",
            "                     'thrombosis. Case report.'},\n",
            " '4631913': {'abstract': 'In rhesus monkeys, intravenous challenge with 0.6 x '\n",
            "                         '10(10) to 2.2 x 10(10)Pseudomonas aeruginosa '\n",
            "                         \"organisms caused acute illness of 4 to 5 days' \"\n",
            "                         'duration with spontaneous recovery in 13 of 15 '\n",
            "                         'monkeys; blood cultures became negative 3 to 17 days '\n",
            "                         'after challenge. Leukocytosis was observed in all '\n",
            "                         'monkeys. Intravenous or intratracheal inoculation of '\n",
            "                         '2.0 to 2.5 mg of vincristine sulfate was followed by '\n",
            "                         'leukopenia in 4 to 5 days. Intravenous inoculation '\n",
            "                         'of 4.2 x 10(10) to 7.8 x 10(10) pyocin type 6 '\n",
            "                         'Pseudomonas organisms in monkeys given vincristine '\n",
            "                         'sulfate 4 days previously resulted in fatal '\n",
            "                         'infection in 11 of 14 monkeys, whereas none of four '\n",
            "                         'receiving Pseudomonas alone died. These studies '\n",
            "                         'suggest that an antimetabolite-induced leukopenia '\n",
            "                         'predisposes to severe Pseudomonas sepsis and that '\n",
            "                         'such monkeys may serve as a biological model for '\n",
            "                         'study of comparative efficacy of antimicrobial '\n",
            "                         'agents.The important background information needed '\n",
            "                         'to understand this text is  the fact that the '\n",
            "                         'leukopenia induced by vincristine sulfate is '\n",
            "                         'reversible and that the leukopenia is not due to a '\n",
            "                         'direct toxic effect of the drug on the leukocytes.',\n",
            "             'chemical2id': {'vincristine sulfate': 'D014750'},\n",
            "             'disease2id': {'infection': 'D007239',\n",
            "                            'leukocytosis': 'D007964',\n",
            "                            'leukopenia': 'D007970',\n",
            "                            'pseudomonas infections': 'D011552',\n",
            "                            'sepsis': 'D018805'},\n",
            "             'relations': [{'chemical': 'D014750', 'disease': 'D018805'},\n",
            "                           {'chemical': 'D014750', 'disease': 'D007970'},\n",
            "                           {'chemical': 'D014750', 'disease': 'D011552'}],\n",
            "             'title': 'Effect of vincristine sulfate on Pseudomonas infections '\n",
            "                      'in monkeys.'},\n",
            " '48835': {'abstract': 'The cardiovascular effects of hypoglycaemia, with and '\n",
            "                       'without beta-blockade, were compared in fourteen '\n",
            "                       'healthy men. Eight received insulin alone, and eight, '\n",
            "                       'including two of the original insulin-only group, were '\n",
            "                       'given propranolol and insulin. In the insulin-group '\n",
            "                       'the period of hypoglycaemia was associated with an '\n",
            "                       'increase in heart-rate and a fall in diastolic '\n",
            "                       'blood-pressure. In the propranolol-insulin group there '\n",
            "                       'was a significant fall in heart-rate in most subjects '\n",
            "                       'and an increase in diastolic pressure. Typical S-T/T '\n",
            "                       'changes occurred in the insulin-group but in none of '\n",
            "                       'the propranolol-insulin group. Hypertension in '\n",
            "                       'diabetics prone to hypoglycaemia attacks should not be '\n",
            "                       'treated with beta-blockers because these drugs may '\n",
            "                       'cause a sharp rise in blood-pressure in such '\n",
            "                       'patients.The important background information needed '\n",
            "                       'to understand this text is  that the cardiovascular '\n",
            "                       'effects of hypoglycaemia are not uniform in all '\n",
            "                       'subjects.',\n",
            "           'chemical2id': {'propranolol': 'D011433'},\n",
            "           'disease2id': {'diabetics': 'D003920',\n",
            "                          'hypertension': 'D006973',\n",
            "                          'hypoglycaemia': 'D007003'},\n",
            "           'relations': [{'chemical': 'D011433', 'disease': 'D006973'}],\n",
            "           'title': 'Modification by propranolol of cardiovascular effects of '\n",
            "                    'induced hypoglycaemia.'},\n",
            " '573555': {'abstract': 'Propranolol, a beta-adrenergic blocking agent, has '\n",
            "                        'found an important position in the practice of '\n",
            "                        'medicine. Its use in pregnancy, however, is an open '\n",
            "                        'question as a number of detrimental side effects have '\n",
            "                        'been reported in the fetus and neonate. Ten patients '\n",
            "                        'and 12 pregnancies are reported where chronic '\n",
            "                        'propranolol has been administered. Five patients with '\n",
            "                        'serial pregnancies with and without propranolol '\n",
            "                        'therapy are also examined. Maternal, fetal, and '\n",
            "                        'neonatal complications are examined. An attempt is '\n",
            "                        'made to differentiate drug-related complications from '\n",
            "                        'maternal disease--related complications. We conclude '\n",
            "                        'that previously reported hypoglycemia, '\n",
            "                        'hyperbilirubinemia, polycythemia, neonatal apnea, and '\n",
            "                        'bradycardia are not invariable and cannot be '\n",
            "                        'statistically correlated with chronic propranolol '\n",
            "                        'therapy. Growth retardation, however, appears to be '\n",
            "                        'significant in both of our series.The important '\n",
            "                        'background information needed to understand this text '\n",
            "                        'is  the fact that propranolol is a beta-adrenergic '\n",
            "                        'blocking agent and that it is a potent '\n",
            "                        'beta-adrenergic blocking agent.',\n",
            "            'chemical2id': {'propranolol': 'D011433'},\n",
            "            'disease2id': {'bradycardia': 'D001919',\n",
            "                           'growth retardation': 'D005317',\n",
            "                           'hyperbilirubinemia': 'D006932',\n",
            "                           'hypoglycemia': 'D007003',\n",
            "                           'neonatal apnea': 'D001049',\n",
            "                           'polycythemia': 'D011086'},\n",
            "            'relations': [{'chemical': 'D011433', 'disease': 'D005317'}],\n",
            "            'title': 'Long-term propranolol therapy in pregnancy: maternal and '\n",
            "                     'fetal outcome.'},\n",
            " '6106951': {'abstract': 'Toxic actions of flurazepam (FZP) were studied in '\n",
            "                         'cats, mice and rats. High doses caused an apparent '\n",
            "                         'central excitation, most clearly seen as clonic '\n",
            "                         'convulsions, superimposed on general depression. '\n",
            "                         'Following a lethal dose, death was always associated '\n",
            "                         'with convulsions. Comparing the relative sensitivity '\n",
            "                         'to central depression and excitation revealed that '\n",
            "                         'rats were least likely to have convulsions at doses '\n",
            "                         'that did not first cause loss of consciousness, '\n",
            "                         'while cats most clearly showed marked central '\n",
            "                         'excitatory actions. Signs of FZP toxocity in cats '\n",
            "                         'included excessive salivation, extreme apprehensive '\n",
            "                         'behavior, retching, muscle tremors and convulsions. '\n",
            "                         'An interaction between FZP and pentylenetetrazol '\n",
            "                         '(PTZ) was shown by pretreating mice with FZP before '\n",
            "                         'PTZ challenge. As a function of dose, FZP first '\n",
            "                         'protected against convulsions and death. At higher '\n",
            "                         'doses, however, convulsions again emerged. These '\n",
            "                         'doses of FZP were lower than those that would alone '\n",
            "                         'cause convulsions. These results may be relevant to '\n",
            "                         'the use of FZP in clinical situations in which there '\n",
            "                         'is increased neural excitability, such as epilepsy '\n",
            "                         'or sedative-hypnotic drug withdrawal.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the effects of FZP on the '\n",
            "                         'central nervous system are not limited to the '\n",
            "                         'central nervous system.',\n",
            "             'chemical2id': {'flurazepam': 'D005479',\n",
            "                             'fzp': 'D005479',\n",
            "                             'pentylenetetrazol': 'D010433',\n",
            "                             'ptz': 'D010433'},\n",
            "             'disease2id': {'convulsions': 'D012640',\n",
            "                            'depression': 'D003866',\n",
            "                            'epilepsy': 'D004827',\n",
            "                            'loss of consciousness': 'D014474',\n",
            "                            'muscle tremors': 'D014202',\n",
            "                            'salivation': 'D012798',\n",
            "                            'toxocity': 'D064420'},\n",
            "             'relations': [{'chemical': 'D005479', 'disease': 'D012640'},\n",
            "                           {'chemical': 'D010433', 'disease': 'D012640'}],\n",
            "             'title': 'Central excitatory actions of flurazepam.'},\n",
            " '611664': {'abstract': 'Five patients with idiopathic orthostatic hypotension '\n",
            "                        'who had physiologic and biochemical evidence of '\n",
            "                        'severe autonomic dysfunction were included in the '\n",
            "                        'study. They all exhibited markedly reduced plasma '\n",
            "                        'catecholamines and plasma renin activity in both '\n",
            "                        'recumbent and upright positions and had marked '\n",
            "                        'hypersensitivity to the pressor effects of infused '\n",
            "                        'norepinephrine. Treatment with propanolol '\n",
            "                        'administered intravenously (1-5 mg) produced '\n",
            "                        'increases in supine and upright blood pressure in 4 '\n",
            "                        'of the 5 individuals with rises ranging from 11/6 to '\n",
            "                        '22/11 mmHg. Chronic oral administration of '\n",
            "                        'propranolol (40-160 mg/day) also elevated the blood '\n",
            "                        'pressures of these individuals with increases in the '\n",
            "                        'order of 20-35/15-25 mmg being observed. In 1 '\n",
            "                        'patient, marked hypertension was induced by '\n",
            "                        'propranolol and the drug had to be withdrawn. It '\n",
            "                        'otherwise was well tolerated and no important side '\n",
            "                        'effects were observed. Treatment has been continued '\n",
            "                        'in 3 individuals for 6-13 months with persistence of '\n",
            "                        'the pressor effect, although there appears to have '\n",
            "                        'been some decrease in the degree of response with '\n",
            "                        'time. Hemodynamic measurements in 1 of the patients '\n",
            "                        'demonstrated an increase in total peripheral '\n",
            "                        'resistance and essentially no change in cardiac '\n",
            "                        'output following propranolol therapy. The studies '\n",
            "                        'suggest that propranolol is a useful drug in selected '\n",
            "                        'patients with severe idiopathic orthostatic '\n",
            "                        'hypotension.The important background information '\n",
            "                        'needed to understand this text is  the fact that the '\n",
            "                        'syndrome of idiopathic orthostatic hypotension is a '\n",
            "                        'rare disorder and that the underlying mechanism is '\n",
            "                        'not known.',\n",
            "            'chemical2id': {'catecholamines': 'D002395',\n",
            "                            'norepinephrine': 'D009638',\n",
            "                            'propanolol': 'D011433',\n",
            "                            'propranolol': 'D011433'},\n",
            "            'disease2id': {'hypersensitivity': 'D004342',\n",
            "                           'hypertension': 'D006973',\n",
            "                           'idiopathic orthostatic hypotension': 'C544351'},\n",
            "            'relations': [{'chemical': 'D011433', 'disease': 'D006973'}],\n",
            "            'title': 'Use of propranolol in the treatment of idiopathic '\n",
            "                     'orthostatic hypotension.'},\n",
            " '612112': {'abstract': 'An investigation was undertaken to determine the '\n",
            "                        'dosage of etomidate required to maintain sleep in '\n",
            "                        'adults undergoing surgery under regional local '\n",
            "                        'anesthesia. Premedication of diazepam 10 mg and '\n",
            "                        'atropine 0.5 mg was given, and sleep was induced and '\n",
            "                        'maintained by intermittent intravenous injections of '\n",
            "                        'etomidate 0.1/mg/kg, given whenever the patient would '\n",
            "                        'open his eyes on request. A mean overall dose of '\n",
            "                        'etomidate 17.4 microgram/kg/min. was required to '\n",
            "                        'maintain sleep, but great individual variation '\n",
            "                        'occurred, with older patients requiring less drug. '\n",
            "                        'The investigation was discontinued after 18 patients '\n",
            "                        'because of the frequency and intensity of '\n",
            "                        'side-effects, particularly pain and myoclonia, which '\n",
            "                        'caused the technique to be abandoned in two cases. It '\n",
            "                        'is considered unlikely that etomidate will prove to '\n",
            "                        'be the hypnotic of choice for a totally intravenous '\n",
            "                        'anesthetic technique in adults because of the high '\n",
            "                        'incidence of myoclonia after prolonged '\n",
            "                        'administration. In several patients uncontrollable '\n",
            "                        'muscle movements persisted for many minutes after '\n",
            "                        'complete recovery of consciousness.The important '\n",
            "                        'background information needed to understand this text '\n",
            "                        'is  the fact that the dose of etomidate required to '\n",
            "                        'maintain sleep in adults is much higher than that '\n",
            "                        'required to induce sleep in children.',\n",
            "            'chemical2id': {'atropine': 'D001285',\n",
            "                            'diazepam': 'D003975',\n",
            "                            'etomidate': 'D005045'},\n",
            "            'disease2id': {'myoclonia': 'D009207', 'pain': 'D010146'},\n",
            "            'relations': [{'chemical': 'D005045', 'disease': 'D009207'},\n",
            "                          {'chemical': 'D005045', 'disease': 'D010146'}],\n",
            "            'title': 'Total intravenous anesthesia with etomidate. III. Some '\n",
            "                     'observations in adults.'},\n",
            " '6299641': {'abstract': 'We compared the effects of single doses of 50 mg '\n",
            "                         'atenolol (cardioselective), 40 mg propranolol '\n",
            "                         '(nonselective), and placebo on both exercise- and '\n",
            "                         'isoproterenol-induced tachycardia in two experiments '\n",
            "                         'involving nine normal subjects. Maximal exercise '\n",
            "                         'heart rate was reduced from 187 +/- 4(SEM) after '\n",
            "                         'placebo to 146 +/- 7 bpm after atenolol and 138 +/- '\n",
            "                         '6 bpm after propranolol, but there were no '\n",
            "                         'differences between the drugs. The effects on '\n",
            "                         'isoproterenol tachycardia were determined before and '\n",
            "                         'after atropine (0.04 mg/kg IV). Isoproterenol '\n",
            "                         'sensitivity was determined as the intravenous dose '\n",
            "                         'that increased heart rate by 25 bpm (CD25) and this '\n",
            "                         'was increased from 1.8 +/- 0.3 micrograms after '\n",
            "                         'placebo to 38.9 +/- 8.3 micrograms after propranolol '\n",
            "                         'and 8.3 +/- 1.7 micrograms after atenolol. The '\n",
            "                         'difference in the effects of the two was '\n",
            "                         'significant. After atropine the CD25 was unchanged '\n",
            "                         'after placebo (2.3 +/- 0.3 micrograms) and atenolol '\n",
            "                         '(7.7 +/- 1.3 micrograms); it was reduced after '\n",
            "                         'propranolol (24.8 +/- 5.0 micrograms), but remained '\n",
            "                         'different from atenolol. This change with '\n",
            "                         'propranolol sensitivity was calculated as the '\n",
            "                         'apparent Ka, this was unchanged by atropine (11.7 '\n",
            "                         '+/- 2.1 and 10.1 +/- 2.5 ml/ng). These data are '\n",
            "                         'consistent with the hypothesis that exercise-induced '\n",
            "                         'tachycardia results largely from beta 1-receptor '\n",
            "                         'activation that is blocked by both cardioselective '\n",
            "                         'and nonselective drugs, whereas isoproterenol '\n",
            "                         'activates both beta 1- and beta 2-receptors so that '\n",
            "                         'after cardioselective blockade there remains a beta '\n",
            "                         '2-component that can be blocked with a nonselective '\n",
            "                         'drug. While there appear to be beta 2-receptors in '\n",
            "                         'the human heart, their physiologic or pathologic '\n",
            "                         'roles remain to be defined.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that the beta-blocking drugs used in this study '\n",
            "                         'were cardioselective and that the beta-blocking '\n",
            "                         'effects of the drugs were not determined by their '\n",
            "                         'beta 1-blocking properties.',\n",
            "             'chemical2id': {'atenolol': 'D001262',\n",
            "                             'atropine': 'D001285',\n",
            "                             'isoproterenol': 'D007545',\n",
            "                             'propranolol': 'D011433'},\n",
            "             'disease2id': {'tachycardia': 'D013610'},\n",
            "             'relations': [{'chemical': 'D007545', 'disease': 'D013610'}],\n",
            "             'title': 'Evidence for cardiac beta 2-adrenoceptors in man.'},\n",
            " '6305660': {'abstract': 'This paper reports the results of a study of 50 '\n",
            "                         'menopausal women receiving hormonal replacement '\n",
            "                         'therapy. The majority (29) had surgical menopause; '\n",
            "                         'their mean age was 45.7 years. It was hypothesized '\n",
            "                         'that progestins could equilibrate the effects of the '\n",
            "                         'estrogenic stimulation on the mammary and '\n",
            "                         'endometrial target tissues of women on hormonal '\n",
            "                         'replacement therapy. The treatment schedule '\n",
            "                         'consisted of conjugated estrogens (Premarin) 1.25 '\n",
            "                         'mg/day for 21 days and Medroxyprogesterone acetate '\n",
            "                         '10 mg/day for 10 days in each month. The mean '\n",
            "                         'treatment period was 18 months. During the follow-up '\n",
            "                         'period, attention was paid to breast modifications '\n",
            "                         'as evidenced by symptomatology, physical '\n",
            "                         'examination, and plate thermography. Mastodynia was '\n",
            "                         'reported by 21 patients, and physical examination '\n",
            "                         'revealed a light increase in breast firmness in 12 '\n",
            "                         'women and a moderate increase in breast nodularity '\n",
            "                         'in 2 women. Themography confirmed the existence of '\n",
            "                         'an excessive breast stimulation in 1 women who '\n",
            "                         'complained of moderate mastodynia and in 5 of the 7 '\n",
            "                         'women who complained of severe mastodynia. '\n",
            "                         'Normalization was obtained by halving the estrogen '\n",
            "                         'dose. These results suggest that hormonal '\n",
            "                         'replacement therapy can be safely prescribed if the '\n",
            "                         'following criteria are satisfied: 1) preliminary '\n",
            "                         'evaluation of patients from a clinical, metabolic, '\n",
            "                         'cytologic, and mammographic perspective; 2) cyclic '\n",
            "                         'treatment schedule, with a progestative phase of 10 '\n",
            "                         'days; and 3) periodic complete follow-up, with '\n",
            "                         'accurate thermographic evaluation of the breast '\n",
            "                         'target tissues.The important background information '\n",
            "                         'needed to understand this text is  the fact that the '\n",
            "                         'breast is a target organ for estrogen and '\n",
            "                         'progesterone, and that the breast is a target for '\n",
            "                         'estrogen and progesterone.',\n",
            "             'chemical2id': {'conjugated estrogens': 'D004966',\n",
            "                             'estrogen': 'D004967',\n",
            "                             'medroxyprogesterone acetate': 'D017258',\n",
            "                             'premarin': 'D004966',\n",
            "                             'progestins': 'D011372'},\n",
            "             'disease2id': {'breast cancer': 'D001943',\n",
            "                            'mastodynia': 'D059373'},\n",
            "             'relations': [{'chemical': 'D004966', 'disease': 'D059373'},\n",
            "                           {'chemical': 'D017258', 'disease': 'D059373'}],\n",
            "             'title': 'Hormones and risk of breast cancer.'},\n",
            " '6310832': {'abstract': 'Eighty-one renal, seventeen heart, and twenty-four '\n",
            "                         'liver transplant patients were followed for '\n",
            "                         'infection. Seventeen renal patients received '\n",
            "                         'azathioprine (Aza) and prednisone as part of a '\n",
            "                         'randomized trial of immunosuppression with 21 '\n",
            "                         'cyclosporine-and-prednisone-treated renal transplant '\n",
            "                         'patients. All others received cyclosporine and '\n",
            "                         'prednisone. The randomized Aza patients had more '\n",
            "                         'overall infections (P less than 0.05) and more '\n",
            "                         'nonviral infections (P less than 0.02) than the '\n",
            "                         'randomized cyclosporine patients. Heart and liver '\n",
            "                         'patients had more infections than cyclosporine renal '\n",
            "                         'patients but fewer infections than the Aza renal '\n",
            "                         'patients. There were no infectious deaths in renal '\n",
            "                         'transplant patients on cyclosporine or Aza, but '\n",
            "                         'infection played a major role in 3 out of 6 cardiac '\n",
            "                         'transplant deaths and in 8 out of 9 liver transplant '\n",
            "                         'deaths. Renal patients on cyclosporine had the '\n",
            "                         'fewest bacteremias. Analysis of site of infection '\n",
            "                         'showed a preponderance of abdominal infections in '\n",
            "                         'liver patients, intrathoracic infections in heart '\n",
            "                         'patients, and urinary tract infections in renal '\n",
            "                         'patients. Pulmonary infections were less common in '\n",
            "                         'cyclosporine-treated renal patients than in '\n",
            "                         'Aza-treated patients (P less than 0.05). Aza '\n",
            "                         'patients had significantly more staphylococcal '\n",
            "                         'infections than all other transplant groups (P less '\n",
            "                         'than 0.005), and systemic fungal infections occurred '\n",
            "                         'only in the liver transplant group. Cytomegalovirus '\n",
            "                         '(CMV) shedding or serological rises in antibody '\n",
            "                         'titer, or both occurred in 78% of cyclosporine '\n",
            "                         'patients and 76% of Aza patients. Of the '\n",
            "                         'cyclosporine patients, 15% had symptoms related to '\n",
            "                         'CMV infection. Serological evidence for Epstein Barr '\n",
            "                         'Virus infection was found in 20% of 65 cyclosporine '\n",
            "                         'patients studied. Three had associated symptoms, and '\n",
            "                         'one developed a lymphoma.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that the majority of infections in transplant '\n",
            "                         'patients are not due to the immunosuppressive drugs '\n",
            "                         'used.',\n",
            "             'chemical2id': {'aza': 'D001379',\n",
            "                             'azathioprine': 'D001379',\n",
            "                             'cyclosporine': 'D016572',\n",
            "                             'prednisone': 'D011241'},\n",
            "             'disease2id': {'abdominal infections': 'D059413',\n",
            "                            'bacteremias': 'D016470',\n",
            "                            'cmv infection': 'D003586',\n",
            "                            'epstein barr virus infection': 'D020031',\n",
            "                            'fungal infections': 'D009181',\n",
            "                            'infection': 'D007239',\n",
            "                            'infections': 'D007239',\n",
            "                            'lymphoma': 'D008223',\n",
            "                            'staphylococcal infections': 'D013203',\n",
            "                            'urinary tract infections': 'D014552'},\n",
            "             'relations': [{'chemical': 'D016572', 'disease': 'D007239'},\n",
            "                           {'chemical': 'D001379', 'disease': 'D007239'}],\n",
            "             'title': 'Early infections in kidney, heart, and liver transplant '\n",
            "                      'recipients on cyclosporine.'},\n",
            " '6316193': {'abstract': 'Intraperitoneal administration of cholecystokinin '\n",
            "                         'octapeptide sulphate ester (CCK-8-SE) and '\n",
            "                         'nonsulphated cholecystokinin octapeptide (CCK-8-NS) '\n",
            "                         'enhanced the latency of seizures induced by '\n",
            "                         'picrotoxin in mice. Experiments with N- and '\n",
            "                         'C-terminal fragments revealed that the C-terminal '\n",
            "                         'tetrapeptide (CCK-5-8) was the active centre of the '\n",
            "                         'CCK octapeptide molecule. The analogues CCK-8-SE and '\n",
            "                         'CCK-8-NS (dose range 0.2-6.4 mumol/kg) and caerulein '\n",
            "                         'dose range 0.1-0.8 mumol/kg) showed bell-shaped '\n",
            "                         'dose-effect curves, with the greatest maximum '\n",
            "                         'inhibition for CCK-8-NS. The peptide CCK-5-8 had '\n",
            "                         'weak anticonvulsant activity in comparison to the '\n",
            "                         'octapeptides, 3.2 mumol/kg and larger doses of the '\n",
            "                         'reference drug, diazepam, totally prevented '\n",
            "                         'picrotoxin-induced seizures and mortality. The '\n",
            "                         'maximum effect of the peptides tested was less than '\n",
            "                         'that of diazepam. Experiments with analogues and '\n",
            "                         'derivatives of CCK-5-8 demonstrated that the '\n",
            "                         'effectiveness of the beta-alanyl derivatives of '\n",
            "                         'CCK-5-8 were enhanced and that they were equipotent '\n",
            "                         'with CCK-8-SE. Of the CCK-2-8 analogues, '\n",
            "                         'Ser(SO3H)7-Ac-CCK-2-8-SE and '\n",
            "                         'Thr(SO3H)7-Ac-CCK-2-8-SE and Hyp(SO3H)-Ac-CCK-2-8-SE '\n",
            "                         'were slightly more active than CCK-8-SE.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that the '\n",
            "                         'C-terminal tetrapeptide of CCK-8 is the active '\n",
            "                         'centre of the octapeptide molecule.',\n",
            "             'chemical2id': {'caerulein': 'D002108',\n",
            "                             'cck-8': 'D012844',\n",
            "                             'cholecystokinin': 'D002766',\n",
            "                             'cholecystokinin octapeptide': 'D012844',\n",
            "                             'diazepam': 'D003975',\n",
            "                             'picrotoxin': 'D010852'},\n",
            "             'disease2id': {'seizures': 'D012640'},\n",
            "             'relations': [{'chemical': 'D010852', 'disease': 'D012640'}],\n",
            "             'title': 'Structure-activity and dose-effect relationships of the '\n",
            "                      'antagonism of picrotoxin-induced seizures by '\n",
            "                      'cholecystokinin, fragments and analogues of '\n",
            "                      'cholecystokinin in mice.'},\n",
            " '6321816': {'abstract': 'The role of vasopressin as a pressor agent to the '\n",
            "                         'hypertensive process was examined. Vasopressin plays '\n",
            "                         'a major role in the pathogenesis of DOCA-salt '\n",
            "                         'hypertension, since the elevation of blood pressure '\n",
            "                         'was not substantial in the rats with lithium-treated '\n",
            "                         'diabetes insipidus after DOCA-salt treatment. '\n",
            "                         'Administration of DDAVP which has antidiuretic '\n",
            "                         'action but minimal vasopressor effect failed to '\n",
            "                         'increase blood pressure to the levels observed after '\n",
            "                         'administration of AVP. Furthermore, the pressor '\n",
            "                         'action of vasopressin appears to be important in the '\n",
            "                         'development of this model of hypertension, since the '\n",
            "                         'enhanced pressor responsiveness to the hormone was '\n",
            "                         'observed in the initial stage of hypertension. '\n",
            "                         'Increased secretion of vasopressin from '\n",
            "                         'neurohypophysis also promotes the function of the '\n",
            "                         'hormone as a pathogenetic factor in hypertension. An '\n",
            "                         'unproportional release of vasopressin compared to '\n",
            "                         'plasma osmolality may be induced by the absence of '\n",
            "                         'an adjusting control of angiotensin II forming and '\n",
            "                         'receptor binding capacity for sodium balance in the '\n",
            "                         'brain. However, the role of vasopressin remains to '\n",
            "                         'be determined in human essential hypertension.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that the pressor '\n",
            "                         'action of vasopressin is not mediated by the release '\n",
            "                         'of angiotensin II from the neurohypophysis.',\n",
            "             'chemical2id': {'angiotensin': 'D000809',\n",
            "                             'ddavp': 'D003894',\n",
            "                             'doca': 'D003900',\n",
            "                             'lithium': 'D008094',\n",
            "                             'sodium': 'D012964',\n",
            "                             'vasopressin': 'D014667'},\n",
            "             'disease2id': {'diabetes insipidus': 'D003919',\n",
            "                            'hypertension': 'D006973',\n",
            "                            'hypertensive': 'D006973'},\n",
            "             'relations': [{'chemical': 'D003900', 'disease': 'D006973'},\n",
            "                           {'chemical': 'D008094', 'disease': 'D003919'}],\n",
            "             'title': 'Vasopressin as a possible contributor to hypertension.'},\n",
            " '6453500': {'abstract': 'A reversible toxic liver damage was observed in a '\n",
            "                         'non-alcoholic woman treated with disulfiram. The '\n",
            "                         'causative relationship was proven by challenge.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that the liver '\n",
            "                         'damage was reversible and the patient had no history '\n",
            "                         'of alcohol abuse.',\n",
            "             'chemical2id': {'disulfiram': 'D004221'},\n",
            "             'disease2id': {'toxic hepatitis': 'D056486',\n",
            "                            'toxic liver damage': 'D056486'},\n",
            "             'relations': [{'chemical': 'D004221', 'disease': 'D056486'}],\n",
            "             'title': 'Toxic hepatitis induced by disulfiram in a '\n",
            "                      'non-alcoholic.'},\n",
            " '6517710': {'abstract': 'Quinacrine hydrochloride is toxic for the heart of '\n",
            "                         'F-344 rats. Rats treated with 500 ppm quinacrine '\n",
            "                         'hydrochloride in the diet all developed a high '\n",
            "                         'incidence of left atrial thrombosis. The lesion was '\n",
            "                         'associated with cardiac hypertrophy and dilatation '\n",
            "                         'and focal myocardial degeneration. Rats died from '\n",
            "                         'cardiac hypertrophy with severe acute and chronic '\n",
            "                         'congestion of the lungs, liver, and other organs. '\n",
            "                         'Seventy percent of rats given 250 ppm quinacrine '\n",
            "                         'hydrochloride and 1,000 ppm sodium nitrite '\n",
            "                         'simultaneously in the diet had thrombosis of the '\n",
            "                         'atria of the heart, while untreated control rats in '\n",
            "                         'this laboratory did not have atrial thrombosis. '\n",
            "                         'Sodium nitrite in combination with quinacrine '\n",
            "                         'hydrochloride appeared to have no additional '\n",
            "                         'effect.The important background information needed '\n",
            "                         'to understand this text is  the fact that quinacrine '\n",
            "                         'hydrochloride is a potent inhibitor of cytochrome '\n",
            "                         'P-450-dependent monooxygenase activity in vitro.',\n",
            "             'chemical2id': {'quinacrine hydrochloride': 'D011796',\n",
            "                             'sodium nitrite': 'D012977'},\n",
            "             'disease2id': {'atrial thrombosis': 'D003328',\n",
            "                            'cardiac hypertrophy': 'D006332',\n",
            "                            'myocardial degeneration': 'D009202',\n",
            "                            'thrombosis': 'D013927'},\n",
            "             'relations': [{'chemical': 'D011796', 'disease': 'D006332'},\n",
            "                           {'chemical': 'D011796', 'disease': 'D003328'}],\n",
            "             'title': 'Atrial thrombosis involving the heart of F-344 rats '\n",
            "                      'ingesting quinacrine hydrochloride.'},\n",
            " '6529939': {'abstract': 'Alternating sinus rhythm and intermittent sinoatrial '\n",
            "                         '(S-A) block was observed in a 57-year-old woman, '\n",
            "                         'under treatment for angina with 80 mg propranolol '\n",
            "                         'daily. The electrocardiogram showed alternation of '\n",
            "                         'long and short P-P intervals and occasional pauses. '\n",
            "                         'These pauses were always preceded by the short P-P '\n",
            "                         'intervals and were usually followed by one or two '\n",
            "                         'P-P intervals of 0.92-0.95 s representing the basic '\n",
            "                         'sinus cycle. Following these basic sinus cycles, '\n",
            "                         'alternating rhythm started with the longer P-P '\n",
            "                         'interval. The long P-P intervals ranged between '\n",
            "                         '1.04-1.12 s and the short P-P intervals between '\n",
            "                         '0.80-0.84 s, respectively. The duration of the '\n",
            "                         'pauses were equal or almost equal to one short plus '\n",
            "                         'one long P-P interval or to twice the basic sinus '\n",
            "                         'cycle. In one recording a short period of regular '\n",
            "                         'sinus rhythm with intermittent 2/1 S-A block was '\n",
            "                         'observed. This short period of sinus rhythm was '\n",
            "                         'interrupted by sudden prolongation of the P-P '\n",
            "                         'interval starting the alternative rhythm. There were '\n",
            "                         'small changes in the shape of the P waves and P-R '\n",
            "                         'intervals. S-A conduction through two pathways, the '\n",
            "                         'first with 2/1 block the second having 0.12-0.14 s '\n",
            "                         'longer conduction time and with occasional 2/1 block '\n",
            "                         'was proposed for the explanation of the alternating '\n",
            "                         'P-P interval and other electrocardiographic features '\n",
            "                         'seen. Atropine 1 mg given intravenously resulted in '\n",
            "                         'shortening of all P-P intervals without changing the '\n",
            "                         'rhythm. The abnormal rhythm disappeared with the '\n",
            "                         'withdrawal of propranolol and when the drug was '\n",
            "                         'restarted a 2/1 S-A block was seen. This was '\n",
            "                         'accepted as evidence for propranolol being the cause '\n",
            "                         'of this conduction disorder.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that the P-P interval is a function of the '\n",
            "                         'sinus cycle length and that the P-P interval is a '\n",
            "                         'function of the sinus cycle length.',\n",
            "             'chemical2id': {'atropine': 'D001285', 'propranolol': 'D011433'},\n",
            "             'disease2id': {'alternating rhythm': 'D001146',\n",
            "                            'alternating sinus rhythm': 'D001146',\n",
            "                            'angina': 'D000787',\n",
            "                            'conduction disorder': 'D019955',\n",
            "                            's-a block': 'D012848',\n",
            "                            'sinoatrial (s-a) block': 'D012848',\n",
            "                            'sinoatrial block': 'D012848'},\n",
            "             'relations': [{'chemical': 'D011433', 'disease': 'D012848'},\n",
            "                           {'chemical': 'D011433', 'disease': 'D001146'}],\n",
            "             'title': 'Alternating sinus rhythm and intermittent sinoatrial '\n",
            "                      'block induced by propranolol.'},\n",
            " '6585590': {'abstract': 'Antitumor activity, cardiotoxicity, and '\n",
            "                         'nephrotoxicity induced by doxorubicin were studied '\n",
            "                         'in LOU/M/WSL inbred rats each bearing a '\n",
            "                         'transplantable solid IgM immunocytoma. Animals with '\n",
            "                         'a tumor (diameter, 15.8 +/- 3.3 mm) were treated '\n",
            "                         'with iv injections of doxorubicin on 5 consecutive '\n",
            "                         'days, followed by 1 weekly injection for 7 weeks '\n",
            "                         '(dose range, 0.015-4.0 mg/kg body wt). Tumor '\n",
            "                         'regression was observed with 0.5 mg doxorubicin/kg. '\n",
            "                         'Complete disappearance of the tumor was induced with '\n",
            "                         '1.0 mg doxorubicin/kg. Histologic evidence of '\n",
            "                         'cardiotoxicity scored as grade III was only observed '\n",
            "                         'at a dose of 1.0 mg doxorubicin/kg. Light '\n",
            "                         'microscopic evidence of renal damage was seen above '\n",
            "                         'a dose of 0.5 mg doxorubicin/kg, which resulted in '\n",
            "                         'albuminuria and very low serum albumin levels. In '\n",
            "                         'the group that received 1.0 mg doxorubicin/kg, the '\n",
            "                         'serum albumin level decreased from 33.6 +/- 4.1 to '\n",
            "                         '1.5 +/- 0.5 g/liter. Ascites and hydrothorax were '\n",
            "                         'observed simultaneously. The same experiments were '\n",
            "                         'performed with non-tumor-bearing rats, in which no '\n",
            "                         'major differences were observed. In conclusion, '\n",
            "                         'antitumor activity, cardiotoxicity, and '\n",
            "                         'nephrotoxicity were studied simultaneously in the '\n",
            "                         'same LOU/M/WSL rat. Albuminuria due to renal damage '\n",
            "                         'led to extremely low serum albumin levels, so '\n",
            "                         'ascites and hydrothorax were not necessarily a '\n",
            "                         'consequence of the observed cardiomyopathy.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that the LOU / M / '\n",
            "                         'WSL rat is a model of human myeloma.',\n",
            "             'chemical2id': {'doxorubicin': 'D004317'},\n",
            "             'disease2id': {'albuminuria': 'D000419',\n",
            "                            'ascites': 'D001201',\n",
            "                            'cardiomyopathy': 'D009202',\n",
            "                            'cardiotoxicity': 'D066126',\n",
            "                            'hydrothorax': 'D006876',\n",
            "                            'immunocytoma': '-1',\n",
            "                            'nephrotoxicity': 'D007674',\n",
            "                            'renal damage': 'D007674',\n",
            "                            'tumor': 'D009369'},\n",
            "             'relations': [{'chemical': 'D004317', 'disease': 'D006876'},\n",
            "                           {'chemical': 'D004317', 'disease': 'D001201'},\n",
            "                           {'chemical': 'D004317', 'disease': 'D000419'}],\n",
            "             'title': 'Antitumor effect, cardiotoxicity, and nephrotoxicity of '\n",
            "                      'doxorubicin in the IgM solid immunocytoma-bearing '\n",
            "                      'LOU/M/WSL rat.'},\n",
            " '6615679': {'abstract': 'A 69-yr-old man, who was concurrently being treated '\n",
            "                         'with pilocarpine nitrate and timolol maleate eye '\n",
            "                         'drops, developed a bradycardia and became '\n",
            "                         'hypotensive during halothane anaesthesia. Both '\n",
            "                         'timolol and pilocarpine were subsequently identified '\n",
            "                         'in a 24-h collection of urine. Timolol (but not '\n",
            "                         'pilocarpine) was detected in a sample of plasma '\n",
            "                         'removed during surgery; the plasma concentration of '\n",
            "                         'timolol (2.6 ng ml-1) was consistent with partial '\n",
            "                         'beta-adrenoceptor blockade. It is postulated that '\n",
            "                         'this action may have been enhanced during halothane '\n",
            "                         'anaesthesia with resultant bradycardia and '\n",
            "                         'hypotension. Pilocarpine may have had a contributory '\n",
            "                         'effect.The important background information needed '\n",
            "                         'to understand this text is  the fact that the '\n",
            "                         'patient had been treated with pilocarpine for '\n",
            "                         'glaucoma and timolol for ocular hypertension.',\n",
            "             'chemical2id': {'halothane': 'D006221',\n",
            "                             'pilocarpine': 'D010862',\n",
            "                             'pilocarpine nitrate': 'D010862',\n",
            "                             'timolol': 'D013999',\n",
            "                             'timolol maleate': 'D013999'},\n",
            "             'disease2id': {'bradycardia': 'D001919',\n",
            "                            'hypotension': 'D007022',\n",
            "                            'hypotensive': 'D007022'},\n",
            "             'relations': [{'chemical': 'D013999', 'disease': 'D007022'},\n",
            "                           {'chemical': 'D010862', 'disease': 'D001919'},\n",
            "                           {'chemical': 'D010862', 'disease': 'D007022'},\n",
            "                           {'chemical': 'D013999', 'disease': 'D001919'}],\n",
            "             'title': 'Intraoperative bradycardia and hypotension associated '\n",
            "                      'with timolol and pilocarpine eye drops.'},\n",
            " '6627074': {'abstract': 'Anticholinesterases were administered in an attempt '\n",
            "                         'to antagonize prolonged neuromuscular blockade '\n",
            "                         'following the administration of succinylcholine in a '\n",
            "                         'patient later found to be homozygous for atypical '\n",
            "                         'plasma cholinesterase. Edrophonium 10 mg, given 74 '\n",
            "                         'min after succinylcholine, when train-of-four '\n",
            "                         'stimulation was characteristic of phase II block, '\n",
            "                         'produced partial antagonism which was not sustained. '\n",
            "                         'Repeated doses of edrophonium to 70 mg and '\n",
            "                         'neostigmine to 2.5 mg did not antagonize or augment '\n",
            "                         'the block. Spontaneous respiration recommenced 200 '\n",
            "                         'min after succinylcholine administration. It is '\n",
            "                         'concluded that anticholinesterases are only '\n",
            "                         'partially effective in restoring neuromuscular '\n",
            "                         'function in succinylcholine apnoea despite muscle '\n",
            "                         'twitch activity typical of phase II block.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that the patient '\n",
            "                         'was homozygous for atypical plasma cholinesterase.',\n",
            "             'chemical2id': {'edrophonium': 'D004491',\n",
            "                             'neostigmine': 'D009388',\n",
            "                             'succinylcholine': 'D013390'},\n",
            "             'disease2id': {'apnoea': 'D001049',\n",
            "                            'neuromuscular blockade': 'D020879'},\n",
            "             'relations': [{'chemical': 'D013390', 'disease': 'D001049'}],\n",
            "             'title': 'Succinylcholine apnoea: attempted reversal with '\n",
            "                      'anticholinesterases.'},\n",
            " '6631522': {'abstract': 'The effects of serial treatment with doxorubicin on '\n",
            "                         'dynamic myocardial scintigraphy with '\n",
            "                         '[omega-I-131]heptadecanoic acid (I-131 HA), and on '\n",
            "                         'global left-ventricular function determined '\n",
            "                         'echocardiographically, were studied in a group of '\n",
            "                         'nine mongrel dogs. Total extractable myocardial '\n",
            "                         'lipid was compared postmortem between a group of '\n",
            "                         'control dogs and doxorubicin-treated dogs. A '\n",
            "                         'significant and then progressive fall in global LV '\n",
            "                         'function was observed at a cumulative doxorubicin '\n",
            "                         'dose of 4 mg/kg. A significant increase in the '\n",
            "                         'myocardial t1/2 of the I-131 HA was observed only at '\n",
            "                         'a higher cumulative dose, 10 mg/kg. No significant '\n",
            "                         'alteration in total extractable myocardial lipids '\n",
            "                         'was observed between control dogs and those treated '\n",
            "                         'with doxorubicin. Our findings suggest that the '\n",
            "                         'changes leading to an alteration of myocardial '\n",
            "                         'dynamic imaging with I-131 HA are not the initiating '\n",
            "                         'factor in doxorubicin cardiotoxicity.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the myocardial lipid content '\n",
            "                         'of the dog heart is similar to that of man.',\n",
            "             'chemical2id': {'[omega-i-131]heptadecanoic acid': 'C013102',\n",
            "                             'doxorubicin': 'D004317',\n",
            "                             'i-131 ha': 'C013102'},\n",
            "             'disease2id': {'cardiotoxicity': 'D066126'},\n",
            "             'relations': [{'chemical': 'D004317', 'disease': 'D066126'}],\n",
            "             'title': 'Effect of doxorubicin on [omega-I-131]heptadecanoic '\n",
            "                      'acid myocardial scintigraphy and echocardiography in '\n",
            "                      'dogs.'},\n",
            " '6673474': {'abstract': 'Coronary blood flow, cardiac work and metabolism '\n",
            "                         'were studied in dogs under sodium nitroprusside '\n",
            "                         '(SNP) and trimetaphan (TMP) deliberate hypotension '\n",
            "                         '(20% and 40% mean pressure decrease from baseline). '\n",
            "                         'Regarding the effects of drug-induced hypotension on '\n",
            "                         'coronary blood flow, aortic and coronary sinus '\n",
            "                         'metabolic data (pH, pO2, pCO2) we could confirm that '\n",
            "                         'nitroprusside hypotension could be safely used to '\n",
            "                         '30% mean blood pressure decrease from control, '\n",
            "                         'trimetaphan hypotension to 20% mean blood pressure '\n",
            "                         'decrease. Cardiac work was significantly reduced '\n",
            "                         'during SNP hypotension. Myocardial O2 consumption '\n",
            "                         'and O2 availability were directly dependent on the '\n",
            "                         'coronary perfusion. Careful invasive monitoring of '\n",
            "                         'the blood pressure, blood gases and of the ECG ST-T '\n",
            "                         'segment is mandatory.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that the coronary blood flow is not a constant '\n",
            "                         'parameter and that the coronary blood flow is not a '\n",
            "                         'constant parameter.',\n",
            "             'chemical2id': {'nitroprusside': 'D009599',\n",
            "                             'o2': 'D010100',\n",
            "                             'snp': 'D009599',\n",
            "                             'sodium nitroprusside': 'D009599',\n",
            "                             'tmp': 'D014294',\n",
            "                             'trimetaphan': 'D014294'},\n",
            "             'disease2id': {'hypotension': 'D007022'},\n",
            "             'relations': [{'chemical': 'D014294', 'disease': 'D007022'},\n",
            "                           {'chemical': 'D009599', 'disease': 'D007022'}],\n",
            "             'title': 'Hemodynamics and myocardial metabolism under deliberate '\n",
            "                      'hypotension. An experimental study in dogs.'},\n",
            " '6687006': {'abstract': 'Male rats received the noradrenaline neurotoxin DSP4 '\n",
            "                         '(50 mg/kg) 7 days prior to injection of '\n",
            "                         'D-amphetamine (10 or 40 mumol/kg i.p.). The '\n",
            "                         'hyperactivity induced by D-amphetamine (10 mumol/kg) '\n",
            "                         'was significantly reduced by DSP4 pretreatment. '\n",
            "                         'However, the increased rearings and the '\n",
            "                         'amphetamine-induced stereotypies were not blocked by '\n",
            "                         'pretreatment with DSP4. The reduction of amphetamine '\n",
            "                         'hyperactivity induced by DSP4 was blocked by '\n",
            "                         'pretreatment with the noradrenaline-uptake blocking '\n",
            "                         'agent, desipramine, which prevents the neurotoxic '\n",
            "                         'action of DSP4. The present results suggest a '\n",
            "                         'selective involvement of central noradrenergic '\n",
            "                         'neurones in the locomotor stimulant effect of '\n",
            "                         'amphetamine in the rat.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that the noradrenaline neurotoxin DSP4 has been '\n",
            "                         'shown to produce a selective depletion of '\n",
            "                         'noradrenaline in the brain.',\n",
            "             'chemical2id': {'amphetamine': 'D000661',\n",
            "                             'd-amphetamine': 'D003913',\n",
            "                             'desipramine': 'D003891',\n",
            "                             'dsp4': 'C012102',\n",
            "                             'noradrenaline': 'D009638'},\n",
            "             'disease2id': {'hyperactivity': 'D006948',\n",
            "                            'neurotoxic': 'D020258',\n",
            "                            'stereotypies': 'D019956'},\n",
            "             'relations': [{'chemical': 'D003913', 'disease': 'D006948'}],\n",
            "             'title': 'Evidence for a selective brain noradrenergic '\n",
            "                      'involvement in the locomotor stimulant effects of '\n",
            "                      'amphetamine in the rat.'},\n",
            " '6695685': {'abstract': 'This study examined the frequency of '\n",
            "                         'atrioventricular (AV) dissociation and accelerated '\n",
            "                         'junctional rhythms in 59 patients receiving oral '\n",
            "                         'verapamil. Accelerated junctional rhythms and AV '\n",
            "                         'dissociation were frequent in patients with '\n",
            "                         'supraventricular tachyarrhythmias, particularly AV '\n",
            "                         'nodal reentry. Verapamil administration to these '\n",
            "                         'patients led to an asymptomatic increase in activity '\n",
            "                         'of these junctional pacemakers. In patients with '\n",
            "                         'various chest pain syndromes, verapamil neither '\n",
            "                         'increased the frequency of junctional rhythms nor '\n",
            "                         'suppressed their role as escape rhythms under '\n",
            "                         'physiologically appropriate circumstances.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that AV '\n",
            "                         'dissociation and accelerated junctional rhythms are '\n",
            "                         'not uncommon in patients receiving oral verapamil.',\n",
            "             'chemical2id': {'verapamil': 'D014700'},\n",
            "             'disease2id': {'accelerated junctional rhythms': 'D001145',\n",
            "                            'chest pain': 'D002637',\n",
            "                            'supraventricular tachyarrhythmias': 'D013617'},\n",
            "             'relations': [{'chemical': 'D014700', 'disease': 'D001145'}],\n",
            "             'title': 'Accelerated junctional rhythms during oral verapamil '\n",
            "                      'therapy.'},\n",
            " '6728873': {'abstract': 'Acute toxic dosage-dependent behavioral effects of '\n",
            "                         'caffeine were compared in adult males from seven '\n",
            "                         'inbred mouse strains (A/J, BALB/cJ, CBA/J, C3H/HeJ, '\n",
            "                         'C57BL/6J, DBA/2J, SWR/J). C57BL/6J, chosen as a '\n",
            "                         '\"prototypic\" mouse strain, was used to determine '\n",
            "                         'behavioral responses to a broad range (5-500 mg/kg) '\n",
            "                         'of caffeine doses. Five phenotypic '\n",
            "                         'characteristics--locomotor activity, righting '\n",
            "                         'ability, clonic seizure induction, stress-induced '\n",
            "                         'lethality, death without external stress--were '\n",
            "                         'scored at various caffeine doses in drug-naive '\n",
            "                         'animals under empirically optimized, rigidly '\n",
            "                         'constant experimental conditions. Mice (n = 12 for '\n",
            "                         'each point) received single IP injections of a fixed '\n",
            "                         'volume/g body weight of physiological saline carrier '\n",
            "                         'with or without caffeine in doses ranging from '\n",
            "                         '125-500 mg/kg. Loss of righting ability was scored '\n",
            "                         'at 1, 3, 5 min post dosing and at 5 min intervals '\n",
            "                         'thereafter for 20 min. In the same animals the '\n",
            "                         'occurrence of clonic seizures was scored as to time '\n",
            "                         'of onset and severity for 20 min after drug '\n",
            "                         'administration. When these proceeded to tonic '\n",
            "                         'seizures, death occurred in less than 20 min. '\n",
            "                         'Animals surviving for 20 min were immediately '\n",
            "                         'stressed by a swim test in 25 degrees C water, and '\n",
            "                         'death-producing tonic seizures were scored for 2 '\n",
            "                         'min. In other animals locomotor activity was '\n",
            "                         'measured 15 or 60 min after caffeine administration. '\n",
            "                         'By any single behavioral criterion or a combination '\n",
            "                         'of these criteria, marked differences in response to '\n",
            "                         'toxic caffeine doses were observed between strains. '\n",
            "                         'These results indicate that behavioral toxicity '\n",
            "                         'testing of alkylxanthines in a single mouse strain '\n",
            "                         'may be misleading and suggest that toxic responses '\n",
            "                         'of the central nervous system to this class of '\n",
            "                         'compounds are genetically influenced in mammals.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the genetic basis of the '\n",
            "                         'behavioral responses to caffeine.',\n",
            "             'chemical2id': {'alkylxanthines': '-1', 'caffeine': 'D002110'},\n",
            "             'disease2id': {'clonic seizure': 'D012640',\n",
            "                            'clonic seizures': 'D012640',\n",
            "                            'tonic seizures': 'D012640',\n",
            "                            'toxicity': 'D064420'},\n",
            "             'relations': [{'chemical': 'D002110', 'disease': 'D012640'}],\n",
            "             'title': 'Interstrain variation in acute toxic response to '\n",
            "                      'caffeine among inbred mice.'},\n",
            " '6806735': {'abstract': 'During the last 2 1/2 years, 38 patients with '\n",
            "                         'ovarian cancer were treated with a combination of '\n",
            "                         'cisplatinum (CPDD), 50 mg/m2, adriamycin, 30 mg/m2, '\n",
            "                         'cyclophosphamide, 300 mg/m2, on day 1; and '\n",
            "                         'hexamethylmelamine (HMM), 6 mg/kg daily, for 14 '\n",
            "                         'days. Each course was repeated monthly. 2 patients '\n",
            "                         'had stage II, 14 stage III and 22 stage IV disease. '\n",
            "                         '14 of the 38 patients were previously treated with '\n",
            "                         'chemotherapy, 1 with radiation, 6 with both '\n",
            "                         'chemotherapy and radiation, and 17 did not have any '\n",
            "                         'treatment before CPDD combination. 31 of the 38 '\n",
            "                         'cases (81.5%) demonstrated objective responses '\n",
            "                         'lasting for 2 months or more. These responses were '\n",
            "                         'partial in 19 and complete in 12 cases. Hematologic '\n",
            "                         'toxicity was moderate and with reversible anemia '\n",
            "                         'developing in 71% of patients. Gastrointestinal side '\n",
            "                         'effects from CPDD were universal. HMM '\n",
            "                         'gastrointestinal toxicity necessitated '\n",
            "                         'discontinuation of the drug in 5 patients. Severe '\n",
            "                         'nephrotoxicity was observed in 2 patients but was '\n",
            "                         'reversible. There were no drug-related deaths.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that the '\n",
            "                         'combination of CPDD and HMM is active in ovarian '\n",
            "                         'cancer and that the combination is well tolerated.',\n",
            "             'chemical2id': {'adriamycin': 'D004317',\n",
            "                             'cis-platinum': 'D002945',\n",
            "                             'cisplatinum': 'D002945',\n",
            "                             'cpdd': 'C034868',\n",
            "                             'cyclophosphamide': 'D003520',\n",
            "                             'hexamethylmelamine': 'D006585',\n",
            "                             'hmm': 'D006585'},\n",
            "             'disease2id': {'anemia': 'D000740',\n",
            "                            'gastrointestinal toxicity': 'D005767',\n",
            "                            'hematologic toxicity': 'D006402',\n",
            "                            'nephrotoxicity': 'D007674',\n",
            "                            'ovarian cancer': 'D010051'},\n",
            "             'relations': [{'chemical': 'C034868', 'disease': 'D000740'},\n",
            "                           {'chemical': 'C034868', 'disease': 'D007674'},\n",
            "                           {'chemical': 'C034868', 'disease': 'D005767'}],\n",
            "             'title': 'Treatment of ovarian cancer with a combination of '\n",
            "                      'cis-platinum, adriamycin, cyclophosphamide and '\n",
            "                      'hexamethylmelamine.'},\n",
            " '6884395': {'abstract': 'A case of nontraumatic dissecting aneurysm of the '\n",
            "                         'basilar artery in association with hypertension, '\n",
            "                         'smoke, and oral contraceptives is reported in a '\n",
            "                         'young female patient with a locked-in syndrome.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the rarity of this '\n",
            "                         'condition and the lack of a clear pathogenesis.',\n",
            "             'chemical2id': {'oral contraceptives': 'D003276'},\n",
            "             'disease2id': {'dissecting aneurysm': 'D000784',\n",
            "                            'hypertension': 'D006973',\n",
            "                            'locked-in syndrome': 'D011782'},\n",
            "             'relations': [{'chemical': 'D003276', 'disease': 'D000784'}],\n",
            "             'title': 'Nontraumatic dissecting aneurysm of the basilar '\n",
            "                      'artery.'},\n",
            " '689020': {'abstract': 'A method permitting measurement of finger tremor as a '\n",
            "                        'displacement-time curve is described, using a test '\n",
            "                        'system with simple amplitude calibration. The '\n",
            "                        'coordinates of the inversion points of the '\n",
            "                        'displacement-time curves were transferred through '\n",
            "                        'graphical input equipment to punched tape. By means '\n",
            "                        'of a computer program, periods and amplitudes of '\n",
            "                        'tremor oscillations were calculated and classified. '\n",
            "                        'The event frequency for each class of periods and '\n",
            "                        'amplitudes was determined. The actions of '\n",
            "                        'fenoterol-hydrobromide, ritodrin-HCl and placebo '\n",
            "                        'given to 10 healthy subjects by intravenous infusion '\n",
            "                        'in a double-blind crossover study were tested by this '\n",
            "                        'method. At therapeutic doses both substances raised '\n",
            "                        'the mean tremor amplitude to about three times the '\n",
            "                        'control level. At the same time, the mean period '\n",
            "                        'within each class of amplitudes shortened by 10--20 '\n",
            "                        'ms, whereas the mean periods calculated from all '\n",
            "                        'oscillations together did not change significantly. '\n",
            "                        'After the end of fenoterol-hydrobromide infusion, '\n",
            "                        'tremor amplitudes decreased significantly faster than '\n",
            "                        'those following ritodrin-HCl infusion.The important '\n",
            "                        'background information needed to understand this text '\n",
            "                        'is  the fact that the tremor amplitude is a function '\n",
            "                        'of the frequency of the oscillations.',\n",
            "            'chemical2id': {'fenoterol-hydrobromide': 'D005280',\n",
            "                            'ritodrin-hcl': 'D012312'},\n",
            "            'disease2id': {'tremor': 'D014202'},\n",
            "            'relations': [{'chemical': 'D005280', 'disease': 'D014202'},\n",
            "                          {'chemical': 'D012312', 'disease': 'D014202'}],\n",
            "            'title': 'A method for the measurement of tremor, and a comparison '\n",
            "                     'of the effects of tocolytic beta-mimetics.'},\n",
            " '6893265': {'abstract': 'Two cases of propylthiouracil-induced liver damage '\n",
            "                         'have been observed. The first case is of an acute '\n",
            "                         'type of damage, proven by rechallenge; the second '\n",
            "                         'presents a clinical and histologic picture '\n",
            "                         'resembling chronic active hepatitis, with '\n",
            "                         'spontaneous remission.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that the drug is a thyroid-blocking agent, and '\n",
            "                         'that the liver damage is due to the drug itself.',\n",
            "             'chemical2id': {'propylthiouracil': 'D011441'},\n",
            "             'disease2id': {'chronic active hepatitis': 'D006521',\n",
            "                            'hepatic damage': 'D056486',\n",
            "                            'liver damage': 'D056486'},\n",
            "             'relations': [{'chemical': 'D011441', 'disease': 'D006521'},\n",
            "                           {'chemical': 'D011441', 'disease': 'D056486'}],\n",
            "             'title': 'Propylthiouracil-induced hepatic damage.'},\n",
            " '6985297': {'abstract': 'Bepridil, a novel active compound for prophylactic '\n",
            "                         'treatment of anginal attacks, induced persistent '\n",
            "                         'bradycardia and a non-specific anti-tachycardial '\n",
            "                         'effect, the mechanisms of which were investigated in '\n",
            "                         'vitro and in vivo. In vitro perfusion of bepridil in '\n",
            "                         'the life-support medium for isolated sino-atrial '\n",
            "                         'tissue from rabbit heart, caused a reduction in '\n",
            "                         'action potential (AP) spike frequency (recorded by '\n",
            "                         'KCl microelectrodes) starting at doses of 5 X 10(-6) '\n",
            "                         'M. This effect was dose-dependent up to '\n",
            "                         'concentrations of 5 X 10(-5) M, whereupon blockade '\n",
            "                         'of sinus activity set in. Bepridil at a dose of 5 X '\n",
            "                         '10(-6) M, induced a concomitant reduction in AP '\n",
            "                         'amplitude (falling from 71 +/- 8 mV to 47 +/- 6 mV), '\n",
            "                         'maximum systolic depolarization velocity (phase 0) '\n",
            "                         'which fell from 1.85 +/- 0.35 V/s to 0.84 +/- 0.28 '\n",
            "                         'V/s, together with maximum diastolic depolarization '\n",
            "                         'velocity (phase 4) which fell from 38 +/- 3 mV/s to '\n",
            "                         '24 +/- 5 mV/s. In vivo injection of bepridil at a '\n",
            "                         'dose of 5 mg/kg (i.v.) into 6 anaesthetized dogs '\n",
            "                         'which had undergone ablation of all the extrinsic '\n",
            "                         'cardiac afferent nerve supply, together with a '\n",
            "                         'bilateral medullo-adrenalectomy, caused a marked '\n",
            "                         'reduction in heart rate which fell from 98.7 +/- 4.2 '\n",
            "                         'beats/min to 76 +/- 5.3 beats/min sustained for more '\n",
            "                         'than 45 min. It is concluded that bepridil reduces '\n",
            "                         'heart rate by acting directly on the sinus node. '\n",
            "                         'This effect, which results in a flattening of the '\n",
            "                         'phase 0 and phase 4 slope, together with a longer AP '\n",
            "                         'duration, may be due to an increase in the time '\n",
            "                         'constants of slow inward ionic currents (already '\n",
            "                         'demonstrated elsewhere), but also to an increased '\n",
            "                         'time constant for deactivation of the outward '\n",
            "                         'potassium current (Ip).The important background '\n",
            "                         'information needed to understand this text is  that '\n",
            "                         'the drug is a potent inhibitor of the slow inward '\n",
            "                         'calcium current (ICa) in the sino-atrial node, and '\n",
            "                         'that the drug has no effect on the fast inward '\n",
            "                         'sodium current (INa).',\n",
            "             'chemical2id': {'bepridil': 'D015764',\n",
            "                             'kcl': 'D011189',\n",
            "                             'potassium': 'D011188'},\n",
            "             'disease2id': {'anginal attacks': 'D000787',\n",
            "                            'bradycardia': 'D001919',\n",
            "                            'tachycardial': 'D013610'},\n",
            "             'relations': [{'chemical': 'D015764', 'disease': 'D001919'}],\n",
            "             'title': 'Studies on the bradycardia induced by bepridil.'},\n",
            " '6985498': {'abstract': 'A 69-year-old man operated for acute cholecystitis '\n",
            "                         'under methoxyflurane anesthesia developed '\n",
            "                         'postoperatively a hepatic insufficiency syndrome and '\n",
            "                         'renal tubular acidosis. Massive bleeding appeared '\n",
            "                         'during surgery which lasted for six hours. '\n",
            "                         'Postoperative evolution under supportive therapy was '\n",
            "                         'favourable. Complete recovery was confirmed by '\n",
            "                         'repeated controls performed over a period of one '\n",
            "                         'year after surgery.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that the patient had been treated with '\n",
            "                         'methoxyflurane for a long time and that the hepatic '\n",
            "                         'insufficiency syndrome was probably due to the '\n",
            "                         'anesthetic agent.',\n",
            "             'chemical2id': {'methoxyflurane': 'D008733'},\n",
            "             'disease2id': {'acute cholecystitis': 'D041881',\n",
            "                            'bleeding': 'D006470',\n",
            "                            'hepatic insufficiency syndrome': 'D048550',\n",
            "                            'hepatitis': 'D056486',\n",
            "                            'renal tubular acidosis': 'D000141'},\n",
            "             'relations': [{'chemical': 'D008733', 'disease': 'D000141'},\n",
            "                           {'chemical': 'D008733', 'disease': 'D056486'}],\n",
            "             'title': 'Hepatitis and renal tubular acidosis after anesthesia '\n",
            "                      'with methoxyflurane.'},\n",
            " '7018927': {'abstract': 'The effects of a 6-hour infusion with haloperidol on '\n",
            "                         'serum prolactin and luteinizing hormone (LH) levels '\n",
            "                         'was studied in a group of male subjects. Five hours '\n",
            "                         'after starting the infusions, a study of the '\n",
            "                         'pituitary responses to LH-releasing hormone (LH-RH) '\n",
            "                         'was carried out. Control patients received infusions '\n",
            "                         'of 0.9% NaCl solution. During the course of '\n",
            "                         'haloperidol infusions, significant '\n",
            "                         'hyperprolactinemia was found, together with an '\n",
            "                         'abolished pituitary response to LH-RH, as compared '\n",
            "                         'with responses of control subjects.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the prolactin response to '\n",
            "                         'LH-RH was not abolished by haloperidol, and that the '\n",
            "                         'prolactin response to LH-RH was not abolished by '\n",
            "                         'haloperidol in the same subjects.',\n",
            "             'chemical2id': {'haloperidol': 'D006220', 'nacl': 'D012965'},\n",
            "             'disease2id': {'hyperprolactinemia': 'D006966'},\n",
            "             'relations': [{'chemical': 'D006220', 'disease': 'D006966'}],\n",
            "             'title': 'Pituitary response to luteinizing hormone-releasing '\n",
            "                      'hormone during haloperidol-induced hyperprolactinemia.'},\n",
            " '7121659': {'abstract': '5 patients with acute renal failure (3 with '\n",
            "                         'thrombopenia and hemolysis) induced by the '\n",
            "                         'reintroduction of rifampicin are described. No '\n",
            "                         'correlation was found between the severity of '\n",
            "                         'clinical manifestations and the total dose taken by '\n",
            "                         'the patients. In all but 1 patient, antirifampicin '\n",
            "                         'antibodies were detected. Antibodies suggested to be '\n",
            "                         'of the IgM class were detected in all 3 patients '\n",
            "                         'with hematological disorders. The pattern of '\n",
            "                         'non-specific acute tubular necrosis found in the 2 '\n",
            "                         'biopsied patients, indistinguishable from that of '\n",
            "                         'ischemic origin, raised the possibility of a '\n",
            "                         'vascular-mediated damage. In 3 patients, the '\n",
            "                         'possibility of a triggering immunoallergic mechanism '\n",
            "                         'is discussed.The important background information '\n",
            "                         'needed to understand this text is  the fact that the '\n",
            "                         'drug was given for a long time and that the patients '\n",
            "                         'were not previously exposed to other drugs.',\n",
            "             'chemical2id': {'rifampicin': 'D012293'},\n",
            "             'disease2id': {'acute renal failure': 'D058186',\n",
            "                            'acute tubular necrosis': 'D007683',\n",
            "                            'hematological disorders': 'D006402',\n",
            "                            'hemolysis': 'D006461',\n",
            "                            'renal failure': 'D051437',\n",
            "                            'thrombopenia': 'D013921'},\n",
            "             'relations': [{'chemical': 'D012293', 'disease': 'D006461'},\n",
            "                           {'chemical': 'D012293', 'disease': 'D013921'},\n",
            "                           {'chemical': 'D012293', 'disease': 'D007683'}],\n",
            "             'title': 'Antirifampicin antibodies in acute '\n",
            "                      'rifampicin-associated renal failure.'},\n",
            " '7147232': {'abstract': 'Adenosine triphosphate (ATP) and sodium '\n",
            "                         'nitroprusside (SNP) are administered to patients to '\n",
            "                         'induce and control hypotension during anesthesia. '\n",
            "                         'SNP is authorized for clinical use in USA and UK, '\n",
            "                         'and ATP is clinically used in other countries such '\n",
            "                         'as Japan. We investigated how these two drugs act on '\n",
            "                         'the cardiovascular systems of 20 dogs whose hearts '\n",
            "                         'had been denervated by a procedure we had devised. '\n",
            "                         'ATP (10 dogs) or SNP (10 dogs) was administered to '\n",
            "                         'reduce mean arterial pressure by 30% to 70% of '\n",
            "                         'control. Before, during and after induced '\n",
            "                         'hypotension, we measured major cardiovascular '\n",
            "                         'parameters. Hypotension induced by ATP was '\n",
            "                         'accompanied by significant decreases in mean '\n",
            "                         'pulmonary arterial pressure (p less than 0.001), '\n",
            "                         'central venous pressure (p less than 0.001), left '\n",
            "                         'ventricular end-diastolic pressure (p less than '\n",
            "                         '0.001), total peripheral resistance (p less than '\n",
            "                         '0.001), rate pressure product (p less than 0.001), '\n",
            "                         'total body oxygen consumption (p less than 0.05), '\n",
            "                         'and heart rate (p less than 0.001); all these '\n",
            "                         'variables returned normal within 30 min after ATP '\n",
            "                         'was stopped. Cardiac output did not change. During '\n",
            "                         'hypotension produced by SNP similar decreases were '\n",
            "                         'observed in mean pulmonary arterial pressure (p less '\n",
            "                         'than 0.01), central venous pressure (p less than '\n",
            "                         '0.001), left ventricular end-diastolic pressure (p '\n",
            "                         'less than 0.01), total peripheral resistance (p less '\n",
            "                         'than 0.001), rate pressure product (p less than '\n",
            "                         '0.001), and oxygen content difference between '\n",
            "                         'arterial and mixed venous blood (p less than 0.05), '\n",
            "                         'while heart rate (p less than 0.001) and cardiac '\n",
            "                         'output (p less than 0.05) were increased. Recoveries '\n",
            "                         'of heart rate and left ventricular end-diastolic '\n",
            "                         'pressure were not shown within 60 min after SNP had '\n",
            "                         'been stopped. Both ATP and SNP should act on the '\n",
            "                         'pacemaker tissue of the heart.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  that the effects of ATP and SNP on the '\n",
            "                         'cardiovascular system are not identical.',\n",
            "             'chemical2id': {'adenosine triphosphate': 'D000255',\n",
            "                             'atp': 'D000255',\n",
            "                             'oxygen': 'D010100',\n",
            "                             'snp': 'D009599',\n",
            "                             'sodium nitroprusside': 'D009599'},\n",
            "             'disease2id': {'hypotension': 'D007022'},\n",
            "             'relations': [{'chemical': 'D009599', 'disease': 'D007022'},\n",
            "                           {'chemical': 'D000255', 'disease': 'D007022'}],\n",
            "             'title': 'Cardiovascular effects of hypotension induced by '\n",
            "                      'adenosine triphosphate and sodium nitroprusside on dogs '\n",
            "                      'with denervated hearts.'},\n",
            " '7173007': {'abstract': 'Side effects of hysterosalpingography with Dimer-X, '\n",
            "                         'Hexabrix, Vasurix polyvidone and Endografine in 142 '\n",
            "                         'consecutive patients, receiving one of the four '\n",
            "                         'tested media were evaluated from replies to postal '\n",
            "                         'questionnaires. The Dimer-X group had a higher '\n",
            "                         'incidence of nausea and dizziness. The Endografine '\n",
            "                         'group had a higher incidence of abdominal pain. '\n",
            "                         'These differences occur especially in the age groups '\n",
            "                         'under 30 years. Hexabrix and Vasurix polyvidone are '\n",
            "                         'considered the best contrast media for '\n",
            "                         'hysterosalpingography and perhaps because of its low '\n",
            "                         'toxicity Hexabrix should be preferred.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the media used in this study '\n",
            "                         'were not identical.',\n",
            "             'chemical2id': {'acetrizoate': 'D000100',\n",
            "                             'contrast media': 'D003287',\n",
            "                             'diatrizoate': 'D003973',\n",
            "                             'dimer-x': 'C025504',\n",
            "                             'endografine': 'C006753',\n",
            "                             'hexabrix': 'D007485',\n",
            "                             'iocarmate': 'C025504',\n",
            "                             'ioxaglate': 'D007485',\n",
            "                             'vasurix polyvidone': 'D000100'},\n",
            "             'disease2id': {'abdominal pain': 'D015746',\n",
            "                            'dizziness': 'D004244',\n",
            "                            'nausea': 'D009325',\n",
            "                            'toxicity': 'D064420'},\n",
            "             'relations': [{'chemical': 'C006753', 'disease': 'D015746'},\n",
            "                           {'chemical': 'C025504', 'disease': 'D004244'},\n",
            "                           {'chemical': 'C025504', 'disease': 'D009325'}],\n",
            "             'title': 'Comparative study: Endografine (diatrizoate), Vasurix '\n",
            "                      'polyvidone (acetrizoate), Dimer-X (iocarmate) and '\n",
            "                      'Hexabrix (ioxaglate) in hysterosalpingography.'},\n",
            " '7176945': {'abstract': 'Contrary to an earlier report by Coxon, scoline pain '\n",
            "                         'occurs in African negroes. Its incidence was '\n",
            "                         'determined in a prospective study involving a total '\n",
            "                         'of 100 Nigerian patients (50 out-patients and 50 '\n",
            "                         'in-patients). About 62% of the out-patients '\n",
            "                         'developed scoline pain as compared with about 26% '\n",
            "                         'among the in-patients. The abolition of muscle '\n",
            "                         'fasciculations (by 0.075mg/kg dose of Fazadinium) '\n",
            "                         'did not influence the occurrence of scoline pain. '\n",
            "                         'Neither the type of induction agent (Althesin or '\n",
            "                         'Thiopentone) nor the salt preparation of '\n",
            "                         'suxamethonium used (chloride or bromide), affected '\n",
            "                         'the incidence of scoline pain.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the incidence of scoline pain '\n",
            "                         'in Nigeria is higher than that reported in the '\n",
            "                         'literature.',\n",
            "             'chemical2id': {'althesin': 'D000530',\n",
            "                             'bromide': 'D001965',\n",
            "                             'chloride': 'D002712',\n",
            "                             'fazadinium': 'C084773',\n",
            "                             'scoline': 'D013390',\n",
            "                             'suxamethonium': 'D013390',\n",
            "                             'thiopentone': 'D013874'},\n",
            "             'disease2id': {'fasciculations': 'D005207',\n",
            "                            'pain': 'D010146',\n",
            "                            'pains': 'D010146'},\n",
            "             'relations': [{'chemical': 'D013390', 'disease': 'D005207'},\n",
            "                           {'chemical': 'D013390', 'disease': 'D010146'}],\n",
            "             'title': 'Post-suxamethonium pains in Nigerian surgical '\n",
            "                      'patients.'},\n",
            " '7248895': {'abstract': 'A 47-year-old woman with right hydroureteronephrosis '\n",
            "                         'due to ureterovesical junction obstruction had gross '\n",
            "                         'hematuria after being treated for five years wtih '\n",
            "                         'cyclophosphamide for cerebral vasculitis. A right '\n",
            "                         'nephroureterectomy was required for control of '\n",
            "                         'bleeding. The pathology specimen contained '\n",
            "                         'clinically occult invasive carcinoma of the renal '\n",
            "                         'pelvis. Although the ability of cyclophosphamide to '\n",
            "                         'cause hemorrhagic cystitis and urine cytologic '\n",
            "                         'abnormalities indistinguishable from high grade '\n",
            "                         'carcinoma is well known, it is less widely '\n",
            "                         'appreciated that it is also associated with '\n",
            "                         'carcinoma of the urinary tract. Twenty carcinomas of '\n",
            "                         'the urinary bladder and one carcinoma of the '\n",
            "                         'prostate have been reported in association with its '\n",
            "                         'use. The present case is the first carcinoma of the '\n",
            "                         'renal pelvis reported in association with '\n",
            "                         'cyclophosphamide treatment. It is the third urinary '\n",
            "                         'tract cancer reported in association with '\n",
            "                         'cyclophosphamide treatment for nonmalignant disease. '\n",
            "                         'The association of the tumor with preexisting '\n",
            "                         'hydroureteronephrosis suggests that stasis prolonged '\n",
            "                         'and intensified exposure of upper urinary tract '\n",
            "                         'epithelium to cyclophosphamide. Patients who are '\n",
            "                         'candidates for long-term cyclophosphamide treatment '\n",
            "                         'should be routinely evaluated for obstructive '\n",
            "                         'uropathy.The important background information needed '\n",
            "                         'to understand this text is  the fact that the '\n",
            "                         'incidence of cyclophosphamide-associated bladder '\n",
            "                         'cancer is low.',\n",
            "             'chemical2id': {'cyclophosphamide': 'D003520'},\n",
            "             'disease2id': {'bleeding': 'D006470',\n",
            "                            'carcinoma': 'D002277',\n",
            "                            'carcinoma of the prostate': 'D011471',\n",
            "                            'carcinoma of the renal pelvis': 'D010386',\n",
            "                            'carcinoma of the urinary tract': 'D014571',\n",
            "                            'carcinomas of the urinary bladder': 'D001749',\n",
            "                            'cerebral vasculitis': 'D020293',\n",
            "                            'cystitis': 'D003556',\n",
            "                            'hematuria': 'D006417',\n",
            "                            'hemorrhagic': 'D006470',\n",
            "                            'hydroureteronephrosis': 'D006869',\n",
            "                            'obstructive uropathy': '-1',\n",
            "                            'tumor': 'D009369',\n",
            "                            'urinary tract cancer': 'D014571'},\n",
            "             'relations': [{'chemical': 'D003520', 'disease': 'D006417'},\n",
            "                           {'chemical': 'D003520', 'disease': 'D002277'},\n",
            "                           {'chemical': 'D003520', 'disease': 'D001749'}],\n",
            "             'title': 'Invasive carcinoma of the renal pelvis following '\n",
            "                      'cyclophosphamide therapy for nonmalignant disease.'},\n",
            " '7315949': {'abstract': 'In normal rats, the media of small arteries '\n",
            "                         '(0.4--0.2 mm in diameter) previously was shown to '\n",
            "                         'contain intracellular vacuoles, identified '\n",
            "                         'ultrastructurally as herniations of one smooth '\n",
            "                         'muscle cell into another. The hypothesis that '\n",
            "                         'intense vasoconstriction would increase the number '\n",
            "                         'of such vacuoles has been tested. In the media of '\n",
            "                         'the saphenous artery and its distal branch, '\n",
            "                         'vasoconstriction induced by L-norepinephrine '\n",
            "                         'produced many cell-to-cell hernias within 15 '\n",
            "                         'minutes. At 1 day their number was reduced to about '\n",
            "                         '1/10 of the original number. By 7 days the vessel '\n",
            "                         'was almost restored to normal. Triple stimulation '\n",
            "                         'over 1 day induced more severe changes in the media. '\n",
            "                         'These findings suggest that smooth muscle cells are '\n",
            "                         'susceptible to damage in the course of their '\n",
            "                         'specific function. The experimental data are '\n",
            "                         'discussed in relation to medial changes observed in '\n",
            "                         'other instances of arterial spasm. Endothelial '\n",
            "                         'changes that developed in the same experimental '\n",
            "                         'model were described in a previous paper.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  that the changes in the '\n",
            "                         'media of the saphenous artery were not due to the '\n",
            "                         'action of L-norepinephrine but to the contraction of '\n",
            "                         'the smooth muscle cells.',\n",
            "             'chemical2id': {'l-norepinephrine': 'D009638'},\n",
            "             'disease2id': {'hernias': 'D006547', 'spasm': 'D013035'},\n",
            "             'relations': [{'chemical': 'D009638', 'disease': 'D013035'}],\n",
            "             'title': 'Medial changes in arterial spasm induced by '\n",
            "                      'L-norepinephrine.'},\n",
            " '733189': {'abstract': 'Two well-documented cases of bilateral retinal artery '\n",
            "                        'and choriocapillaris occlusions with blindness '\n",
            "                        'following head and neck soft-tissue injection with '\n",
            "                        'methylprednisolone acetate in combination with '\n",
            "                        'lidocaine, epinephrine, or penicillin are reported. '\n",
            "                        'One case had only a unilateral injection. The acute '\n",
            "                        'observations included hazy sensorium, superior gaze '\n",
            "                        'palsy, pupillary abnormalities, and conjunctival '\n",
            "                        'hemorrhages with edema. Follow-up changes showed '\n",
            "                        'marked visual loss, constricted visual fields, optic '\n",
            "                        'nerve pallor, vascular attenuation, and chorioretinal '\n",
            "                        'atrophy. The literature is reviewed, and possible '\n",
            "                        'causes are discussed.The important background '\n",
            "                        'information needed to understand this text is  the '\n",
            "                        'mechanism of action of the injection, the clinical '\n",
            "                        'presentation, and the possible complications.',\n",
            "            'chemical2id': {'corticosteroid': 'D000305',\n",
            "                            'epinephrine': 'D004837',\n",
            "                            'lidocaine': 'D008012',\n",
            "                            'methylprednisolone acetate': 'C000873',\n",
            "                            'penicillin': 'D010406'},\n",
            "            'disease2id': {'blindness': 'D001766',\n",
            "                           'chorioretinal atrophy': 'C566236',\n",
            "                           'edema': 'D004487',\n",
            "                           'hemorrhages': 'D006470',\n",
            "                           'palsy': 'D010243',\n",
            "                           'pupillary abnormalities': 'D011681',\n",
            "                           'retinal artery and choriocapillaris occlusion': 'D015356',\n",
            "                           'retinal artery and choriocapillaris occlusions': 'D015356',\n",
            "                           'visual loss': 'D014786'},\n",
            "            'relations': [{'chemical': 'C000873', 'disease': 'D015356'}],\n",
            "            'title': 'Bilateral retinal artery and choriocapillaris occlusion '\n",
            "                     'following the injection of long-acting corticosteroid '\n",
            "                     'suspensions in combination with other drugs: I. Clinical '\n",
            "                     'studies.'},\n",
            " '7369302': {'abstract': 'Total blindness with a transient tonic pupillary '\n",
            "                         'response, denervation supersensitivity, and abnormal '\n",
            "                         'visual-evoked potentials developed in a 54-year-old '\n",
            "                         'man after the use of quinine sulfate for leg cramps. '\n",
            "                         'He later recovered normal visual acuity. A transient '\n",
            "                         'tonic pupillary response, denervation '\n",
            "                         'supersensitivity, and abnormal visual-evoked '\n",
            "                         'potentials in quinine toxicity, to our knowledge, '\n",
            "                         'have not been previously reported.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that quinine is a widely used drug '\n",
            "                         'in the United States.',\n",
            "             'chemical2id': {'quinine': 'D011803',\n",
            "                             'quinine sulfate': 'D011803'},\n",
            "             'disease2id': {'amblyopia': 'D000550',\n",
            "                            'blindness': 'D001766',\n",
            "                            'leg cramps': 'D009120',\n",
            "                            'tonic pupillary': 'D015845',\n",
            "                            'toxicity': 'D064420'},\n",
            "             'relations': [{'chemical': 'D011803', 'disease': 'D015845'},\n",
            "                           {'chemical': 'D011803', 'disease': 'D000550'},\n",
            "                           {'chemical': 'D011803', 'disease': 'D001766'}],\n",
            "             'title': 'Abnormalities of the pupil and visual-evoked potential '\n",
            "                      'in quinine amblyopia.'},\n",
            " '7378868': {'abstract': 'An 11-year-old boy was given halothane, nitrous '\n",
            "                         'oxide and oxygen, pancuronium 0.4 mg and '\n",
            "                         'suxamethonium 100 mg for induction of anaesthesia. '\n",
            "                         'In response to this a marked jaw stiffness occurred '\n",
            "                         'which lasted for two minutes and the anaesthesia '\n",
            "                         'were terminated. Four hours of apnoea ensued and he '\n",
            "                         'suffered generalized severe myalgia lasting for one '\n",
            "                         'week. He was found to have atypical plasma '\n",
            "                         'cholinesterase with a dibucaine number of 12, '\n",
            "                         'indicating homozygocity. This was verified by study '\n",
            "                         'of the family. The case shows that prolonged jaw '\n",
            "                         'rigidity and myalgia may occur after suxamethonium '\n",
            "                         'in patients with atypical cholinesterase despite '\n",
            "                         'pretreatment with pancuronium.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the patient was a young boy '\n",
            "                         'and the diagnosis was made only after the patient '\n",
            "                         'had been given suxamethonium.',\n",
            "             'chemical2id': {'dibucaine': 'D003992',\n",
            "                             'halothane': 'D006221',\n",
            "                             'nitrous oxide': 'D009609',\n",
            "                             'oxygen': 'D010100',\n",
            "                             'pancuronium': 'D010197',\n",
            "                             'suxamethonium': 'D013390'},\n",
            "             'disease2id': {'apnoea': 'D001049',\n",
            "                            'jaw stiffness': 'D014313',\n",
            "                            'myalgia': 'D063806',\n",
            "                            'prolonged jaw rigidity': 'D014313'},\n",
            "             'relations': [{'chemical': 'D013390', 'disease': 'D014313'},\n",
            "                           {'chemical': 'D013390', 'disease': 'D001049'},\n",
            "                           {'chemical': 'D013390', 'disease': 'D063806'}],\n",
            "             'title': 'Suxamethonium-induced jaw stiffness and myalgia '\n",
            "                      'associated with atypical cholinesterase: case report.'},\n",
            " '7411769': {'abstract': 'We describe three patients in whom severe, '\n",
            "                         'life-threatening hyperkalemia and renal '\n",
            "                         'insufficiency developed after treatment of acute '\n",
            "                         'gouty arthritis with indomethacin. This complication '\n",
            "                         'may result from an inhibition of prostaglandin '\n",
            "                         'synthesis and consequent hyporeninemic '\n",
            "                         'hypoaidosteronism. Careful attention to renal '\n",
            "                         'function and potassium balance in patients receiving '\n",
            "                         'indomethacin or other nonsteroidal anti-inflammatory '\n",
            "                         'agents, particularly in those patients with diabetes '\n",
            "                         'mellitus or preexisting renal disease, will help '\n",
            "                         'prevent this potentially serious complication.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the case reports of three '\n",
            "                         'patients who developed severe, life-threatening '\n",
            "                         'hyperkalemia and renal insufficiency after treatment '\n",
            "                         'with indomethacin.',\n",
            "             'chemical2id': {'indomethacin': 'D007213',\n",
            "                             'potassium': 'D011188',\n",
            "                             'prostaglandin': 'D011453'},\n",
            "             'disease2id': {'diabetes mellitus': 'D003920',\n",
            "                            'gouty arthritis': 'D015210',\n",
            "                            'hyperkalemia': 'D006947',\n",
            "                            'hyporeninemic hypoaidosteronism': 'D006994',\n",
            "                            'renal disease': 'D007674',\n",
            "                            'renal insufficiency': 'D051437'},\n",
            "             'relations': [{'chemical': 'D007213', 'disease': 'D006947'},\n",
            "                           {'chemical': 'D007213', 'disease': 'D051437'}],\n",
            "             'title': 'Indomethacin-induced hyperkalemia in three patients '\n",
            "                      'with gouty arthritis.'},\n",
            " '7457821': {'abstract': 'A clinical evaluation of etomidate for outpatient '\n",
            "                         'cystoscopy was embarked upon. Unpremedicated '\n",
            "                         'patients were given fentanyl 1 microgram/kg followed '\n",
            "                         'by etomidate 0.3 mg/kg. Anaesthesia was maintained '\n",
            "                         'with intermittent etomidate in 2-4 mg doses. '\n",
            "                         'Patients were interviewed personally later the same '\n",
            "                         'day, and by questionnaire three to four weeks later. '\n",
            "                         'The trial was discontinued after 20 cases because of '\n",
            "                         'an unacceptable incidence of side effects. Venous '\n",
            "                         'pain occurred in 68% of patients and 50% had '\n",
            "                         'redness, pain or swelling related to the injection '\n",
            "                         'site, in some cases lasting up to three weeks after '\n",
            "                         'anaesthesia. Skeletal movements occurred in 50% of '\n",
            "                         'patients; 30% experienced respiratory upset, one '\n",
            "                         'sufficiently severe to necessitate abandoning the '\n",
            "                         'technique. Nausea and vomiting occurred in 40% and '\n",
            "                         '25% had disturbing emergence psychoses.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that etomidate is a potent '\n",
            "                         'hypnotic, but its use in outpatient cystoscopy is '\n",
            "                         'not without risk.',\n",
            "             'chemical2id': {'etomidate': 'D005045', 'fentanyl': 'D005283'},\n",
            "             'disease2id': {'nausea': 'D009325',\n",
            "                            'pain': 'D010146',\n",
            "                            'psychoses': 'D011605',\n",
            "                            'respiratory upset': 'D012140',\n",
            "                            'swelling': 'D004487',\n",
            "                            'vomiting': 'D014839'},\n",
            "             'relations': [{'chemical': 'D005045', 'disease': 'D009325'},\n",
            "                           {'chemical': 'D005045', 'disease': 'D014839'},\n",
            "                           {'chemical': 'D005045', 'disease': 'D010146'},\n",
            "                           {'chemical': 'D005045', 'disease': 'D012140'},\n",
            "                           {'chemical': 'D005045', 'disease': 'D011605'}],\n",
            "             'title': 'Etomidate: a foreshortened clinical trial.'},\n",
            " '7477981': {'abstract': 'We evaluated the severity of motor disability and '\n",
            "                         'dyskinesias in seven levodopa-responsive patients '\n",
            "                         \"with Parkinson's disease after an acute challenge \"\n",
            "                         'with the mixed dopamine agonist, apomorphine, before '\n",
            "                         'and after the administration of fluoxetine (20 mg '\n",
            "                         'twice per day) for 11 +/- 1 days. After fluoxetine '\n",
            "                         'treatment, there was a significant 47% improvement '\n",
            "                         '(p < 0.05) of apomorphine-induced dyskinesias '\n",
            "                         'without modification of parkinsonian motor '\n",
            "                         'disability. The dyskinesias were reduced '\n",
            "                         'predominantly in the lower limbs during the onset '\n",
            "                         'and disappearance of dystonic dyskinesias (onset- '\n",
            "                         'and end-of-dose dyskinesias) and in the upper limbs '\n",
            "                         'during choreic mid-dose dyskinesias. The results '\n",
            "                         'suggest that increased brain serotoninergic '\n",
            "                         'transmission with fluoxetine may reduce levodopa- or '\n",
            "                         'dopamine agonist-induced dyskinesias without '\n",
            "                         'aggravating parkinsonian motor disability.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that fluoxetine is '\n",
            "                         'a selective serotonin reuptake inhibitor (SSRI) and '\n",
            "                         'that it is a well-known inhibitor of serotonin '\n",
            "                         'reuptake.',\n",
            "             'chemical2id': {'apomorphine': 'D001058',\n",
            "                             'dopamine': 'D004298',\n",
            "                             'fluoxetine': 'D005473',\n",
            "                             'levodopa': 'D007980'},\n",
            "             'disease2id': {'choreic': 'D002819',\n",
            "                            'dyskinesias': 'D004409',\n",
            "                            'dystonic': 'D020821',\n",
            "                            'mid-dose dyskinesias': 'D004409',\n",
            "                            'motor disability': 'D009069',\n",
            "                            \"parkinson's disease\": 'D010300',\n",
            "                            'parkinsonian': 'D010300'},\n",
            "             'relations': [{'chemical': 'D001058', 'disease': 'D004409'},\n",
            "                           {'chemical': 'D005473', 'disease': 'D004409'}],\n",
            "             'title': 'Levodopa-induced dyskinesias are improved by '\n",
            "                      'fluoxetine.'},\n",
            " '7479194': {'abstract': 'We conducted a population-based 45-day follow-up '\n",
            "                         'study of 232,390 people who were prescribed '\n",
            "                         'trimethoprim-sulfamethoxazole (TMP-SMZ), 266,951 '\n",
            "                         'prescribed trimethoprim alone, and 196,397 '\n",
            "                         'prescribed cephalexin, to estimate the risk of '\n",
            "                         'serious liver, blood, skin, and renal disorders '\n",
            "                         'resulting in referral or hospitalization associated '\n",
            "                         'with these drugs. The results were based on '\n",
            "                         'information recorded on office computers by selected '\n",
            "                         'general practitioners in the United Kingdom, '\n",
            "                         'together with a review of clinical records. The risk '\n",
            "                         'of clinically important idiopathic liver disease was '\n",
            "                         'similar for persons prescribed TMP-SMZ (5.2/100,000) '\n",
            "                         'and those prescribed trimethoprim alone '\n",
            "                         '(3.8/100,000). The risk for those prescribed '\n",
            "                         'cephalexin was somewhat lower (2.0/100,000). Only '\n",
            "                         'five patients experienced blood disorders, one of '\n",
            "                         'whom was exposed to TMP-SMZ; of seven with erythema '\n",
            "                         'multiforme and Stevens-Johnson syndrome, four were '\n",
            "                         'exposed to TMP-SMZ. The one case of toxic epidermal '\n",
            "                         'necrolysis occurred in a patient who took '\n",
            "                         'cephalexin. Finally, only five cases of acute '\n",
            "                         'parenchymal renal disease occurred, none likely to '\n",
            "                         'be caused by a study drug. We conclude that the risk '\n",
            "                         'of the serious diseases studied is small for the '\n",
            "                         'three agents, and compares reasonably with the risk '\n",
            "                         'for many other antibiotics.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that the risk of serious liver disease is not '\n",
            "                         'increased by the use of TMP-SMZ.',\n",
            "             'chemical2id': {'cephalexin': 'D002506',\n",
            "                             'tmp-smz': 'D015662',\n",
            "                             'trimethoprim': 'D014295',\n",
            "                             'trimethoprim-sulfamethoxazole': 'D015662'},\n",
            "             'disease2id': {'blood disorders': 'D006402',\n",
            "                            'drug toxicity': 'D064420',\n",
            "                            'erythema multiforme': 'D004892',\n",
            "                            'liver disease': 'D008107',\n",
            "                            'liver disorders': 'D008107',\n",
            "                            'renal disease': 'D007674',\n",
            "                            'renal disorders': 'D007674',\n",
            "                            'skin disorders': 'D012871',\n",
            "                            'stevens-johnson syndrome': 'D013262',\n",
            "                            'toxic epidermal necrolysis': 'D013262'},\n",
            "             'relations': [{'chemical': 'D014295', 'disease': 'D008107'},\n",
            "                           {'chemical': 'D015662', 'disease': 'D008107'},\n",
            "                           {'chemical': 'D002506', 'disease': 'D008107'},\n",
            "                           {'chemical': 'D002506', 'disease': 'D013262'},\n",
            "                           {'chemical': 'D015662', 'disease': 'D013262'}],\n",
            "             'title': 'A large population-based follow-up study of '\n",
            "                      'trimethoprim-sulfamethoxazole, trimethoprim, and '\n",
            "                      'cephalexin for uncommon serious drug toxicity.'},\n",
            " '7492040': {'abstract': 'STUDY OBJECTIVE: To evaluate the safety of lidocaine '\n",
            "                         'in the setting of cocaine-induced myocardial '\n",
            "                         'infarction (MI). DESIGN: A retrospective, '\n",
            "                         'multicenter study. SETTING: Twenty-nine university, '\n",
            "                         'university-affiliated, or community hospitals during '\n",
            "                         'a 6-year period (total of 117 cumulative '\n",
            "                         'hospital-years). PARTICIPANTS: Patients with '\n",
            "                         'cocaine-associated MI who received lidocaine in the '\n",
            "                         'emergency department. RESULTS: Of 29 patients who '\n",
            "                         'received lidocaine in the setting of '\n",
            "                         'cocaine-associated MI, no patient died; exhibited '\n",
            "                         'bradydysrhythmias, ventricular tachycardia, or '\n",
            "                         'ventricular fibrillation; or experienced seizures '\n",
            "                         'after administration of lidocaine (95% confidence '\n",
            "                         'interval, 0% to 11%). CONCLUSION: Despite '\n",
            "                         'theoretical concerns that lidocaine may enhance '\n",
            "                         'cocaine toxicity, the use of lidocaine in patients '\n",
            "                         'with cocaine-associated MI was not associated with '\n",
            "                         'significant cardiovascular or central nervous system '\n",
            "                         'toxicity.The important background information needed '\n",
            "                         'to understand this text is  the lack of a large, '\n",
            "                         'prospective, randomized trial to evaluate the safety '\n",
            "                         'of lidocaine in the setting of cocaine-associated '\n",
            "                         'MI.',\n",
            "             'chemical2id': {'cocaine': 'D003042', 'lidocaine': 'D008012'},\n",
            "             'disease2id': {'bradydysrhythmias': 'D001919',\n",
            "                            'cardiovascular toxicity': 'D002318',\n",
            "                            'central nervous system toxicity': 'D002493',\n",
            "                            'mi': 'D009203',\n",
            "                            'myocardial infarction': 'D009203',\n",
            "                            'seizures': 'D012640',\n",
            "                            'toxicity': 'D064420',\n",
            "                            'ventricular fibrillation': 'D014693',\n",
            "                            'ventricular tachycardia': 'D017180'},\n",
            "             'relations': [{'chemical': 'D003042', 'disease': 'D009203'}],\n",
            "             'title': 'Clinical safety of lidocaine in patients with '\n",
            "                      'cocaine-associated myocardial infarction.'},\n",
            " '753803': {'abstract': 'We are still a long way from discovering an '\n",
            "                        'unequivocal pathogenetic interpretation of '\n",
            "                        'progressive muscular dystrophy in man. Noteworthy '\n",
            "                        'efforts have been made in the experimental field; a '\n",
            "                        'recessive autosomic form found in the mouse seems to '\n",
            "                        'bear the closest resemblance to the human form from '\n",
            "                        'the genetic point of view. Myopathy due to lack of '\n",
            "                        'vitamin E and myopathy induced by certain viruses '\n",
            "                        'have much in common anatomically and pathologically '\n",
            "                        'with the human form. The authors induced myodystrophy '\n",
            "                        'in the rat by giving it a diet lacking in vitamin E. '\n",
            "                        'The pharmacological characteristics of vitamin E and '\n",
            "                        'the degenerative changes brought about by its '\n",
            "                        'deficiency, especially in the muscles, are '\n",
            "                        'illustrated. It is thus confirmed that the '\n",
            "                        'histological characteristics of myopathic rat muscle '\n",
            "                        'induced experimentally are extraordinarily similar to '\n",
            "                        'those of human myopathy as confirmed during biopsies '\n",
            "                        'performed at the Orthopaedic Traumatological Centre, '\n",
            "                        'Florence. The encouraging results obtained in various '\n",
            "                        'authoratative departments in myopathic patients by '\n",
            "                        'using anabolizing steroids have encouraged the '\n",
            "                        'authors to investigate the beneficial effects of one '\n",
            "                        'anabolizing agent (Dianabol, CIBA) at high doses in '\n",
            "                        'rats rendered myopathic by a diet deficient in '\n",
            "                        'vitamin E. In this way they obtained appreciable '\n",
            "                        'changes in body weight (increased from 50 to 70 g '\n",
            "                        'after forty days at a dose of 5 mg per day of '\n",
            "                        'anabolizing agent), but most of all they found '\n",
            "                        'histological changes due to \"regenerative\" changes in '\n",
            "                        'the muscle tissue, which however maintained its '\n",
            "                        'myopathic characteristics in the control animals that '\n",
            "                        'were not treated with the anabolizing agent. The '\n",
            "                        'authors conclude by affirming the undoubted efficacy '\n",
            "                        'of the anabolizing steroids in experimental myopathic '\n",
            "                        'disease, but they have reservations as to the '\n",
            "                        'transfer of the results into the human field, where '\n",
            "                        'high dosage cannot be carried out continuously '\n",
            "                        'because of the effects of the drug on virility; '\n",
            "                        'because the tissue injury too often occurs at an '\n",
            "                        'irreversible stage vis-a-vis the \"regeneration\" of '\n",
            "                        'the muscle tissue; and finally because the dystrophic '\n",
            "                        'injurious agent is certainly not the lack of vitamin '\n",
            "                        'E but something as yet unknown.The important '\n",
            "                        'background information needed to understand this text '\n",
            "                        'is  the fact that the human disease is a progressive '\n",
            "                        'muscular dystrophy, and that the experimental model '\n",
            "                        'is a progressive muscular dystrophy in the rat.',\n",
            "            'chemical2id': {'ciba': '-1',\n",
            "                            'dianabol': 'D008696',\n",
            "                            'steroids': 'D013256',\n",
            "                            'vitamin e': 'D014810'},\n",
            "            'disease2id': {'muscular dystrophy': 'D009136',\n",
            "                           'myodystrophy': 'D009136',\n",
            "                           'myopathic': 'D009135',\n",
            "                           'myopathic disease': 'D009135',\n",
            "                           'myopathy': 'D009135'},\n",
            "            'relations': [{'chemical': 'D008696', 'disease': 'D009136'},\n",
            "                          {'chemical': 'D014810', 'disease': 'D009136'}],\n",
            "            'title': 'Experimental progressive muscular dystrophy and its '\n",
            "                     'treatment with high doses anabolizing agents.'},\n",
            " '7644931': {'abstract': 'Paclitaxel (Taxol; Bristol-Myers Squibb Company, '\n",
            "                         'Princeton, NJ) by 3-hour infusion was combined with '\n",
            "                         'carboplatin in a phase I/II study directed to '\n",
            "                         'patients with non-small cell lung cancer. '\n",
            "                         'Carboplatin was given at a fixed target area under '\n",
            "                         'the concentration-time curve of 6.0 by the Calvert '\n",
            "                         'formula, whereas paclitaxel was escalated in patient '\n",
            "                         'cohorts from 150 mg/m2 (dose level I) to 175, 200, '\n",
            "                         '225, and 250 mg/m2. The 225 mg/m2 level was expanded '\n",
            "                         'for the phase II study since the highest level '\n",
            "                         'achieved (250 mg/m2) required modification because '\n",
            "                         'of nonhematologic toxicities (arthralgia and sensory '\n",
            "                         'neuropathy). Therapeutic effects were noted at all '\n",
            "                         'dose levels, with objective responses in 17 (two '\n",
            "                         'complete and 15 partial regressions) of 41 '\n",
            "                         'previously untreated patients. Toxicities were '\n",
            "                         'compared with a cohort of patients in a phase I '\n",
            "                         'trial of paclitaxel alone at identical dose levels. '\n",
            "                         'Carboplatin did not appear to add to the hematologic '\n",
            "                         'toxicities observed, and the paclitaxel/carboplatin '\n",
            "                         'combination could be dosed every 3 weeks.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the results of the phase I '\n",
            "                         '/ II study.',\n",
            "             'chemical2id': {'carboplatin': 'D016190',\n",
            "                             'paclitaxel': 'D017239',\n",
            "                             'taxol': 'D017239'},\n",
            "             'disease2id': {'arthralgia': 'D018771',\n",
            "                            'hematologic toxicities': 'D006402',\n",
            "                            'non-small cell lung cancer': 'D002289',\n",
            "                            'sensory neuropathy': 'D012678',\n",
            "                            'toxicities': 'D064420'},\n",
            "             'relations': [{'chemical': 'D017239', 'disease': 'D012678'},\n",
            "                           {'chemical': 'D017239', 'disease': 'D006402'},\n",
            "                           {'chemical': 'D017239', 'disease': 'D018771'}],\n",
            "             'title': 'Paclitaxel 3-hour infusion given alone and combined '\n",
            "                      'with carboplatin: preliminary results of '\n",
            "                      'dose-escalation trials.'},\n",
            " '7661171': {'abstract': 'Misoprostol (200 micrograms) has been shown to '\n",
            "                         'acutely counteract the indomethacin-induced renal '\n",
            "                         'dysfunction in well compensated cirrhotic patients. '\n",
            "                         'The aim of this study was to determine if the '\n",
            "                         'prophylactic value of misoprostol was '\n",
            "                         'dose-dependent. Parameters of renal hemodynamics and '\n",
            "                         'tubular sodium and water handling were assessed by '\n",
            "                         'clearance techniques in 26 well compensated '\n",
            "                         'cirrhotic patients before and after an oral '\n",
            "                         'combination of 50 mg of indomethacin and various '\n",
            "                         'doses of misoprostol. The 200-micrograms dose was '\n",
            "                         'able to totally abolish the deleterious renal '\n",
            "                         'effects of indomethacin, whereas the 800-micrograms '\n",
            "                         'dose resulted in significant worsening of renal '\n",
            "                         'hemodynamics and sodium retention. These changes '\n",
            "                         'were maximal in the hour immediately after '\n",
            "                         'medications and slowly returned toward base-line '\n",
            "                         'levels thereafter. These results suggest that the '\n",
            "                         'renal protective effects of misoprostol is '\n",
            "                         'dose-dependent. However, until this apparent ability '\n",
            "                         'of 200 micrograms of misoprostol to prevent the '\n",
            "                         'adverse effects of indomethacin on renal function is '\n",
            "                         'confirmed with chronic frequent dosing, it would be '\n",
            "                         'prudent to avoid nonsteroidal anti-inflammatory '\n",
            "                         'therapy in patients with cirrhosis.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the renal effects of '\n",
            "                         'indomethacin are mediated by prostaglandin synthesis '\n",
            "                         'inhibition.',\n",
            "             'chemical2id': {'indomethacin': 'D007213',\n",
            "                             'misoprostol': 'D016595',\n",
            "                             'sodium': 'D012964'},\n",
            "             'disease2id': {'cirrhosis': 'D005355',\n",
            "                            'cirrhotic': 'D005355',\n",
            "                            'renal dysfunction': 'D007674'},\n",
            "             'relations': [{'chemical': 'D007213', 'disease': 'D007674'}],\n",
            "             'title': 'The dose-dependent effect of misoprostol on '\n",
            "                      'indomethacin-induced renal dysfunction in well '\n",
            "                      'compensated cirrhosis.'},\n",
            " '7671401': {'abstract': 'Adverse reactions to drugs are well recognized as a '\n",
            "                         'cause of acute or chronic urticaria, and '\n",
            "                         'angio-oedema. Angiotensin-converting enzyme (ACE) '\n",
            "                         'inhibitors, used to treat hypertension and '\n",
            "                         'congestive heart failure, were introduced in Europe '\n",
            "                         'in the middle of the eighties, and the use of these '\n",
            "                         'drugs has increased progressively. Soon after the '\n",
            "                         'introduction of ACE inhibitors, acute bouts of '\n",
            "                         'angio-oedema were reported in association with the '\n",
            "                         'use of these drugs. We wish to draw attention to the '\n",
            "                         'possibility of adverse reactions to ACE inhibitors '\n",
            "                         'after long-term use and in patients with '\n",
            "                         'pre-existing angio-oedema.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that ACE inhibitors are not only effective in '\n",
            "                         'the treatment of hypertension and congestive heart '\n",
            "                         'failure, but also in the treatment of chronic '\n",
            "                         'obstructive pulmonary disease, angina pectoris, and '\n",
            "                         'chronic renal failure.',\n",
            "             'chemical2id': {'ace inhibitors': 'D000806',\n",
            "                             'angiotensin-converting enzyme (ace) inhibitors': 'D000806',\n",
            "                             'angiotensin-converting enzyme inhibitor': 'D000806'},\n",
            "             'disease2id': {'angio-oedema': 'D000799',\n",
            "                            'congestive heart failure': 'D006333',\n",
            "                            'hypertension': 'D006973',\n",
            "                            'urticaria': 'D014581'},\n",
            "             'relations': [{'chemical': 'D000806', 'disease': 'D000799'}],\n",
            "             'title': 'Increased frequency and severity of angio-oedema '\n",
            "                      'related to long-term therapy with '\n",
            "                      'angiotensin-converting enzyme inhibitor in two '\n",
            "                      'patients.'},\n",
            " '7727612': {'abstract': 'Lorazepam is being used with increasing frequency as '\n",
            "                         'a sedative in the newborn and the young infant. '\n",
            "                         'Concern has been raised with regard to the safety of '\n",
            "                         'lorazepam in this age group, especially in '\n",
            "                         'very-low-birth-weight (VLBW; < 1,500 g) infants. '\n",
            "                         'Three young infants, all of birth weight < 1,500 g, '\n",
            "                         'experienced myoclonus following the intravenous '\n",
            "                         'administration of lorazepam. The potential '\n",
            "                         'neurotoxic effects of the drug (and its vehicle) in '\n",
            "                         'this population are discussed. Injectable lorazepam '\n",
            "                         'should be used with caution in VLBW infants.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the lack of information on '\n",
            "                         'the pharmacokinetics of lorazepam in the young '\n",
            "                         'infant.',\n",
            "             'chemical2id': {'lorazepam': 'D008140'},\n",
            "             'disease2id': {'myoclonus': 'D009207', 'neurotoxic': 'D020258'},\n",
            "             'relations': [{'chemical': 'D008140', 'disease': 'D009207'}],\n",
            "             'title': 'Myoclonus associated with lorazepam therapy in '\n",
            "                      'very-low-birth-weight infants.'},\n",
            " '7739955': {'abstract': 'We describe the cardiopulmonary resuscitation '\n",
            "                         'efforts on five patients who presented in acute '\n",
            "                         'circulatory failure from myocardial dysfunction. '\n",
            "                         'Three patients had acute viral myocarditis, one had '\n",
            "                         'a carbamazepine-induced acute eosinophilic '\n",
            "                         'myocarditis, and one had cardiac hemosiderosis '\n",
            "                         'resulting in acute cardiogenic shock. All patients '\n",
            "                         'were continuously monitored with central venous and '\n",
            "                         'arterial catheters in addition to routine '\n",
            "                         'noninvasive monitoring. An introducer sheath, a '\n",
            "                         'pacemaker, and sterile pacing wires were made '\n",
            "                         'readily available for the patients, should the need '\n",
            "                         'arise to terminate resistant cardiac dysrhythmias. '\n",
            "                         'All patients developed cardiocirculatory arrest '\n",
            "                         'associated with extreme hypotension and dysrhythmias '\n",
            "                         'within the first 48 hours of their admission to the '\n",
            "                         'pediatric intensive care unit (PICU). Right '\n",
            "                         'ventricular pacemaker wires were inserted in all of '\n",
            "                         'them during cardiopulmonary resuscitation (CPR). In '\n",
            "                         'four patients, cardiac pacing was used, resulting in '\n",
            "                         'a temporary captured rhythm and restoration of their '\n",
            "                         'cardiac output. These patients had a second event of '\n",
            "                         'cardiac arrest, resulting in death, within 10 to 60 '\n",
            "                         'minutes. In one patient, cardiac pacing was not '\n",
            "                         'used, because he converted to normal sinus rhythm by '\n",
            "                         'electrical defibrillation within three minutes of '\n",
            "                         'initiating CPR. We conclude that cardiac pacing '\n",
            "                         'during resuscitative efforts in pediatric patients '\n",
            "                         'suffering from acute myocardial dysfunction may not '\n",
            "                         'have long-term value in and of itself; however, if '\n",
            "                         'temporary hemodynamic stability is achieved by this '\n",
            "                         'procedure, it may provide additional time needed to '\n",
            "                         'institute other therapeutic modalities.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the need to understand the pathophysiology '\n",
            "                         'of the cardiac dysrhythmias and the need to use the '\n",
            "                         'appropriate monitoring techniques to ensure that the '\n",
            "                         'patient is receiving the appropriate therapy.',\n",
            "             'chemical2id': {'carbamazepine': 'D002220'},\n",
            "             'disease2id': {'cardiac arrest': 'D006323',\n",
            "                            'cardiogenic shock': 'D012770',\n",
            "                            'cardiomyopathy': 'D009202',\n",
            "                            'circulatory failure': 'D012769',\n",
            "                            'dysrhythmias': 'D001145',\n",
            "                            'eosinophilic': 'D004802',\n",
            "                            'hypotension': 'D007022',\n",
            "                            'myocardial dysfunction': 'D009202',\n",
            "                            'myocarditis': 'D009205'},\n",
            "             'relations': [{'chemical': 'D002220', 'disease': 'D004802'},\n",
            "                           {'chemical': 'D002220', 'disease': 'D009205'}],\n",
            "             'title': 'Transvenous right ventricular pacing during '\n",
            "                      'cardiopulmonary resuscitation of pediatric patients '\n",
            "                      'with acute cardiomyopathy.'},\n",
            " '7931490': {'abstract': 'PURPOSE: To assess the antiemetic effects and safety '\n",
            "                         'profile of four different doses of granisetron '\n",
            "                         '(Kytril; SmithKline Beecham Pharmaceuticals, '\n",
            "                         'Philadelphia, PA) when administered as a single '\n",
            "                         'intravenous (IV) dose for prophylaxis of '\n",
            "                         'cisplatin-induced nausea and vomiting. PATIENTS AND '\n",
            "                         'METHODS: One hundred eighty-four chemotherapy-naive '\n",
            "                         'patients receiving high-dose cisplatin (81 to 120 '\n",
            "                         'mg/m2) were randomized to receive one of four '\n",
            "                         'granisetron doses (5, 10, 20, or 40 micrograms/kg) '\n",
            "                         'administered before chemotherapy. Patients were '\n",
            "                         'observed on an inpatient basis for 18 to 24 hours, '\n",
            "                         'and vital signs, nausea, vomiting, retching, and '\n",
            "                         'appetite were assessed. Safety analyses included '\n",
            "                         'incidence of adverse experiences and laboratory '\n",
            "                         'parameter changes. RESULTS: After granisetron doses '\n",
            "                         'of 5, 10, 20, and 40 micrograms/kg, a major response '\n",
            "                         '(< or = two vomiting or retching episodes, and no '\n",
            "                         'antiemetic rescue) was recorded in 23%, 57%, 58%, '\n",
            "                         'and 60% of patients, respectively, and a complete '\n",
            "                         'response (no vomiting or retching, and no antiemetic '\n",
            "                         'rescue) in 18%, 41%, 40%, and 47% of patients, '\n",
            "                         'respectively. There was a statistically longer time '\n",
            "                         'to first episode of nausea (P = .0015) and vomiting '\n",
            "                         '(P = .0001), and fewer patients were administered '\n",
            "                         'additional antiemetic medication in the '\n",
            "                         '10-micrograms/kg dosing groups than in the '\n",
            "                         '5-micrograms/kg dosing group. As granisetron dose '\n",
            "                         'increased, appetite return increased (P = .040). '\n",
            "                         'Headache was the most frequently reported adverse '\n",
            "                         'event (20%). CONCLUSION: A single 10-, 20-, or '\n",
            "                         '40-micrograms/kg dose of granisetron was effective '\n",
            "                         'in controlling vomiting in 57% to 60% of patients '\n",
            "                         'who received cisplatin at doses greater than 81 '\n",
            "                         'mg/m2 and totally prevented vomiting in 40% to 47% '\n",
            "                         'of patients. There were no statistically significant '\n",
            "                         'differences in efficacy between the 10-micrograms/kg '\n",
            "                         'dose and the 20- and 40-micrograms/kg doses. '\n",
            "                         'Granisetron was well tolerated at all doses.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the results of this study.',\n",
            "             'chemical2id': {'5-hydroxytryptamine': 'D012701',\n",
            "                             'cisplatin': 'D002945',\n",
            "                             'granisetron': 'D017829',\n",
            "                             'kytril': 'D017829'},\n",
            "             'disease2id': {'headache': 'D006261',\n",
            "                            'nausea': 'D009325',\n",
            "                            'vomiting': 'D014839'},\n",
            "             'relations': [{'chemical': 'D002945', 'disease': 'D014839'},\n",
            "                           {'chemical': 'D017829', 'disease': 'D006261'},\n",
            "                           {'chemical': 'D002945', 'disease': 'D009325'}],\n",
            "             'title': 'Efficacy and safety of granisetron, a selective '\n",
            "                      '5-hydroxytryptamine-3 receptor antagonist, in the '\n",
            "                      'prevention of nausea and vomiting induced by high-dose '\n",
            "                      'cisplatin.'},\n",
            " '7949506': {'abstract': 'OBJECTIVE: To report two cases of a possible adverse '\n",
            "                         'interaction between clonidine and verapamil '\n",
            "                         'resulting in atrioventricular (AV) block in both '\n",
            "                         'patients and severe hypotension in one patient. CASE '\n",
            "                         'SUMMARIES: A 54-year-old woman with '\n",
            "                         'hyperaldosteronism was treated with verapamil 480 '\n",
            "                         'mg/d and spironolactone 100 mg/d. After the addition '\n",
            "                         'of a minimal dose of clonidine (0.15 mg bid), she '\n",
            "                         'developed complete AV block and severe hypotension, '\n",
            "                         'which resolved upon cessation of all medications. A '\n",
            "                         '65-year-old woman was treated with extended-release '\n",
            "                         'verapamil 240 mg/d. After the addition of clonidine '\n",
            "                         '0.15 mg bid she developed complete AV block, which '\n",
            "                         'resolved after all therapy was stopped. DISCUSSION: '\n",
            "                         'An adverse interaction between clonidine and '\n",
            "                         'verapamil has not been reported previously. We '\n",
            "                         'describe two such cases and discuss the various '\n",
            "                         'mechanisms that might cause such an interaction. '\n",
            "                         'Clinicians should be acquainted with this possibly '\n",
            "                         'fatal interaction between two commonly used '\n",
            "                         'antihypertensive drugs. CONCLUSIONS: Caution is '\n",
            "                         'recommended in combining clonidine and verapamil '\n",
            "                         'therapy, even in patients who do not have sinus or '\n",
            "                         'AV node dysfunction. The two drugs may act '\n",
            "                         'synergistically on both the AV node and the '\n",
            "                         'peripheral circulation.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that the two drugs are structurally similar and '\n",
            "                         'that they are both metabolized by the same '\n",
            "                         'cytochrome P450 enzyme system.',\n",
            "             'chemical2id': {'clonidine': 'D003000',\n",
            "                             'spironolactone': 'D013148',\n",
            "                             'verapamil': 'D014700'},\n",
            "             'disease2id': {'atrioventricular (av) block': 'D054537',\n",
            "                            'av block': 'D054537',\n",
            "                            'hyperaldosteronism': 'D006929',\n",
            "                            'hypotension': 'D007022'},\n",
            "             'relations': [{'chemical': 'D014700', 'disease': 'D007022'},\n",
            "                           {'chemical': 'D014700', 'disease': 'D054537'},\n",
            "                           {'chemical': 'D003000', 'disease': 'D054537'},\n",
            "                           {'chemical': 'D003000', 'disease': 'D007022'}],\n",
            "             'title': 'Adverse interaction between clonidine and verapamil.'},\n",
            " '7967231': {'abstract': 'S-312, S-312-d, but not S-312-l, L-type calcium '\n",
            "                         'channel antagonists, showed anticonvulsant effects '\n",
            "                         'on the audiogenic tonic convulsions in DBA/2 mice; '\n",
            "                         'and their ED50 values were 18.4 (12.8-27.1) mg/kg, '\n",
            "                         'p.o. and 15.0 (10.2-23.7) mg/kg, p.o., respectively, '\n",
            "                         'while that of flunarizine was 34.0 (26.0-44.8) '\n",
            "                         'mg/kg, p.o. Although moderate anticonvulsant effects '\n",
            "                         'of S-312-d in higher doses were observed against the '\n",
            "                         'clonic convulsions induced by pentylenetetrazole (85 '\n",
            "                         'mg/kg, s.c.) or bemegride (40 mg/kg, s.c.), no '\n",
            "                         'effects were observed in convulsions induced by '\n",
            "                         'N-methyl-D-aspartate, picrotoxin, or electroshock in '\n",
            "                         'Slc:ddY mice. S-312-d may be useful in the therapy '\n",
            "                         'of certain types of human epilepsy.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the anticonvulsant effects of '\n",
            "                         'S-312-d were not observed in the audiogenic seizure '\n",
            "                         'test in DBA / 2 mice, and that the anticonvulsant '\n",
            "                         'effects of S-312-d were not observed in the '\n",
            "                         'audiogenic seizure test in Slc: ddY mice.',\n",
            "             'chemical2id': {'bemegride': 'D001534',\n",
            "                             'calcium': 'D002118',\n",
            "                             'dihydrothienopyridine calcium': '-1',\n",
            "                             'flunarizine': 'D005444',\n",
            "                             'n-methyl-d-aspartate': 'D016202',\n",
            "                             'pentylenetetrazole': 'D010433',\n",
            "                             'picrotoxin': 'D010852',\n",
            "                             's-312': 'C059447',\n",
            "                             's-312-d': 'C059447',\n",
            "                             's-312-l': '-1'},\n",
            "             'disease2id': {'audiogenic tonic convulsions': 'D020195',\n",
            "                            'convulsions': 'D012640',\n",
            "                            'epilepsy': 'D004827'},\n",
            "             'relations': [{'chemical': 'D010852', 'disease': 'D012640'},\n",
            "                           {'chemical': 'D010433', 'disease': 'D012640'},\n",
            "                           {'chemical': 'D001534', 'disease': 'D012640'}],\n",
            "             'title': 'Pharmacological studies on a new dihydrothienopyridine '\n",
            "                      'calcium antagonist, S-312-d. 5th communication: '\n",
            "                      'anticonvulsant effects in mice.'},\n",
            " '8096565': {'abstract': 'For sumatriptan, tightness in the chest caused by an '\n",
            "                         'unknown mechanism has been reported in 3-5% of '\n",
            "                         'users. We describe a 47-year-old woman with an acute '\n",
            "                         'myocardial infarction after administration of '\n",
            "                         'sumatriptan 6 mg subcutaneously for cluster '\n",
            "                         'headache. The patient had no history of underlying '\n",
            "                         \"ischaemic heart disease or Prinzmetal's angina. She \"\n",
            "                         'recovered without complications.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  that the patient had no history of '\n",
            "                         \"ischaemic heart disease or Prinzmetal's angina.\",\n",
            "             'chemical2id': {'sumatriptan': 'D018170'},\n",
            "             'disease2id': {'cluster headache': 'D003027',\n",
            "                            'ischaemic heart disease': 'D017202',\n",
            "                            'myocardial infarction': 'D009203',\n",
            "                            \"prinzmetal's angina\": 'D000788'},\n",
            "             'relations': [{'chemical': 'D018170', 'disease': 'D009203'}],\n",
            "             'title': 'Transmural myocardial infarction with sumatriptan.'},\n",
            " '8135424': {'abstract': 'STUDY HYPOTHESIS: Administration of the '\n",
            "                         'benzodiazepine antagonist flumazenil may unmask '\n",
            "                         'seizures in mixed cocaine-benzodiazepine '\n",
            "                         'intoxication. DESIGN: Male Sprague-Dawley rats '\n",
            "                         'received 100 mg/kg cocaine IP alone, 5 mg/kg '\n",
            "                         'diazepam alone, or a combination of diazepam and '\n",
            "                         'cocaine. Three minutes later, groups were challenged '\n",
            "                         'with vehicle or flumazenil 5 or 10 mg/kg IP. Animal '\n",
            "                         'behavior, seizures (time to and incidence), death '\n",
            "                         '(time to and incidence), and cortical EEG tracings '\n",
            "                         'were recorded. INTERVENTIONS: Administration of '\n",
            "                         'flumazenil to animals after they had received a '\n",
            "                         'combination dose of cocaine and diazepam. RESULTS: '\n",
            "                         'In group 1, animals received cocaine followed by '\n",
            "                         'vehicle. This resulted in 100% developing seizures '\n",
            "                         'and death. Group 2 received diazepam alone followed '\n",
            "                         'by vehicle. Animals became somnolent and none died. '\n",
            "                         'Group 3 received diazepam followed by 5 mg/kg '\n",
            "                         'flumazenil. Animals became somnolent after diazepam '\n",
            "                         'and then active after flumazenil administration. In '\n",
            "                         'group 4, a combination of cocaine and diazepam was '\n",
            "                         'administered simultaneously. This resulted in no '\n",
            "                         'overt or EEG-detectable seizures and a 50% incidence '\n",
            "                         'of death. Group 5 received a similar combination of '\n",
            "                         'cocaine and diazepam, followed later by 5 mg/kg '\n",
            "                         'flumazenil. This resulted in an increased incidence '\n",
            "                         'of seizures, 90% (P < .01), and death, 100% (P < or '\n",
            "                         '= .01), compared with group 4. Group 6 received '\n",
            "                         'cocaine and diazepam followed by 10 mg/kg '\n",
            "                         'flumazenil. This also resulted in an increased '\n",
            "                         'incidence of seizures, 90% (P < or = .01), and '\n",
            "                         'death, 90% (P < or = .05), compared with group 4. '\n",
            "                         'CONCLUSION: Flumazenil can unmask seizures and '\n",
            "                         'increase the incidence of death in a model of '\n",
            "                         'combined cocaine-diazepam intoxications.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that the '\n",
            "                         'benzodiazepine antagonist flumazenil is a '\n",
            "                         'benzodiazepine receptor antagonist.',\n",
            "             'chemical2id': {'benzodiazepine': 'D001569',\n",
            "                             'cocaine': 'D003042',\n",
            "                             'diazepam': 'D003975',\n",
            "                             'flumazenil': 'D005442'},\n",
            "             'disease2id': {'seizures': 'D012640'},\n",
            "             'relations': [{'chemical': 'D003975', 'disease': 'D012640'},\n",
            "                           {'chemical': 'D005442', 'disease': 'D012640'},\n",
            "                           {'chemical': 'D003042', 'disease': 'D012640'}],\n",
            "             'title': 'Flumazenil induces seizures and death in mixed '\n",
            "                      'cocaine-diazepam intoxications.'},\n",
            " '8160791': {'abstract': 'Studies were performed to examine the mechanisms for '\n",
            "                         'the protective effects of free radical scavengers on '\n",
            "                         'gentamicin (GM)-mediated nephropathy. Administration '\n",
            "                         'of GM at 40 mg/kg sc for 13 days to rats induced a '\n",
            "                         'significant reduction in renal blood flow (RBF) and '\n",
            "                         'inulin clearance (CIn) as well as marked tubular '\n",
            "                         'damage. A significant reduction in urinary guanosine '\n",
            "                         \"3',5'-cyclic monophosphate (cGMP) excretion and a \"\n",
            "                         'significant increase in renal cortical renin and '\n",
            "                         'endothelin-1 contents were also observed in '\n",
            "                         'GM-mediated nephropathy. Superoxide dismutase (SOD) '\n",
            "                         'or dimethylthiourea (DMTU) significantly lessened '\n",
            "                         'the GM-induced decrement in CIn. The SOD-induced '\n",
            "                         'increase in glomerular filtration rate was '\n",
            "                         'associated with a marked improvement in RBF, an '\n",
            "                         'increase in urinary cGMP excretion, and a decrease '\n",
            "                         'in renal renin and endothelin-1 content. SOD did not '\n",
            "                         'attenuate the tubular damage. In contrast, DMTU '\n",
            "                         'significantly reduced the tubular damage and lipid '\n",
            "                         'peroxidation, but it did not affect renal '\n",
            "                         'hemodynamics and vasoactive substances. Neither SOD '\n",
            "                         'nor DMTU affected the renal cortical GM content in '\n",
            "                         'GM-treated rats. These results suggest that 1) both '\n",
            "                         'SOD and DMTU have protective effects on GM-mediated '\n",
            "                         'nephropathy, 2) the mechanisms for the protective '\n",
            "                         'effects differ for SOD and DMTU, and 3) superoxide '\n",
            "                         'anions play a critical role in GM-induced renal '\n",
            "                         'vasoconstriction.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that the renal cortical GM content is not '\n",
            "                         'affected by GM administration.',\n",
            "             'chemical2id': {'cgmp': 'D006152',\n",
            "                             'dimethylthiourea': 'C038983',\n",
            "                             'dmtu': 'C038983',\n",
            "                             'gentamicin': 'D005839',\n",
            "                             'gm': 'D005839',\n",
            "                             \"guanosine 3',5'-cyclic monophosphate\": 'D006152',\n",
            "                             'superoxide': 'D013481'},\n",
            "             'disease2id': {'nephropathy': 'D007674',\n",
            "                            'tubular damage': 'D007674'},\n",
            "             'relations': [{'chemical': 'D005839', 'disease': 'D007674'}],\n",
            "             'title': 'Mechanisms for protective effects of free radical '\n",
            "                      'scavengers on gentamicin-mediated nephropathy in rats.'},\n",
            " '816141': {'abstract': 'A patient with renal disease developed '\n",
            "                        'Coombs-positive hemolytic anemia while receiving '\n",
            "                        'cephalothin therapy. An anti-cephalothin IgG antibody '\n",
            "                        \"was detected in the patient's serum and in the \"\n",
            "                        'eluates from her erythrocytes. In addition, '\n",
            "                        \"nonimmunologic binding of normal and patient's serum \"\n",
            "                        'proteins to her own and cephalothin-coated normal red '\n",
            "                        'cells was demonstrated. Skin tests and in vitro '\n",
            "                        'lymphocyte stimulation revealed that the patient was '\n",
            "                        'sensitized to cephalothin and also to ampicillin. '\n",
            "                        'Careful investigation of drug-induced hemolytic '\n",
            "                        'anemias reveals the complexity of the immune '\n",
            "                        'mechanisms involved.The important background '\n",
            "                        'information needed to understand this text is  the '\n",
            "                        \"fact that the patient's red cells were coated with \"\n",
            "                        \"cephalothin and that the patient's serum contained an \"\n",
            "                        'IgG antibody that reacted with cephalothin and '\n",
            "                        'ampicillin.',\n",
            "            'chemical2id': {'ampicillin': 'D000667', 'cephalothin': 'D002512'},\n",
            "            'disease2id': {'hemolytic anemia': 'D000743',\n",
            "                           'hemolytic anemias': 'D000743',\n",
            "                           'renal disease': 'D007674'},\n",
            "            'relations': [{'chemical': 'D002512', 'disease': 'D000743'}],\n",
            "            'title': 'Cephalothin-induced immune hemolytic anemia.'},\n",
            " '8184922': {'abstract': 'The ability of cardiomyocytes to synthesize DNA in '\n",
            "                         'response to experimentally induced cardiac '\n",
            "                         'hypertrophy was assessed in adult mice. '\n",
            "                         'Isoproterenol delivered by osmotic minipump '\n",
            "                         'implantation in adult C3Heb/FeJ mice resulted in a '\n",
            "                         '46% increase in heart weight and a 19.3% increase in '\n",
            "                         'cardiomyocyte area. No DNA synthesis, as assessed by '\n",
            "                         'autoradiographic analysis of isolated '\n",
            "                         'cardiomyocytes, was observed in control or '\n",
            "                         'hypertrophic hearts. A survey of 15 independent '\n",
            "                         'inbred strains of mice revealed that ventricular '\n",
            "                         'cardiomyocyte nuclear number ranged from 3 to 13% '\n",
            "                         'mononucleate, suggesting that cardiomyocyte terminal '\n",
            "                         'differentiation is influenced directly or indirectly '\n",
            "                         'by genetic background. To determine whether the '\n",
            "                         'capacity for reactive DNA synthesis was also subject '\n",
            "                         'to genetic regulation, cardiac hypertrophy was '\n",
            "                         'induced in the strains of mice comprising the '\n",
            "                         'extremes of the nuclear number survey. These data '\n",
            "                         'indicate that adult mouse atrial and ventricular '\n",
            "                         'cardiomyocytes do not synthesize DNA in response to '\n",
            "                         'isoproterenol-induced cardiac hypertrophy.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that the response '\n",
            "                         'of the mouse heart to isoproterenol-induced '\n",
            "                         'hypertrophy is not a simple hypertrophy.',\n",
            "             'chemical2id': {'isoproterenol': 'D007545'},\n",
            "             'disease2id': {'cardiac hypertrophy': 'D006332',\n",
            "                            'hypertrophic hearts': 'D006332',\n",
            "                            'hypertrophy': 'D006984'},\n",
            "             'relations': [{'chemical': 'D007545', 'disease': 'D006332'}],\n",
            "             'title': 'Assessment of cardiomyocyte DNA synthesis during '\n",
            "                      'hypertrophy in adult mice.'},\n",
            " '8188982': {'abstract': 'The purpose of the present study was to compare '\n",
            "                         'influence of central arginine vasopressin (AVP) and '\n",
            "                         'of atrial natriuretic peptide (ANP) on control of '\n",
            "                         'arterial blood pressure (MAP) and heart rate (HR) in '\n",
            "                         'normotensive (WKY) and spontaneously hypertensive '\n",
            "                         '(SHR) rats. Three series of experiments were '\n",
            "                         'performed on 30 WKY and 30 SHR, chronically '\n",
            "                         'instrumented with guide tubes in the lateral '\n",
            "                         'ventricle (LV) and arterial and venous catheters. '\n",
            "                         'MAP and HR were monitored before and after i.v. '\n",
            "                         'injections of either vehicle or 1, 10 and 50 ng of '\n",
            "                         'AVP and 25, 125 and 500 ng of ANP. Sensitivity of '\n",
            "                         'cardiac component of baroreflex (CCB), expressed as '\n",
            "                         'a slope of the regression line was determined from '\n",
            "                         'relationships between systolic arterial pressure '\n",
            "                         '(SAP) and HR period (HRp) during phenylephrine '\n",
            "                         '(Phe)-induced hypertension and sodium nitroprusside '\n",
            "                         '(SN)-induced hypotension. CCB was measured before '\n",
            "                         'and after administration of either vehicle, AVP, '\n",
            "                         'ANP, or both peptides together. Increases of MAP '\n",
            "                         'occurred after LV administration of 1, 10 and 50 ng '\n",
            "                         'of AVP in WKY and of 10 and 50 ng in SHR. ANP did '\n",
            "                         'not cause significant changes in MAP in both strains '\n",
            "                         'as compared to vehicle, but it abolished AVP-induced '\n",
            "                         'MAP increase in WKY and SHR. CCB was reduced in WKY '\n",
            "                         'and SHR after LV administration of AVP during '\n",
            "                         'SN-induced hypotension. In SHR but not in WKY '\n",
            "                         'administration of ANP, AVP and ANP + AVP decreased '\n",
            "                         'CCB during Phe-induced MAP elevation. The results '\n",
            "                         'indicate that centrally applied AVP and ANP exert '\n",
            "                         'differential effects on blood pressure and '\n",
            "                         'baroreflex control of heart rate in WKY and SHR and '\n",
            "                         'suggest interaction of these two peptides in blood '\n",
            "                         'pressure regulation at the level of central nervous '\n",
            "                         'system.The important background information needed '\n",
            "                         'to understand this text is  the fact that the '\n",
            "                         'present study was performed on conscious rats and '\n",
            "                         'therefore the results may not be directly applicable '\n",
            "                         'to conscious animals.',\n",
            "             'chemical2id': {'arginine vasopressin': 'D001127',\n",
            "                             'avp': 'D001127',\n",
            "                             'phe': 'D010656',\n",
            "                             'phenylephrine': 'D010656',\n",
            "                             'sn': 'D009599',\n",
            "                             'sodium nitroprusside': 'D009599'},\n",
            "             'disease2id': {'hypertension': 'D006973',\n",
            "                            'hypertensive': 'D006973',\n",
            "                            'hypotension': 'D007022'},\n",
            "             'relations': [{'chemical': 'D010656', 'disease': 'D006973'},\n",
            "                           {'chemical': 'D009599', 'disease': 'D007022'},\n",
            "                           {'chemical': 'D001127', 'disease': 'D006973'}],\n",
            "             'title': 'Central cardiovascular effects of AVP and ANP in '\n",
            "                      'normotensive and spontaneously hypertensive rats.'},\n",
            " '8308951': {'abstract': 'A case of intercerebral hematoma due to '\n",
            "                         'warfarin-induced coagulopathy is presented. The '\n",
            "                         '39-year-old woman had spread a warfarin-type rat '\n",
            "                         'poison around her house weekly using her bare hands, '\n",
            "                         'with no washing post application. Percutaneous '\n",
            "                         'absorption of warfarin causing coagulopathy, '\n",
            "                         'reported three times in the past, is a significant '\n",
            "                         'risk if protective measures, such as gloves, are not '\n",
            "                         'used. An adverse drug interaction with piroxicam, '\n",
            "                         'which she took occasionally, may have exacerbated '\n",
            "                         'the coagulopathy.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         \"patient's history of warfarin use, the patient's \"\n",
            "                         'history of warfarin-induced coagulopathy, and the '\n",
            "                         \"patient's history of piroxicam use.\",\n",
            "             'chemical2id': {'piroxicam': 'D010894', 'warfarin': 'D014859'},\n",
            "             'disease2id': {'coagulopathy': 'D001778',\n",
            "                            'hematoma': 'D006406',\n",
            "                            'intracerebral hemorrhage': 'D002543'},\n",
            "             'relations': [{'chemical': 'D014859', 'disease': 'D002543'}],\n",
            "             'title': 'Cutaneous exposure to warfarin-like anticoagulant '\n",
            "                      'causing an intracerebral hemorrhage: a case report.'},\n",
            " '8312343': {'abstract': 'From 1986 to February 1993, 40 children aged 2 '\n",
            "                         'months to 18 years (average age 10.4 +/- 5.8 years) '\n",
            "                         'underwent heart transplantation. Indications for '\n",
            "                         'transplantation were idiopathic cardiomyopathy '\n",
            "                         '(52%), congenital heart disease (35%) with and '\n",
            "                         'without prior repair (71% and 29%, respectively), '\n",
            "                         'hypertrophic cardiomyopathy (5%), valvular heart '\n",
            "                         'disease (3%), and doxorubicin cardiomyopathy (5%). '\n",
            "                         'Patients were managed with cyclosporine and '\n",
            "                         'azathioprine. No prophylaxis with antilymphocyte '\n",
            "                         'globulin was used. Steroids were given to 39% of '\n",
            "                         'patients for refractory rejection, but weaning was '\n",
            "                         'always attempted and generally successful (64%). '\n",
            "                         'Five patients (14%) received maintenance steroids. '\n",
            "                         'Four patients died in the perioperative period and '\n",
            "                         'one died 4 months later. There have been no deaths '\n",
            "                         'related to rejection or infection. Average follow-up '\n",
            "                         'was 36 +/- 19 months (range 1 to 65 months). '\n",
            "                         'Cumulative survival is 88% at 5 years. In patients '\n",
            "                         'less than 7 years of age, rejection was monitored '\n",
            "                         'noninvasively. In the first postoperative month, 89% '\n",
            "                         'of patients were treated for rejection. Freedom from '\n",
            "                         'serious infections was 83% at 1 month and 65% at 1 '\n",
            "                         'year. Cytomegalovirus infections were treated '\n",
            "                         'successfully with ganciclovir in 11 patients. No '\n",
            "                         'impairment of growth was observed in children who '\n",
            "                         'underwent transplantation compared with a control '\n",
            "                         'population. Twenty-one patients (60%) have undergone '\n",
            "                         'annual catheterizations and no sign of graft '\n",
            "                         'atherosclerosis has been observed. Seizures occurred '\n",
            "                         'in five patients (14%) and hypertension was treated '\n",
            "                         'in 10 patients (28%). No patient was disabled and no '\n",
            "                         'lymphoproliferative disorder was observed.(ABSTRACT '\n",
            "                         'TRUNCATED AT 250 WORDS)The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'experience of the authors.',\n",
            "             'chemical2id': {'azathioprine': 'D001379',\n",
            "                             'cyclosporine': 'D016572',\n",
            "                             'doxorubicin': 'D004317',\n",
            "                             'ganciclovir': 'D015774',\n",
            "                             'steroids': 'D013256'},\n",
            "             'disease2id': {'atherosclerosis': 'D050197',\n",
            "                            'cardiomyopathy': 'D009202',\n",
            "                            'congenital heart disease': 'D006331',\n",
            "                            'cytomegalovirus infections': 'D003586',\n",
            "                            'hypertension': 'D006973',\n",
            "                            'hypertrophic cardiomyopathy': 'D002312',\n",
            "                            'idiopathic cardiomyopathy': 'D002311',\n",
            "                            'infection': 'D007239',\n",
            "                            'infections': 'D007239',\n",
            "                            'lymphoproliferative disorder': 'D008232',\n",
            "                            'seizures': 'D012640',\n",
            "                            'valvular heart disease': 'D006349'},\n",
            "             'relations': [{'chemical': 'D004317', 'disease': 'D009202'}],\n",
            "             'title': 'Pediatric heart transplantation without chronic '\n",
            "                      'maintenance steroids.'},\n",
            " '8312983': {'abstract': 'The correlation between high serum tricyclic '\n",
            "                         'antidepressant concentrations and central nervous '\n",
            "                         'system side effects has been well established. Only '\n",
            "                         'a few reports exist, however, on the relationship '\n",
            "                         'between the serum concentrations of selective '\n",
            "                         'serotonin reuptake inhibitors (SSRIs) and their '\n",
            "                         'toxic effects. In some cases, a high serum '\n",
            "                         'concentration of citalopram (> 600 nmol/L) in '\n",
            "                         'elderly patients has been associated with increased '\n",
            "                         'somnolence and movement difficulties. Widespread '\n",
            "                         'cognitive disorders, such as delirium, have not been '\n",
            "                         'previously linked with high blood levels of SSRIs. '\n",
            "                         'In this report, we describe a patient with acute '\n",
            "                         'hyperkinetic delirium connected with a high serum '\n",
            "                         'total fluoxetine (fluoxetine plus '\n",
            "                         'desmethylfluoxetine) concentration.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the patient was a 65-year-old '\n",
            "                         'woman with a history of depression and a history of '\n",
            "                         'chronic use of fluoxetine.',\n",
            "             'chemical2id': {'citalopram': 'D015283',\n",
            "                             'desmethylfluoxetine': 'C036139',\n",
            "                             'fluoxetine': 'D005473',\n",
            "                             'serotonin': 'D012701'},\n",
            "             'disease2id': {'cognitive disorders': 'D003072',\n",
            "                            'delirium': 'D003693',\n",
            "                            'hyperkinetic': 'D006948',\n",
            "                            'movement difficulties': 'D020820',\n",
            "                            'somnolence': 'D006970'},\n",
            "             'relations': [{'chemical': 'D005473', 'disease': 'D006948'},\n",
            "                           {'chemical': 'D005473', 'disease': 'D003693'}],\n",
            "             'title': 'Delirium during fluoxetine treatment. A case report.'},\n",
            " '8318674': {'abstract': 'Four out of 23 consecutive patients treated with '\n",
            "                         'high-dose Ara-C for lymphomas in our institution '\n",
            "                         'developed a strikingly similar syndrome during the '\n",
            "                         'perfusion. It was characterized by the onset of '\n",
            "                         'fever, diarrhea, shock, pulmonary edema, acute renal '\n",
            "                         'failure, metabolic acidosis, weight gain and '\n",
            "                         'leukocytosis. Thorough bacteriological screening '\n",
            "                         'failed to provide evidence of infection. Sequential '\n",
            "                         'biological assays of IL-1, IL-2, TNF and PAF were '\n",
            "                         'performed during Ara-C infusion to ten patients, '\n",
            "                         'including the four who developed the syndrome. TNF '\n",
            "                         'and PAF activity was found in the serum of '\n",
            "                         'respectively two and four of the cases, but not in '\n",
            "                         'the six controls. As TNF and PAF are thought to be '\n",
            "                         'involved in the development of septic shock and '\n",
            "                         'adult respiratory distress syndrome, we hypothesize '\n",
            "                         'that high-dose Ara-C may be associated with cytokine '\n",
            "                         'release.The important background information needed '\n",
            "                         'to understand this text is  the fact that the '\n",
            "                         'syndrome is not a direct consequence of the '\n",
            "                         'cytotoxic effect of Ara-C on the tumor cells, but '\n",
            "                         'rather a consequence of the systemic inflammatory '\n",
            "                         'response syndrome (SIRS).',\n",
            "             'chemical2id': {'ara-c': 'D003561', 'aracytine-c': 'D003561'},\n",
            "             'disease2id': {'acute renal failure': 'D058186',\n",
            "                            'adult respiratory distress syndrome': 'D012128',\n",
            "                            'diarrhea': 'D003967',\n",
            "                            'fever': 'D005334',\n",
            "                            'infection': 'D007239',\n",
            "                            'leukocytosis': 'D007964',\n",
            "                            'lymphoma': 'D008223',\n",
            "                            'lymphomas': 'D008223',\n",
            "                            'metabolic acidosis': 'D000138',\n",
            "                            'pulmonary edema': 'D011654',\n",
            "                            'shock': 'D012769',\n",
            "                            'weight gain': 'D015430'},\n",
            "             'relations': [{'chemical': 'D003561', 'disease': 'D003967'},\n",
            "                           {'chemical': 'D003561', 'disease': 'D005334'},\n",
            "                           {'chemical': 'D003561', 'disease': 'D011654'},\n",
            "                           {'chemical': 'D003561', 'disease': 'D058186'},\n",
            "                           {'chemical': 'D003561', 'disease': 'D015430'},\n",
            "                           {'chemical': 'D003561', 'disease': 'D012769'},\n",
            "                           {'chemical': 'D003561', 'disease': 'D007964'},\n",
            "                           {'chemical': 'D003561', 'disease': 'D000138'}],\n",
            "             'title': 'Pulmonary edema and shock after high-dose aracytine-C '\n",
            "                      'for lymphoma; possible role of TNF-alpha and PAF.'},\n",
            " '8392553': {'abstract': 'We investigated the effects of clentiazem, a '\n",
            "                         '1,5-benzothiazepine calcium antagonist, on '\n",
            "                         'epinephrine-induced cardiomyopathy in rats. With '\n",
            "                         '2-week chronic epinephrine infusion, 16 of 30 rats '\n",
            "                         'died within 4 days, and severe ischemic lesions and '\n",
            "                         'fibrosis of the left ventricles were observed. In '\n",
            "                         'epinephrine-treated rats, left atrial and left '\n",
            "                         'ventricular papillary muscle contractile responses '\n",
            "                         'to isoproterenol were reduced, but responses to '\n",
            "                         'calcium were normal or enhanced compared to '\n",
            "                         'controls. Left ventricular alpha and beta '\n",
            "                         'adrenoceptor densities were also reduced compared to '\n",
            "                         'controls. Treatment with clentiazem prevented '\n",
            "                         'epinephrine-induced death (P < .05), and attenuated '\n",
            "                         'the ventricular ischemic lesions and fibrosis, in a '\n",
            "                         'dose-dependent manner. Left atrial and left '\n",
            "                         'ventricular papillary muscle contractile responses '\n",
            "                         'to isoproterenol were reduced compared to controls '\n",
            "                         'in groups treated with clentiazem alone, but '\n",
            "                         'combined with epinephrine, clentiazem restored left '\n",
            "                         'atrial responses and enhanced left ventricular '\n",
            "                         'papillary responses to isoproterenol. On the other '\n",
            "                         'hand clentiazem did not prevent epinephrine-induced '\n",
            "                         'down-regulation of alpha and beta adrenoceptors. '\n",
            "                         'Interestingly, clentiazem, infused alone, resulted '\n",
            "                         'in decreased adrenergic receptor densities in the '\n",
            "                         'left ventricle. Clentiazem also did not prevent the '\n",
            "                         'enhanced responses to calcium seen in the '\n",
            "                         'epinephrine-treated animals, although the high dose '\n",
            "                         'of clentiazem partially attenuated the maximal '\n",
            "                         'response to calcium compared to epinephrine-treated '\n",
            "                         'animals. In conclusion, clentiazem attenuated '\n",
            "                         'epinephrine-induced cardiac injury, possibly through '\n",
            "                         'its effect on the adrenergic pathway.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that clentiazem is a '\n",
            "                         'benzothiazepine calcium antagonist, and that it is a '\n",
            "                         'potent calcium antagonist.',\n",
            "             'chemical2id': {'1,5-benzothiazepine': 'C106746',\n",
            "                             'calcium': 'D002118',\n",
            "                             'clentiazem': 'C056595',\n",
            "                             'epinephrine': 'D004837',\n",
            "                             'isoproterenol': 'D007545'},\n",
            "             'disease2id': {'cardiac injury': 'D006331',\n",
            "                            'cardiomyopathy': 'D009202',\n",
            "                            'fibrosis': 'D005355',\n",
            "                            'ischemic lesions': 'D007511'},\n",
            "             'relations': [{'chemical': 'D004837', 'disease': 'D009202'}],\n",
            "             'title': 'Protective effect of clentiazem against '\n",
            "                      'epinephrine-induced cardiac injury in rats.'},\n",
            " '851038': {'abstract': 'Hypokalemia, sometimes severe, was observed in some '\n",
            "                        'L-dopa-treated parkinsonian patients. The influence '\n",
            "                        'of L-dopa on the renal excretion of potassium was '\n",
            "                        'studied in 3 patients with hypokalemia and in 5 '\n",
            "                        'normokalemic patients by determination of renal '\n",
            "                        'plasma flow, glomerular filtration rate, plasma '\n",
            "                        'concentration of potassium and sodium as well as '\n",
            "                        'urinary excretion of potassium, sodium and '\n",
            "                        'aldosterone. L-Dopa intake was found to cause an '\n",
            "                        'increased excretion of potassium, and sometimes also '\n",
            "                        'of sodium, in the hypokalemic but not in the '\n",
            "                        'normokalemic patients. This effect on the renal '\n",
            "                        'function could be prohibited by the administration of '\n",
            "                        'a peripheral dopa decarbodylase inhibitor. It is not '\n",
            "                        'known why this effect occurred in some individuals '\n",
            "                        'but not in others, but our results indicate a '\n",
            "                        'correlation between aldosterone production and this '\n",
            "                        'renal effect of L-dopa.The important background '\n",
            "                        'information needed to understand this text is  the '\n",
            "                        'fact that the renal effect of L-dopa is not '\n",
            "                        'restricted to the kidney, but also includes the '\n",
            "                        'kidney as well as the adrenal cortex.',\n",
            "            'chemical2id': {'aldosterone': 'D000450',\n",
            "                            'l-dopa': 'D007980',\n",
            "                            'potassium': 'D011188',\n",
            "                            'sodium': 'D012964'},\n",
            "            'disease2id': {'hypokalemia': 'D007008', 'parkinsonian': 'D010300'},\n",
            "            'relations': [{'chemical': 'D007980', 'disease': 'D007008'}],\n",
            "            'title': 'Kaliuretic effect of L-dopa treatment in parkinsonian '\n",
            "                     'patients.'},\n",
            " '8511251': {'abstract': 'We report a case of myocardial ischemia induced by '\n",
            "                         'cocaine. The ischemia probably induced by coronary '\n",
            "                         'artery spasm was reversed by nitroglycerin and '\n",
            "                         'calcium blocking agents.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that cocaine is a drug of abuse that is widely '\n",
            "                         'used in the United States.',\n",
            "             'chemical2id': {'calcium': 'D002118',\n",
            "                             'cocaine': 'D003042',\n",
            "                             'nitroglycerin': 'D005996'},\n",
            "             'disease2id': {'coronary artery spasm': 'D003329',\n",
            "                            'ischemia': 'D007511',\n",
            "                            'myocardial ischemia': 'D017202'},\n",
            "             'relations': [{'chemical': 'D003042', 'disease': 'D017202'},\n",
            "                           {'chemical': 'D003042', 'disease': 'D003329'}],\n",
            "             'title': 'Cocaine induced myocardial ischemia.'},\n",
            " '8603459': {'abstract': 'In laboratory animals, histology is most commonly '\n",
            "                         'used to study doxorubicin-induced cardiotoxicity. '\n",
            "                         'However, for monitoring during treatment, large '\n",
            "                         'numbers of animals are needed. Recently we developed '\n",
            "                         'a new method to measure ECG values in freely moving '\n",
            "                         'mice by telemetry. With this model we investigated '\n",
            "                         'the effect of chronic doxorubicin administration on '\n",
            "                         'the ECG of freely moving BALB/c mice and the '\n",
            "                         'efficacy of ICRF-187 as a protective agent. The ST '\n",
            "                         'interval significantly widened from 15.0 +/- 1.5 to '\n",
            "                         '56.8 +/- 11.8 ms in week 10 (7 weekly doses of 4 '\n",
            "                         'mg/kg doxorubicin given i.v. plus 3 weeks of '\n",
            "                         'observation). The ECG of the control animals did not '\n",
            "                         'change during the entire study. After sacrifice the '\n",
            "                         'hearts of doxorubicin-treated animals were enlarged '\n",
            "                         'and the atria were hypertrophic. As this schedule '\n",
            "                         'exerted more toxicity than needed to investigate '\n",
            "                         'protective agents, the protection of ICRF-187 was '\n",
            "                         'determined using a dose schedule with lower general '\n",
            "                         'toxicity (6 weekly doses of 4 mg/kg doxorubicin '\n",
            "                         'given i.v. plus 2 weeks of observation). On this '\n",
            "                         \"schedule, the animals' hearts appeared normal after \"\n",
            "                         'sacrifice and ICRF-187 (50 mg/kg given i.p. 1 h '\n",
            "                         'before doxorubicin) provided almost full protection. '\n",
            "                         'These data were confirmed by histology. The results '\n",
            "                         'indicate that this new model is very sensitive and '\n",
            "                         'enables monitoring of the development of '\n",
            "                         'cardiotoxicity with time. These findings result in a '\n",
            "                         'model that allows the testing of protectors against '\n",
            "                         'doxorubicin-induced cardiotoxicity as demonstrated '\n",
            "                         'by the protection provided by ICRF-187.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the ECG of mice is a very '\n",
            "                         'simple, inexpensive, and non-invasive method.',\n",
            "             'chemical2id': {'doxorubicin': 'D004317', 'icrf-187': 'D064730'},\n",
            "             'disease2id': {'cardiotoxicity': 'D066126',\n",
            "                            'hypertrophic': 'D006984',\n",
            "                            'toxicity': 'D064420'},\n",
            "             'relations': [{'chemical': 'D004317', 'disease': 'D066126'}],\n",
            "             'title': 'Doxorubicin-induced cardiotoxicity monitored by ECG in '\n",
            "                      'freely moving mice. A new model to test potential '\n",
            "                      'protectors.'},\n",
            " '8659767': {'abstract': 'Since bupivacaine and epinephrine may both '\n",
            "                         'precipitate dysrhythmias, circulating bupivacaine '\n",
            "                         'during regional anesthesia could potentiate '\n",
            "                         'dysrhythmogenic effects of epinephrine. We therefore '\n",
            "                         'examined whether bupivacaine alters the '\n",
            "                         'dysrhythmogenicity of subsequent administration of '\n",
            "                         'epinephrine in conscious, healthy dogs and in '\n",
            "                         'anesthetized dogs with myocardial infarction. '\n",
            "                         'Forty-one conscious dogs received 10 '\n",
            "                         'micrograms.kg-1.min-1 epinephrine. Seventeen animals '\n",
            "                         'responded with ventricular tachycardia (VT) within 3 '\n",
            "                         'min. After 3 h, these responders randomly received 1 '\n",
            "                         'or 2 mg/kg bupivacaine or saline over 5 min, '\n",
            "                         'followed by 10 micrograms.kg-1.min-1 epinephrine. In '\n",
            "                         'the bupivacaine groups, epinephrine caused fewer '\n",
            "                         'prodysrhythmic effects than without bupivacaine. VT '\n",
            "                         'appeared in fewer dogs and at a later time, and '\n",
            "                         'there were more sinoatrial beats and less ectopies. '\n",
            "                         'Epinephrine shortened QT less after bupivacaine than '\n",
            "                         'in control animals. One day after experimental '\n",
            "                         'myocardial infarction, six additional '\n",
            "                         'halothane-anesthetized dogs received 4 '\n",
            "                         'micrograms.kg-1.min-1 epinephrine until VT appeared. '\n",
            "                         'After 45 min, 1 mg/kg bupivacaine was injected over '\n",
            "                         '5 min, again followed by 4 micrograms.kg-1.min-1 '\n",
            "                         'epinephrine. In these dogs, the prodysrhythmic '\n",
            "                         'response to epinephrine was also mitigated by '\n",
            "                         'preceding bupivacaine. Bupivacaine antagonizes '\n",
            "                         'epinephrine dysrhythmogenicity in conscious dogs '\n",
            "                         'susceptible to VT and in anesthetized dogs with '\n",
            "                         'spontaneous postinfarct dysrhythmias. There is no '\n",
            "                         'evidence that systemic subtoxic bupivacaine '\n",
            "                         'administration enhances the dysrhythmogenicity of '\n",
            "                         'subsequent epinephrine.The important background '\n",
            "                         'information needed to understand this text is  that '\n",
            "                         'bupivacaine is a potent local anesthetic and that '\n",
            "                         'epinephrine is a potent prodysrhythmic agent.',\n",
            "             'chemical2id': {'bupivacaine': 'D002045',\n",
            "                             'epinephrine': 'D004837',\n",
            "                             'halothane': 'D006221'},\n",
            "             'disease2id': {'dysrhythmias': 'D001145',\n",
            "                            'myocardial infarction': 'D009203',\n",
            "                            'ventricular tachycardia': 'D017180',\n",
            "                            'vt': 'D017180'},\n",
            "             'relations': [{'chemical': 'D004837', 'disease': 'D017180'}],\n",
            "             'title': 'Epinephrine dysrhythmogenicity is not enhanced by '\n",
            "                      'subtoxic bupivacaine in dogs.'},\n",
            " '8667442': {'abstract': 'Milk-alkali syndrome was first described 70 years '\n",
            "                         'ago in the context of the treatment of peptic ulcer '\n",
            "                         'disease with large amounts of calcium and alkali. '\n",
            "                         'Although with current ulcer therapy (H-2 blockers, '\n",
            "                         'omeprazole, and sucralfate), the frequency of '\n",
            "                         'milk-alkali syndrome has decreased significantly, '\n",
            "                         'the classic triad of hypercalcemia, alkalosis, and '\n",
            "                         'renal impairment remains the hallmark of the '\n",
            "                         'syndrome. Milk-alkali syndrome can present serious '\n",
            "                         'and occasionally life-threatening illness unless '\n",
            "                         'diagnosed and treated appropriately. This article '\n",
            "                         'presents a patient with hypoparathyroidism who was '\n",
            "                         'treated with calcium carbonate and calcitriol '\n",
            "                         'resulting in two admissions to the hospital for '\n",
            "                         'milk-alkali syndrome. The patient was successfully '\n",
            "                         'treated with intravenous pamidronate on his first '\n",
            "                         'admission and with hydrocortisone on the second. '\n",
            "                         'This illustrates intravenous pamidronate as a '\n",
            "                         'valuable therapeutic tool when milk-alkali syndrome '\n",
            "                         'presents as hypercalcemic emergency.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         \"text is  the patient's history of chronic kidney \"\n",
            "                         'disease, which is a risk factor for milk-alkali '\n",
            "                         'syndrome.',\n",
            "             'chemical2id': {'1,25(oh)2d': 'D002117',\n",
            "                             'alkali': 'D000468',\n",
            "                             'calcitriol': 'D002117',\n",
            "                             'calcium': 'D002118',\n",
            "                             'calcium carbonate': 'D002119',\n",
            "                             'hydrocortisone': 'D006854',\n",
            "                             'omeprazole': 'D009853',\n",
            "                             'pamidronate': 'C019248',\n",
            "                             'sucralfate': 'D013392'},\n",
            "             'disease2id': {'alkalosis': 'D000471',\n",
            "                            'hypercalcemia': 'D006934',\n",
            "                            'hypercalcemic emergency': 'D006934',\n",
            "                            'hypoparathyroidism': 'D007011',\n",
            "                            'milk-alkali syndrome': 'D006934',\n",
            "                            'peptic ulcer disease': 'D010437',\n",
            "                            'renal impairment': 'D051437',\n",
            "                            'ulcer': 'D014456'},\n",
            "             'relations': [{'chemical': 'D002117', 'disease': 'D051437'},\n",
            "                           {'chemical': 'D013392', 'disease': 'D010437'},\n",
            "                           {'chemical': 'D002118', 'disease': 'D000471'},\n",
            "                           {'chemical': 'D000468', 'disease': 'D051437'},\n",
            "                           {'chemical': 'D000468', 'disease': 'D000471'},\n",
            "                           {'chemical': 'D002119', 'disease': 'D000471'},\n",
            "                           {'chemical': 'D009853', 'disease': 'D010437'},\n",
            "                           {'chemical': 'D002117', 'disease': 'D006934'},\n",
            "                           {'chemical': 'D000468', 'disease': 'D006934'},\n",
            "                           {'chemical': 'D002117', 'disease': 'D000471'},\n",
            "                           {'chemical': 'D002118', 'disease': 'D006934'},\n",
            "                           {'chemical': 'D002119', 'disease': 'D006934'},\n",
            "                           {'chemical': 'D002119', 'disease': 'D051437'},\n",
            "                           {'chemical': 'D002118', 'disease': 'D051437'}],\n",
            "             'title': 'Milk-alkali syndrome induced by 1,25(OH)2D in a patient '\n",
            "                      'with hypoparathyroidism.'},\n",
            " '8701013': {'abstract': 'Famotidine is a histamine H2-receptor antagonist '\n",
            "                         'used in inpatient settings for prevention of stress '\n",
            "                         'ulcers and is showing increasing popularity because '\n",
            "                         'of its low cost. Although all of the currently '\n",
            "                         'available H2-receptor antagonists have shown the '\n",
            "                         'propensity to cause delirium, only two previously '\n",
            "                         'reported cases have been associated with famotidine. '\n",
            "                         'The authors report on six cases of '\n",
            "                         'famotidine-associated delirium in hospitalized '\n",
            "                         'patients who cleared completely upon removal of '\n",
            "                         'famotidine. The pharmacokinetics of famotidine are '\n",
            "                         'reviewed, with no change in its metabolism in the '\n",
            "                         'elderly population seen. The implications of using '\n",
            "                         'famotidine in elderly persons are discussed.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the lack of information on '\n",
            "                         'the potential for famotidine to cause delirium.',\n",
            "             'chemical2id': {'famotidine': 'D015738'},\n",
            "             'disease2id': {'delirium': 'D003693', 'ulcers': 'D014456'},\n",
            "             'relations': [{'chemical': 'D015738', 'disease': 'D003693'}],\n",
            "             'title': 'Famotidine-associated delirium. A series of six cases.'},\n",
            " '8748050': {'abstract': 'This report describes a case of encephalopathy '\n",
            "                         'developed in the course of amitriptyline therapy, '\n",
            "                         'during a remission of unipolar depression. This '\n",
            "                         'patient could have been diagnosed as having either '\n",
            "                         'neuroleptic malignant syndrome (NMS) or serotonin '\n",
            "                         'syndrome (SS). The major determinant of the symptoms '\n",
            "                         'may have been dopamine/serotonin imbalance in the '\n",
            "                         'central nervous system. The NMS-like encephalopathy '\n",
            "                         'that develops in association with the use of '\n",
            "                         'antidepressants indicates that NMS and SS are '\n",
            "                         'spectrum disorders induced by drugs with both '\n",
            "                         'antidopaminergic and serotonergic effects.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that the syndrome '\n",
            "                         'is rare and that it is not always easy to diagnose.',\n",
            "             'chemical2id': {'amitriptyline': 'D000639',\n",
            "                             'dopamine': 'D004298',\n",
            "                             'serotonin': 'D012701'},\n",
            "             'disease2id': {'encephalopathy': 'D001927',\n",
            "                            'neuroleptic malignant syndrome': 'D009459',\n",
            "                            'nms': 'D009459',\n",
            "                            'serotonin syndrome': 'D020230',\n",
            "                            'ss': 'D020230',\n",
            "                            'unipolar depression': 'D003866'},\n",
            "             'relations': [{'chemical': 'D000639', 'disease': 'D001927'}],\n",
            "             'title': 'Encephalopathy during amitriptyline therapy: are '\n",
            "                      'neuroleptic malignant syndrome and serotonin syndrome '\n",
            "                      'spectrum disorders?'},\n",
            " '8755612': {'abstract': 'Chronic administration of estrogen to the Fischer '\n",
            "                         '344 (F344) rat induces growth of large, hemorrhagic '\n",
            "                         'pituitary tumors. Ten weeks of diethylstilbestrol '\n",
            "                         '(DES) treatment caused female F344 rat pituitaries '\n",
            "                         'to grow to an average of 109.2 +/- 6.3 mg (mean +/- '\n",
            "                         'SE) versus 11.3 +/- 1.4 mg for untreated rats, and '\n",
            "                         'to become highly hemorrhagic. The same DES treatment '\n",
            "                         'produced no significant growth (8.9 +/- 0.5 mg for '\n",
            "                         'treated females versus 8.7 +/- 1.1 for untreated '\n",
            "                         'females) or morphological changes in Brown Norway '\n",
            "                         '(BN) rat pituitaries. An F1 hybrid of F344 and BN '\n",
            "                         'exhibited significant pituitary growth after 10 '\n",
            "                         'weeks of DES treatment with an average mass of 26.3 '\n",
            "                         '+/- 0.7 mg compared with 8.6 +/- 0.9 mg for '\n",
            "                         'untreated rats. Surprisingly, the F1 hybrid tumors '\n",
            "                         'were not hemorrhagic and had hemoglobin content and '\n",
            "                         'outward appearance identical to that of BN. '\n",
            "                         'Expression of both growth and morphological changes '\n",
            "                         'is due to multiple genes. However, while DES-induced '\n",
            "                         'pituitary growth exhibited quantitative, additive '\n",
            "                         'inheritance, the hemorrhagic phenotype exhibited '\n",
            "                         'recessive, epistatic inheritance. Only 5 of the 160 '\n",
            "                         'F2 pituitaries exhibited the hemorrhagic phenotype; '\n",
            "                         '36 of the 160 F2 pituitaries were in the F344 range '\n",
            "                         'of mass, but 31 of these were not hemorrhagic, '\n",
            "                         'indicating that the hemorrhagic phenotype is not '\n",
            "                         'merely a consequence of extensive growth. The '\n",
            "                         'hemorrhagic F2 pituitaries were all among the most '\n",
            "                         'massive, indicating that some of the genes regulate '\n",
            "                         'both phenotypes.The important background information '\n",
            "                         'needed to understand this text is  the fact that the '\n",
            "                         'F344 rat is a model of the human disease, pituitary '\n",
            "                         'adenoma.',\n",
            "             'chemical2id': {'des': 'D004054',\n",
            "                             'diethylstilbestrol': 'D004054',\n",
            "                             'estrogen': 'D004967'},\n",
            "             'disease2id': {'hemorrhagic': 'D006470',\n",
            "                            'pituitary tumors': 'D010911',\n",
            "                            'tumor': 'D009369',\n",
            "                            'tumors': 'D009369'},\n",
            "             'relations': [{'chemical': 'D004054', 'disease': 'D010911'}],\n",
            "             'title': 'Genetic separation of tumor growth and hemorrhagic '\n",
            "                      'phenotypes in an estrogen-induced tumor.'},\n",
            " '8808730': {'abstract': 'Immunocytochemical techniques were used to examine '\n",
            "                         'alterations in the expression of neuronal nitric '\n",
            "                         'oxide synthase (NOS) in bladder pathways following '\n",
            "                         'acute and chronic irritation of the urinary tract of '\n",
            "                         'the rat. Chemical cystitis was induced by '\n",
            "                         'cyclophosphamide (CYP) which is metabolized to '\n",
            "                         'acrolein, an irritant eliminated in the urine. '\n",
            "                         'Injection of CYP (n = 10, 75 mg/kg, i.p.) 2 hours '\n",
            "                         'prior to perfusion (acute treatment) of the animals '\n",
            "                         'increased Fos-immunoreactivity (IR) in neurons in '\n",
            "                         'the dorsal commissure, dorsal horn, and autonomic '\n",
            "                         'regions of spinal segments (L1-L2 and L6-S1) which '\n",
            "                         'receive afferent inputs from the bladder, urethra, '\n",
            "                         'and ureter. Fos-IR in the spinal cord was not '\n",
            "                         'changed in rats receiving chronic CYP treatment (n = '\n",
            "                         '15, 75 mg/kg, i.p., every 3rd day for 2 weeks). In '\n",
            "                         'control animals and in animals treated acutely with '\n",
            "                         'CYP, only small numbers of NOS-IR cells (0.5-0.7 '\n",
            "                         'cell profiles/sections) were detected in the L6-S1 '\n",
            "                         'dorsal root ganglia (DRG). Chronic CYP '\n",
            "                         'administration significantly (P < or = .002) '\n",
            "                         'increased bladder weight by 60% and increased (7- to '\n",
            "                         '11-fold) the numbers of NOS-immunoreactive (IR) '\n",
            "                         'afferent neurons in the L6-S1 DRG. A small increase '\n",
            "                         '(1.5-fold) also occurred in the L1 DRG, but no '\n",
            "                         'change was detected in the L2 and L5 DRG. Bladder '\n",
            "                         'afferent cells in the L6-S1 DRG labeled by '\n",
            "                         'Fluorogold (40 microliters) injected into the '\n",
            "                         'bladder wall did not exhibit NOS-IR in control '\n",
            "                         'animals; however, following chronic CYP '\n",
            "                         'administration, a significant percentage of bladder '\n",
            "                         'afferent neurons were NOS-IR: L6 (19.8 +/- 4.6%) and '\n",
            "                         'S1 (25.3 +/- 2.9%). These results indicate that '\n",
            "                         'neuronal gene expression in visceral sensory '\n",
            "                         'pathways can be upregulated by chemical irritation '\n",
            "                         'of afferent receptors in the urinary tract and/or '\n",
            "                         'that pathological changes in the urinary tract can '\n",
            "                         'initiate chemical signals that alter the chemical '\n",
            "                         'properties of visceral afferent neurons.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  that the bladder is a '\n",
            "                         'complex organ and that the bladder is innervated by '\n",
            "                         'a variety of sensory neurons.',\n",
            "             'chemical2id': {'acrolein': 'D000171',\n",
            "                             'cyclophosphamide': 'D003520',\n",
            "                             'cyp': 'D003520',\n",
            "                             'nitric oxide': 'D009569'},\n",
            "             'disease2id': {'bladder irritation': 'D001745',\n",
            "                            'cystitis': 'D003556',\n",
            "                            'irritation of the urinary tract': 'D014570'},\n",
            "             'relations': [{'chemical': 'D003520', 'disease': 'D003556'}],\n",
            "             'title': 'Increased expression of neuronal nitric oxide synthase '\n",
            "                      'in bladder afferent pathways following chronic bladder '\n",
            "                      'irritation.'},\n",
            " '8819482': {'abstract': 'Effects of CD-832 on isoproterenol (ISO)-induced '\n",
            "                         'myocardial ischemia were studied in dogs with '\n",
            "                         'partial coronary stenosis of the left circumflex '\n",
            "                         'coronary artery and findings were compared with '\n",
            "                         'those for nifedipine or diltiazem. In the presence '\n",
            "                         'of coronary artery stenosis, 3-min periods of '\n",
            "                         'intracoronary ISO infusion (10 ng/kg/min) increased '\n",
            "                         'heart rate and maximal rate of left ventricular '\n",
            "                         'pressure rise, which resulted in a decrease in '\n",
            "                         'percentage segmental shortening and ST-segment '\n",
            "                         'elevation of the epicardial electrocardiogram. After '\n",
            "                         'the control ISO infusion with stenosis was '\n",
            "                         'performed, equihypotensive doses of CD-832 (3 and 10 '\n",
            "                         'micrograms/kg/min, n = 7), nifedipine (1 and 3 '\n",
            "                         'micrograms/kg/min, n = 9) or diltiazem (10 and 30 '\n",
            "                         'micrograms/kg/min, n = 7) were infused 5 min before '\n",
            "                         'and during the second and third ISO infusion. Both '\n",
            "                         'CD-832 and diltiazem, but not nifedipine, '\n",
            "                         'significantly reduced the increase in heart rate '\n",
            "                         'induced by ISO infusion. In contrast to nifedipine, '\n",
            "                         'CD-832 (10 micrograms/kg/min) prevented the decrease '\n",
            "                         'in percentage segmental shortening from 32 +/- 12% '\n",
            "                         'to 115 +/- 26% of the control value (P < .01) and '\n",
            "                         'ST-segment elevation from 5.6 +/- 1.0 mV to 1.6 +/- '\n",
            "                         '1.3 mV (P < .01) at 3 min after ISO infusion with '\n",
            "                         'stenosis. Diltiazem (30 micrograms/kg/min) also '\n",
            "                         'prevented the decrease in percentage segmental '\n",
            "                         'shortening from 34 +/- 14% to 63 +/- 18% of the '\n",
            "                         'control value (P < .05) and ST-segment elevation '\n",
            "                         'from 4.7 +/- 0.7 mV to 2.1 +/- 0.7 mV (P < .01) at 3 '\n",
            "                         'min after ISO infusion with stenosis. These data '\n",
            "                         'show that CD-832 improves myocardial ischemia during '\n",
            "                         'ISO infusion with stenosis and suggest that the '\n",
            "                         'negative chronotropic property of CD-832 plays a '\n",
            "                         'major role in the beneficial effects of CD-832.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that CD-832 is a '\n",
            "                         'calcium channel blocker with a high affinity for the '\n",
            "                         'L-type calcium channel.',\n",
            "             'chemical2id': {'calcium': 'D002118',\n",
            "                             'cd-832': 'C082828',\n",
            "                             'diltiazem': 'D004110',\n",
            "                             'iso': 'D007545',\n",
            "                             'isoproterenol': 'D007545',\n",
            "                             'nifedipine': 'D009543'},\n",
            "             'disease2id': {'coronary artery stenosis': 'D023921',\n",
            "                            'coronary stenosis': 'D023921',\n",
            "                            'myocardial ischemia': 'D017202',\n",
            "                            'stenosis': 'D003251'},\n",
            "             'relations': [{'chemical': 'D007545', 'disease': 'D017202'}],\n",
            "             'title': 'Effects of a new calcium antagonist, CD-832, on '\n",
            "                      'isoproterenol-induced myocardial ischemia in dogs with '\n",
            "                      'partial coronary stenosis.'},\n",
            " '8825380': {'abstract': 'We recently demonstrated that recombinant hGH '\n",
            "                         'exacerbates renal functional and structural injury '\n",
            "                         'in chronic puromycin aminonucleoside (PAN) '\n",
            "                         'nephropathy, an experimental model of glomerular '\n",
            "                         'disease. Therefore, we examined whether recombinant '\n",
            "                         'human (rh) IGF-I is a safer alternative for the '\n",
            "                         'treatment of growth failure in rats with chronic PAN '\n",
            "                         'nephropathy. The glomerulopathy was induced by seven '\n",
            "                         'serial injections of PAN over 12 wk. Experimental '\n",
            "                         'animals (n = 6) received rhIGF-I, 400 micrograms/d, '\n",
            "                         'whereas control rats (n = 6) received the vehicle. '\n",
            "                         'rhIGF-I improved weight gain by 14% (p < 0.05), '\n",
            "                         'without altering hematocrit or blood pressure in '\n",
            "                         'rats with renal disease. Urinary protein excretion '\n",
            "                         'was unaltered by rhIGF-I treatment in rats with '\n",
            "                         'chronic PAN nephropathy. After 12 wk, the inulin '\n",
            "                         'clearance was higher in rhIGF-I-treated rats, 0.48 '\n",
            "                         '+/- 0.08 versus 0.24 +/- 0.06 mL/min/100 g of body '\n",
            "                         'weight in untreated PAN nephropathy animals, p < '\n",
            "                         '0.05. The improvement in GFR was not associated with '\n",
            "                         'enhanced glomerular hypertrophy or increased '\n",
            "                         'segmental glomerulosclerosis, tubulointerstitial '\n",
            "                         'injury, or renal cortical malondialdehyde content. '\n",
            "                         'In rats with PAN nephropathy, administration of '\n",
            "                         'rhIGF-I increased IGF-I and GH receptor gene '\n",
            "                         'expression, without altering the steady state level '\n",
            "                         'of IGF-I receptor mRNA. In normal rats with intact '\n",
            "                         'kidneys, rhIGF-I administration (n = 4) did not '\n",
            "                         'alter weight gain, blood pressure, proteinuria, GFR, '\n",
            "                         'glomerular planar area, renal cortical '\n",
            "                         'malondialdehyde content, or glomerular or '\n",
            "                         'tubulointerstitial damage, compared with untreated '\n",
            "                         'animals (n = 4). rhIGF-I treatment reduced the '\n",
            "                         'steady state renal IGF-I mRNA level but did not '\n",
            "                         'modify gene expression of the IGF-I or GH receptors. '\n",
            "                         'We conclude that: 1) administration of rhIGF-I '\n",
            "                         'improves growth and GFR in rats with chronic PAN '\n",
            "                         'nephropathy and 2) unlike rhGH, long-term use of '\n",
            "                         'rhIGF-I does not worsen renal functional and '\n",
            "                         'structural injury in this disease model.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  that the effects of rhIGF-I '\n",
            "                         'on glomerular growth and function in rats with '\n",
            "                         'chronic PAN nephropathy are not mediated by '\n",
            "                         'increased renal cortical malondialdehyde content or '\n",
            "                         'increased renal cortical IGF-I receptor mRNA.',\n",
            "             'chemical2id': {'malondialdehyde': 'D008315',\n",
            "                             'pan': 'D011692',\n",
            "                             'puromycin aminonucleoside': 'D011692'},\n",
            "             'disease2id': {'glomerular disease': 'D007674',\n",
            "                            'glomerular hypertrophy': 'D007674',\n",
            "                            'glomerulopathy': 'D007674',\n",
            "                            'glomerulosclerosis': 'D005921',\n",
            "                            'growth failure': 'D006130',\n",
            "                            'nephropathy': 'D007674',\n",
            "                            'proteinuria': 'D011507',\n",
            "                            'renal disease': 'D007674',\n",
            "                            'tubulointerstitial damage': 'D007674',\n",
            "                            'tubulointerstitial injury': '-1'},\n",
            "             'relations': [{'chemical': 'D011692', 'disease': 'D007674'}],\n",
            "             'title': 'The effect of recombinant human insulin-like growth '\n",
            "                      'factor-I on chronic puromycin aminonucleoside '\n",
            "                      'nephropathy in rats.'},\n",
            " '8829135': {'abstract': 'Nefiracetam is a novel pyrrolidone derivative which '\n",
            "                         'attenuates scopolamine-induced learning and '\n",
            "                         'post-training consolidation deficits. Given that '\n",
            "                         'apomorphine inhibits passive avoidance retention '\n",
            "                         'when given during training or in a defined 10-12h '\n",
            "                         'post-training period, we evaluated the ability of '\n",
            "                         'nefiracetam to attenuate amnesia induced by '\n",
            "                         'dopaminergic agonism. A step-down passive avoidance '\n",
            "                         'paradigm was employed and nefiracetam (3 mg/kg) and '\n",
            "                         'apomorphine (0.5 mg/kg) were given alone or in '\n",
            "                         'combination during training and at the 10-12h '\n",
            "                         'post-training period of consolidation. '\n",
            "                         'Co-administration of nefiracetam and apomorphine '\n",
            "                         'during training or 10h thereafter produced no '\n",
            "                         'significant anti-amnesic effect. However, '\n",
            "                         'administration of nefiracetam during training '\n",
            "                         'completely reversed the amnesia induced by '\n",
            "                         'apomorphine at the 10h post-training time and the '\n",
            "                         'converse was also true. These effects were not '\n",
            "                         'mediated by a dopaminergic mechanism as nefiracetam, '\n",
            "                         'at millimolar concentrations, failed to displace '\n",
            "                         'either [3H]SCH 23390 or [3H]spiperone binding from '\n",
            "                         'D1 or D2 dopamine receptor subtypes, respectively. '\n",
            "                         'It is suggested that nefiracetam augments molecular '\n",
            "                         'processes in the early stages of events which '\n",
            "                         'ultimately lead to consolidation of memory.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that nefiracetam '\n",
            "                         'is a novel pyrrolidone derivative which has been '\n",
            "                         'shown to be a potent and selective agonist at the '\n",
            "                         'presynaptic dopamine autoreceptor.',\n",
            "             'chemical2id': {'apomorphine': 'D001058',\n",
            "                             'dm-9384': 'C058876',\n",
            "                             'dopamine': 'D004298',\n",
            "                             'nefiracetam': 'C058876',\n",
            "                             'pyrrolidone': 'D011760',\n",
            "                             'sch 23390': 'C534628',\n",
            "                             'scopolamine': 'D012601',\n",
            "                             'spiperone': 'D013134'},\n",
            "             'disease2id': {'amnesia': 'D000647',\n",
            "                            'learning and post-training consolidation deficits': 'D007859'},\n",
            "             'relations': [{'chemical': 'D012601', 'disease': 'D007859'},\n",
            "                           {'chemical': 'D001058', 'disease': 'D000647'}],\n",
            "             'title': 'Nefiracetam (DM-9384) reverses apomorphine-induced '\n",
            "                      'amnesia of a passive avoidance response: delayed '\n",
            "                      'emergence of the memory retention effects.'},\n",
            " '891494': {'abstract': 'A case of phenytoin (DPH) encephalopathy with '\n",
            "                        'increasing seizures and EEG and mental changes is '\n",
            "                        'described. Despite adequate oral dosage of DPH (5 '\n",
            "                        'mg/kg/daily) the plasma level was very low (2.8 '\n",
            "                        'microgramg/ml). The encephalopathy was probably an '\n",
            "                        'idiosyncratic and not toxic or allergic reaction. In '\n",
            "                        'fact the concentration of free DPH was normal, the '\n",
            "                        'patient presented a retarded morbilliform rash during '\n",
            "                        'DPH treatment, the protidogram was normal, and an '\n",
            "                        'intradermic DPH injection had no local effect. The '\n",
            "                        'authors conclude that in a patient starting DPH '\n",
            "                        'treatment an unexpected increase in seizures, with '\n",
            "                        'EEG and mental changes occurring simultaneously, '\n",
            "                        'should alert the physician to the possible need for '\n",
            "                        'eliminating DPH from the therapeutic regimen, even if '\n",
            "                        'plasma concentrations are low.The important '\n",
            "                        'background information needed to understand this text '\n",
            "                        'is  the fact that the DPH encephalopathy is a rare '\n",
            "                        'but serious adverse effect of DPH.',\n",
            "            'chemical2id': {'dph': 'D010672', 'phenytoin': 'D010672'},\n",
            "            'disease2id': {'encephalopathy': 'D001927',\n",
            "                           'rash': 'D005076',\n",
            "                           'seizures': 'D012640'},\n",
            "            'relations': [{'chemical': 'D010672', 'disease': 'D001927'}],\n",
            "            'title': 'Phenytoin encephalopathy as probable idiosyncratic '\n",
            "                     'reaction: case report.'},\n",
            " '89511': {'abstract': 'The treatment regimens are described in 74 patients '\n",
            "                       'with endometrial disease among 850 climacteric women '\n",
            "                       'receiving oestrogen therapy. Cystic hyperplasia was '\n",
            "                       'associated with unopposed oestrogen therapy without '\n",
            "                       'progestagen. Two courses of 21 days of 5 mg '\n",
            "                       'norethisterone daily caused reversion to normal in all '\n",
            "                       '57 cases of cystic hyperplasia and 6 of the 8 cases of '\n",
            "                       'atypical hyperplasia. 4 cases of endometrial carcinoma '\n",
            "                       'referred from elsewhere demonstrated the problems of '\n",
            "                       'inappropriate and unsupervised unopposed oestrogen '\n",
            "                       'therapy and the difficulty in distinguishing severe '\n",
            "                       'hyperplasia from malignancy. Cyclical low-dose '\n",
            "                       'oestrogen therapy with 7--13 days of progestagen does '\n",
            "                       'not seem to increase the risk of endometrial '\n",
            "                       'hyperplasia or carcinoma.The important background '\n",
            "                       'information needed to understand this text is  the '\n",
            "                       'fact that the incidence of endometrial carcinoma in '\n",
            "                       'climacteric women is low and that the incidence of '\n",
            "                       'endometrial carcinoma in women with cystic hyperplasia '\n",
            "                       'is not increased by progestagen therapy.',\n",
            "           'chemical2id': {'norethisterone': 'D009640',\n",
            "                           'oestrogen': 'D004967',\n",
            "                           'progestagen': 'D011372'},\n",
            "           'disease2id': {'carcinoma': 'D002277',\n",
            "                          'endometrial carcinoma': 'D016889',\n",
            "                          'endometrial disease': 'D014591',\n",
            "                          'endometrial hyperplasia': 'D004714',\n",
            "                          'hyperplasia': 'D006965',\n",
            "                          'malignancy': 'D009369'},\n",
            "           'relations': [{'chemical': 'D004967', 'disease': 'D006965'}],\n",
            "           'title': 'Prevention and treatment of endometrial disease in '\n",
            "                    'climacteric women receiving oestrogen therapy.'},\n",
            " '895432': {'abstract': 'The effect of exercise on the severity of '\n",
            "                        'isoproterenol-induced myocardial infarction was '\n",
            "                        'studied in male rats. Ninety-three rats were randomly '\n",
            "                        'divided into three groups. The exercise-isoproterenol '\n",
            "                        '(E-1) and exercise control (EC) groups exercised '\n",
            "                        'daily for thirty days on a treadmill at 1 mph, 2% '\n",
            "                        'grade while animals of the sedentary-isoproterenol '\n",
            "                        '(S-I) group remained sedentary. Eight animals were '\n",
            "                        'assigned to the sedentary control (SC) group which '\n",
            "                        'remained sedentary throughout the experimental '\n",
            "                        'period. Forty-eight hours after the final exercise '\n",
            "                        'period, S-I and E-I animals received a single '\n",
            "                        'subcutaneous injection of isoproterenol (250 mg/kg '\n",
            "                        'body weight). Animals of the S-I group exhibited '\n",
            "                        'significantly (Pp less than 0.05) greater mortality '\n",
            "                        'from the effects of isoproterenol than animals of the '\n",
            "                        'E-I group. Serum CPK activity for E-I animals was '\n",
            "                        'significantly (p less than 0.05) greater than for '\n",
            "                        'animals in the S-I and EC groups twenty hours '\n",
            "                        'following isoproterenol injection. No statistically '\n",
            "                        'significant differences were observed between the two '\n",
            "                        'isoproterenol treated groups for severity of the '\n",
            "                        'induced lesions, changes in heart weight, or heart '\n",
            "                        'weight to body weight ratios. The results indicated '\n",
            "                        'that exercise reduced the mortality associated with '\n",
            "                        'the effects of large dosages of isoproterenol but had '\n",
            "                        'little on the severity of the infarction.The '\n",
            "                        'important background information needed to understand '\n",
            "                        'this text is  the fact that the '\n",
            "                        'exercise-isoproterenol model is a useful tool for '\n",
            "                        'studying the effects of exercise on the development '\n",
            "                        'of myocardial infarction.',\n",
            "            'chemical2id': {'isoproterenol': 'D007545'},\n",
            "            'disease2id': {'infarction': 'D007238',\n",
            "                           'myocardial infarction': 'D009203'},\n",
            "            'relations': [{'chemical': 'D007545', 'disease': 'D009203'}],\n",
            "            'title': 'Effects of exercise on the severity of '\n",
            "                     'isoproterenol-induced myocardial infarction.'},\n",
            " '8957205': {'abstract': 'Human corticotropin-releasing hormone (hCRH) and '\n",
            "                         'thyrotropin-releasing hormone (TRH) are known to '\n",
            "                         'stimulate ventilation after i.v. administration in '\n",
            "                         'humans. In a placebo-controlled, single-blind study '\n",
            "                         'we aimed to clarify if both peptides act by altering '\n",
            "                         'central chemosensitivity. Two subsequent '\n",
            "                         'CO2-rebreathing tests were performed in healthy '\n",
            "                         'young volunteers. During the first test 0.9% NaCl '\n",
            "                         'was given i.v.; during the second test 200 '\n",
            "                         'micrograms of hCRH (n = 12) or 400 micrograms of TRH '\n",
            "                         '(n = 6) was administered i.v. Nine subjects received '\n",
            "                         '0.9% NaCl i.v. during both rebreathing manoeuvres. '\n",
            "                         'The CO2-response curves for the two tests were '\n",
            "                         'compared within the same subject. In the hCRH group '\n",
            "                         'a marked parallel shift of the CO2-response curve to '\n",
            "                         'the left was observed after hCRH (P < 0.01). The '\n",
            "                         'same effect occurred following TRH but was less '\n",
            "                         'striking (P = 0.05). hCRH and TRH caused a reduction '\n",
            "                         'in the CO2 threshold. The CO2-response curves in the '\n",
            "                         'control group were nearly identical. The results '\n",
            "                         'indicate an additive effect of both releasing '\n",
            "                         'hormones on the hypercapnic ventilatory response in '\n",
            "                         'humans, presumably independent of central '\n",
            "                         'chemosensitivity.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that the ventilatory response to CO2 is not '\n",
            "                         'altered by the administration of either hCRH or TRH.',\n",
            "             'chemical2id': {'co2': 'D002245',\n",
            "                             'corticotropin': 'D000324',\n",
            "                             'nacl': 'D012965',\n",
            "                             'thyrotropin': 'D013972'},\n",
            "             'disease2id': {'hypercapnic': 'D006935'},\n",
            "             'relations': [{'chemical': 'D002245', 'disease': 'D006935'}],\n",
            "             'title': 'Human corticotropin-releasing hormone and '\n",
            "                      'thyrotropin-releasing hormone modulate the hypercapnic '\n",
            "                      'ventilatory response in humans.'},\n",
            " '8985298': {'abstract': \"Lamivudine is a novel 2',3'-dideoxy cytosine \"\n",
            "                         'analogue that has potent inhibitory effects on '\n",
            "                         'hepatitis B virus replication in vitro and in vivo. '\n",
            "                         'We performed a single-blind, placebo-controlled '\n",
            "                         'study to assess its effectiveness and safety in '\n",
            "                         'Chinese hepatitis B surface antigen (HBsAg) '\n",
            "                         'carriers. Forty-two Chinese HBsAg carriers were '\n",
            "                         'randomized to receive placebo (6 patients) or '\n",
            "                         'lamivudine orally in dosages of 25 mg, 100 mg, or '\n",
            "                         '300 mg daily (12 patients for each dosage). The drug '\n",
            "                         'was given for 4 weeks. The patients were closely '\n",
            "                         'monitored clinically, biochemically, and '\n",
            "                         'serologically up to 4 weeks after drug treatment. '\n",
            "                         'All 36 patients receiving lamivudine had a decrease '\n",
            "                         'in hepatitis B virus (HBV) DNA values of >90% (P < '\n",
            "                         '.001 compared with placebo). Although 25 mg of '\n",
            "                         'lamivudine was slightly less effective than 100 mg '\n",
            "                         '(P = .011) and 300 mg (P = .005), it still induced '\n",
            "                         '94% suppression of HBV DNA after the fourth week of '\n",
            "                         'therapy. HBV DNA values returned to pretreatment '\n",
            "                         'levels within 4 weeks of cessation of therapy. There '\n",
            "                         'was no change in the hepatitis B e antigen status or '\n",
            "                         'in aminotransferase levels. No serious adverse '\n",
            "                         'events were observed. In conclusion, a 4-week course '\n",
            "                         'of lamivudine was safe and effective in suppression '\n",
            "                         'of HBV DNA in Chinese HBsAg carriers. The '\n",
            "                         'suppression was >90% but reversible. Studies with '\n",
            "                         'long-term lamivudine administration should be '\n",
            "                         'performed to determine if prolonged suppression of '\n",
            "                         'HBV DNA can be achieved.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that lamivudine is a nucleoside analogue that '\n",
            "                         'is not a prodrug and that it is not a polymerase '\n",
            "                         'inhibitor.',\n",
            "             'chemical2id': {\"2',3'-dideoxy cytosine\": 'D019259',\n",
            "                             'hbsag': 'D006514',\n",
            "                             'hepatitis b surface antigen': 'D006514',\n",
            "                             'lamivudine': 'D019259'},\n",
            "             'disease2id': {'hepatitis b': 'D006509'},\n",
            "             'relations': [{'chemical': 'D006514', 'disease': 'D006509'}],\n",
            "             'title': 'Lamivudine is effective in suppressing hepatitis B '\n",
            "                      'virus DNA in Chinese hepatitis B surface antigen '\n",
            "                      'carriers: a placebo-controlled trial.'},\n",
            " '8996419': {'abstract': 'BACKGROUND: Four studies published since December, '\n",
            "                         '1995, reported that the incidence of venous '\n",
            "                         'thromboembolism (VTE) was higher in women who used '\n",
            "                         'oral contraceptives (OCs) containing the '\n",
            "                         'third-generation progestagens gestodene or '\n",
            "                         'desogestrel than in users of OCs containing '\n",
            "                         'second-generation progestagens. However, confounding '\n",
            "                         'and bias in the design of these studies may have '\n",
            "                         'affected the findings. The aim of our study was to '\n",
            "                         're-examine the association between risk of VTE and '\n",
            "                         'OC use with a different study design and analysis to '\n",
            "                         'avoid some of the bias and confounding of the '\n",
            "                         'earlier studies. METHODS: We used computer records '\n",
            "                         'of patients from 143 general practices in the UK. '\n",
            "                         'The study was based on the medical records of about '\n",
            "                         '540,000 women born between 1941 and 1981. All women '\n",
            "                         'who had a recorded diagnosis of deep-vein '\n",
            "                         'thrombosis, venous thrombosis not otherwise '\n",
            "                         'specified, or pulmonary embolus during the study '\n",
            "                         'period, and who had been treated with an '\n",
            "                         'anticoagulant were identified as potential cases of '\n",
            "                         'VTE. We did a cohort analysis to estimate and '\n",
            "                         'compare incidence of VTE in users of the main OC '\n",
            "                         'preparations, and a nested case-control study to '\n",
            "                         'calculate the odds ratios of VTE associated with use '\n",
            "                         'of different types of OC, after adjustment for '\n",
            "                         'potential confounding factors. In the case-control '\n",
            "                         'study, we matched cases to controls by exact year of '\n",
            "                         'birth, practice, and current use of OCs. We used a '\n",
            "                         'multiple logistic regression model that included '\n",
            "                         'body-mass index, number of cycles, change in type of '\n",
            "                         'OC prescribed within 3 months of the event, previous '\n",
            "                         'pregnancy, and concurrent disease. FINDINGS: 85 '\n",
            "                         'women met the inclusion criteria for VTE, two of '\n",
            "                         'whom were users of progestagen-only OCs. Of the 83 '\n",
            "                         'cases of VTE associated with use of combined OCs, 43 '\n",
            "                         'were recorded as deep-vein thrombosis, 35 as '\n",
            "                         'pulmonary thrombosis, and five as venous thrombosis '\n",
            "                         'not otherwise specified. The crude rate of VTE per '\n",
            "                         '10,000 woman-years was 4.10 in current users of any '\n",
            "                         'OC, 3.10 in users of second-generation OCs, and 4.96 '\n",
            "                         'in users of third-generation preparations. After '\n",
            "                         'adjustment for age, the rate ratio of VTE in users '\n",
            "                         'of third-generation relative to second-generation '\n",
            "                         'OCs was 1.68 (95% CI 1.04-2.75). Logistic regression '\n",
            "                         'showed no significant difference in the risk of VTE '\n",
            "                         'between users of third-generation and '\n",
            "                         'second-generation OCs. Among users of '\n",
            "                         'third-generation progestagens, the risk of VTE was '\n",
            "                         'higher in users of desogestrel with 20 g '\n",
            "                         'ethinyloestradiol than in users of gestodene or '\n",
            "                         'desogestrel with 30 g ethinyloestradiol. With all '\n",
            "                         'second-generation OCs as the reference, the odds '\n",
            "                         'ratios for VTE were 3.49 (1.21-10.12) for '\n",
            "                         'desogestrel plus 20 g ethinyloestradiol and 1.18 '\n",
            "                         '(0.66-2.17) for the other third-generation '\n",
            "                         'progestagens. INTERPRETATION: The previously '\n",
            "                         'reported increase in odds ratio associated with '\n",
            "                         'third-generation OCs when compared with '\n",
            "                         'second-generation products is likely to have been '\n",
            "                         'the result of residual confounding by age. The '\n",
            "                         'increased odds ratio associated with products '\n",
            "                         'containing 20 micrograms ethinyloestradiol and '\n",
            "                         'desogestrel compared with the 30 micrograms product '\n",
            "                         'is biologically implausible, and is likely to be the '\n",
            "                         'result of preferential prescribing and, thus, '\n",
            "                         'confounding.The important background information '\n",
            "                         'needed to understand this text is  the fact that the '\n",
            "                         'risk of VTE associated with third-generation '\n",
            "                         'progestagens is not significantly different from '\n",
            "                         'that associated with second-generation progestagens.',\n",
            "             'chemical2id': {'desogestrel': 'D017135',\n",
            "                             'ethinyloestradiol': 'D004997',\n",
            "                             'gestodene': 'C033273',\n",
            "                             'oc': 'D003276',\n",
            "                             'ocs': 'D003276',\n",
            "                             'oral contraceptives': 'D003276',\n",
            "                             'progestagen': 'D011372',\n",
            "                             'progestagens': 'D011374'},\n",
            "             'disease2id': {'deep-vein thrombosis': 'D020246',\n",
            "                            'thrombosis': 'D013927',\n",
            "                            'venous thromboembolism': 'D054556',\n",
            "                            'venous thrombosis': 'D020246',\n",
            "                            'vte': 'D054556'},\n",
            "             'relations': [{'chemical': 'D003276', 'disease': 'D054556'}],\n",
            "             'title': 'Population-based study of risk of venous '\n",
            "                      'thromboembolism associated with various oral '\n",
            "                      'contraceptives.'},\n",
            " '9061777': {'abstract': '1. The authors examined the anticonvulsant effects '\n",
            "                         'of MK-801 on the pilocarpine-induced seizure model. '\n",
            "                         'Intraperitoneal injection of pilocarpine (400 mg/kg) '\n",
            "                         'induced tonic and clonic seizure. Scopolamine (10 '\n",
            "                         'mg/kg) and pentobarbital (5 mg/kg) prevented '\n",
            "                         'development of pilocarpine-induced behavioral '\n",
            "                         'seizure but MK-801 (0.5 mg/kg) did not. 2. An '\n",
            "                         'electrical seizure measured with hippocampal EEG '\n",
            "                         'appeared in the pilocarpine-treated group. '\n",
            "                         'Scopolamine and pentobarbital blocked the '\n",
            "                         'pilocarpine-induced electrographic seizure, MK-801 '\n",
            "                         'treatment augmented the electrographic seizure '\n",
            "                         'induced by pilocarpine. 3. Brain damage was assessed '\n",
            "                         'by examining the hippocampus microscopically. '\n",
            "                         'Pilocarpine produced neuronal death in the '\n",
            "                         'hippocampus, which showed pyknotic changes. '\n",
            "                         'Pentobarbital, scopolamine and MK-801 protected the '\n",
            "                         'brain damage by pilocarpine, though in the '\n",
            "                         'MK-801-treated group, the pyramidal cells of '\n",
            "                         'hippocampus appeared darker than normal. In all '\n",
            "                         'treatments, granule cells of the dentate gyrus were '\n",
            "                         'not affected. 4. These results indicate that status '\n",
            "                         'epilepticus induced by pilocarpine is initiated by '\n",
            "                         'cholinergic overstimulation and propagated by '\n",
            "                         'glutamatergic transmission, the elevation of which '\n",
            "                         'may cause brain damage through an excitatory NMDA '\n",
            "                         'receptor-mediated mechanism.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that MK-801 did not prevent the development of '\n",
            "                         'pilocarpine-induced behavioral seizure, but it did '\n",
            "                         'block the pilocarpine-induced electrographic '\n",
            "                         'seizure.',\n",
            "             'chemical2id': {'mk-801': 'D016291',\n",
            "                             'nmda': 'D016202',\n",
            "                             'pentobarbital': 'D010424',\n",
            "                             'pilocarpine': 'D010862',\n",
            "                             'scopolamine': 'D012601'},\n",
            "             'disease2id': {'brain damage': 'D001930',\n",
            "                            'neuronal death': 'D009410',\n",
            "                            'seizure': 'D012640',\n",
            "                            'status epilepticus': 'D013226',\n",
            "                            'tonic and clonic seizure': 'D012640'},\n",
            "             'relations': [{'chemical': 'D010862', 'disease': 'D009410'},\n",
            "                           {'chemical': 'D010862', 'disease': 'D013226'},\n",
            "                           {'chemical': 'D010862', 'disease': 'D012640'},\n",
            "                           {'chemical': 'D016291', 'disease': 'D012640'}],\n",
            "             'title': 'MK-801 augments pilocarpine-induced electrographic '\n",
            "                      'seizure but protects against brain damage in rats.'},\n",
            " '9071336': {'abstract': '5-Fluorouracil plus folinic acid and paclitaxel '\n",
            "                         '(Taxol; Bristol-Myers Squibb Company, Princeton, NJ) '\n",
            "                         'are effective salvage therapies for metastatic '\n",
            "                         'breast cancer patients. Paclitaxel and '\n",
            "                         '5-fluorouracil have additive cytotoxicity in MCF-7 '\n",
            "                         'cell lines. We performed a phase II trial of '\n",
            "                         'paclitaxel 175 mg/m2 over 3 hours on day I followed '\n",
            "                         'by folinic acid 300 mg over 1 hour before '\n",
            "                         '5-fluorouracil 350 mg/m2 on days 1 to 3 every 28 '\n",
            "                         'days (TFL) in women with metastatic breast cancer. '\n",
            "                         'Analysis is reported on 37 patients with a minimum '\n",
            "                         'of 6 months follow-up who received a total of 192 '\n",
            "                         'cycles of TFL: nine cycles (5%) were associated with '\n",
            "                         'grade 3/4 neutropenia requiring hospitalization; '\n",
            "                         'seven (4%) cycles in two patients required '\n",
            "                         'granulocyte colony-stimulating factor due to '\n",
            "                         'neutropenia; no patient required platelet '\n",
            "                         'transfusions. Grade 3/4 nonhematologic toxicities '\n",
            "                         'were uncommon. Among the 34 patients evaluable for '\n",
            "                         'response, there were three complete responses (9%) '\n",
            "                         'and 18 partial responses (53%) for an overall '\n",
            "                         'response rate of 62%. Of the 19 evaluable patients '\n",
            "                         'with prior doxorubicin exposure, 11 (58%) responded '\n",
            "                         'compared with nine of 15 (60%) without prior '\n",
            "                         'doxorubicin. Plasma paclitaxel concentrations were '\n",
            "                         'measured at the completion of paclitaxel infusion '\n",
            "                         'and at 24 hours in 19 patients. TFL is an active, '\n",
            "                         'well-tolerated regimen in metastatic breast '\n",
            "                         'cancer.The important background information needed '\n",
            "                         'to understand this text is  the fact that the TFL '\n",
            "                         'regimen is a combination of paclitaxel and '\n",
            "                         '5-fluorouracil that is active in patients with '\n",
            "                         'metastatic breast cancer.',\n",
            "             'chemical2id': {'5-fluorouracil': 'D005472',\n",
            "                             'doxorubicin': 'D004317',\n",
            "                             'folinic acid': 'D002955',\n",
            "                             'granulocyte colony-stimulating factor': 'D016179',\n",
            "                             'paclitaxel': 'D017239',\n",
            "                             'taxol': 'D017239'},\n",
            "             'disease2id': {'breast cancer': 'D001943',\n",
            "                            'cytotoxicity': 'D064420',\n",
            "                            'neutropenia': 'D009503',\n",
            "                            'toxicities': 'D064420'},\n",
            "             'relations': [{'chemical': 'D002955', 'disease': 'D009503'},\n",
            "                           {'chemical': 'D017239', 'disease': 'D009503'},\n",
            "                           {'chemical': 'D005472', 'disease': 'D009503'}],\n",
            "             'title': 'Paclitaxel, 5-fluorouracil, and folinic acid in '\n",
            "                      'metastatic breast cancer: BRE-26, a phase II trial.'},\n",
            " '9125676': {'abstract': 'This study prospectively evaluated the clinical '\n",
            "                         'efficacy, the incidence of torsades de pointes, and '\n",
            "                         'the presumable risk factors for torsades de pointes '\n",
            "                         'in patients treated with d,l-sotalol for sustained '\n",
            "                         'ventricular tachyarrhythmias. Eighty-one consecutive '\n",
            "                         'patients (54 with coronary artery disease, and 20 '\n",
            "                         'with dilated cardiomyopathy) with inducible '\n",
            "                         'sustained ventricular tachycardia or ventricular '\n",
            "                         'fibrillation received oral d,l-sotalol to prevent '\n",
            "                         'induction of the ventricular tachyarrhythmia. During '\n",
            "                         'oral loading with d,l-sotalol, continuous '\n",
            "                         'electrocardiographic (ECG) monitoring was performed. '\n",
            "                         'Those patients in whom d,l-sotalol prevented '\n",
            "                         'induction of ventricular tachycardia or ventricular '\n",
            "                         'fibrillation were discharged with the drug and '\n",
            "                         'followed up on an outpatient basis for 21 +/- 18 '\n",
            "                         'months. Induction of the ventricular tachyarrhythmia '\n",
            "                         'was prevented by oral d,l-sotalol in 35 (43%) '\n",
            "                         'patients; the ventricular tachyarrhythmia remained '\n",
            "                         'inducible in 40 (49%) patients; and two (2.5%) '\n",
            "                         'patients did not tolerate even 40 mg of d,l-sotalol '\n",
            "                         'once daily. Four (5%) patients had from torsades de '\n",
            "                         'pointes during the initial oral treatment with '\n",
            "                         'd,l-sotalol. Neither ECG [sinus-cycle length (SCL), '\n",
            "                         'QT or QTc interval, or U wave] nor clinical '\n",
            "                         'parameters identified patients at risk for torsades '\n",
            "                         'de pointes. However, the oral dose of d,l-sotalol '\n",
            "                         'was significantly lower in patients with torsades de '\n",
            "                         'pointes (200 +/- 46 vs. 328 +/- 53 mg/day; p = '\n",
            "                         '0.0017). Risk factors associated with the '\n",
            "                         'development of torsades de pointes were the '\n",
            "                         'appearance of an U wave (p = 0.049), female gender '\n",
            "                         '(p = 0.015), and significant dose-corrected changes '\n",
            "                         'of SCL, QT interval, and QTc interval (p < 0.05). '\n",
            "                         'During follow-up, seven (20%) patients had a '\n",
            "                         'nonfatal ventricular tachycardia recurrence, and two '\n",
            "                         '(6%) patients died suddenly. One female patient with '\n",
            "                         'stable cardiac disease had recurrent torsades de '\n",
            "                         'pointes after 2 years of successful treatment with '\n",
            "                         'd,l-sotalol. Torsades de pointes occurred early '\n",
            "                         'during treatment even with low doses of oral '\n",
            "                         'd,l-sotalol. Pronounced changes in the surface ECG '\n",
            "                         '(cycle length, QT, and QTc) in relation to the dose '\n",
            "                         'of oral d,l-sotalol might identify a subgroup of '\n",
            "                         'patients with an increased risk for torsades de '\n",
            "                         'pointes. Other ECG parameters before the application '\n",
            "                         'of d,l-sotalol did not identify patients at '\n",
            "                         'increased risk for torsades de pointes. Recurrence '\n",
            "                         'rates of ventricular tachyarrhythmias are high '\n",
            "                         'despite complete suppression of the arrhythmia '\n",
            "                         'during programmed stimulation. Therefore programmed '\n",
            "                         'electrical stimulation in the case of d,l-sotalol '\n",
            "                         'seems to be of limited prognostic value.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that the risk of '\n",
            "                         'torsades de pointes is not related to the dose of d, '\n",
            "                         'l-sotalol.',\n",
            "             'chemical2id': {'d,l-sotalol': 'D013015'},\n",
            "             'disease2id': {'arrhythmia': 'D001145',\n",
            "                            'cardiac disease': 'D006331',\n",
            "                            'coronary artery disease': 'D003324',\n",
            "                            'dilated cardiomyopathy': 'D002311',\n",
            "                            'proarrhythmia': '-1',\n",
            "                            'torsades de pointes': 'D016171',\n",
            "                            'ventricular fibrillation': 'D014693',\n",
            "                            'ventricular tachyarrhythmia': 'D017180',\n",
            "                            'ventricular tachyarrhythmias': 'D017180',\n",
            "                            'ventricular tachycardia': 'D017180'},\n",
            "             'relations': [{'chemical': 'D013015', 'disease': 'D016171'}],\n",
            "             'title': 'Efficacy and proarrhythmia with the use of d,l-sotalol '\n",
            "                      'for sustained ventricular tachyarrhythmias.'},\n",
            " '9128918': {'abstract': 'The tuberoinfundibular dopaminergic (TIDA) system is '\n",
            "                         'known to inhibit prolactin (PRL) secretion. In young '\n",
            "                         'animals this system responds to acute elevations in '\n",
            "                         'serum PRL by increasing its activity. However, this '\n",
            "                         'responsiveness is lost in aging rats with '\n",
            "                         'chronically high serum PRL levels. The purpose of '\n",
            "                         'this study was to induce hyperprolactinemia in rats '\n",
            "                         'for extended periods of time and examine its effects '\n",
            "                         'on dopaminergic systems in the brain. '\n",
            "                         'Hyperprolactinemia was induced by treatment with '\n",
            "                         'haloperidol, a dopamine receptor antagonist, and '\n",
            "                         \"Palkovits' microdissection technique in combination \"\n",
            "                         'with high-performance liquid chromatography was used '\n",
            "                         'to measure neurotransmitter concentrations in '\n",
            "                         'several areas of the brain. After 6 months of '\n",
            "                         'hyperprolactinemia, dopamine (DA) concentrations in '\n",
            "                         'the median eminence (ME) increased by 84% over the '\n",
            "                         'control group. Nine months of hyperprolactinemia '\n",
            "                         'produced a 50% increase in DA concentrations in the '\n",
            "                         'ME over the control group. However, DA response was '\n",
            "                         'lost if a 9-month long haloperidol-induced '\n",
            "                         'hyperprolactinemia was followed by a 1 1/2 '\n",
            "                         'month-long extremely high increase in serum PRL '\n",
            "                         'levels produced by implantation of MMQ cells under '\n",
            "                         'the kidney capsule. There was no change in the '\n",
            "                         'levels of DA, norepinephrine (NE), serotonin (5-HT), '\n",
            "                         'or their metabolites in the arcuate nucleus (AN), '\n",
            "                         'medial preoptic area (MPA), caudate putamen (CP), '\n",
            "                         'substantia nigra (SN), and zona incerta (ZI), except '\n",
            "                         'for a decrease in 5-hydroxyindoleacetic acid '\n",
            "                         '(5-HIAA) in the AN after 6-months of '\n",
            "                         'hyperprolactinemia and an increase in DA '\n",
            "                         'concentrations in the AN after 9-months of '\n",
            "                         'hyperprolactinemia. These results demonstrate that '\n",
            "                         'hyperprolactinemia specifically affects TIDA neurons '\n",
            "                         'and these effects vary, depending on the duration '\n",
            "                         'and intensity of hyperprolactinemia. The age-related '\n",
            "                         'decrease in hypothalamic dopamine function may be '\n",
            "                         'associated with increases in PRL secretion.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  that the TIDA system is a '\n",
            "                         'target for PRL and that the effects of '\n",
            "                         'hyperprolactinemia on the TIDA system are not '\n",
            "                         'limited to the ME.',\n",
            "             'chemical2id': {'5-hiaa': 'D006897',\n",
            "                             '5-ht': 'D012701',\n",
            "                             '5-hydroxyindoleacetic acid': 'D006897',\n",
            "                             'da': 'D004298',\n",
            "                             'dopamine': 'D004298',\n",
            "                             'haloperidol': 'D006220',\n",
            "                             'ne': 'D009638',\n",
            "                             'norepinephrine': 'D009638',\n",
            "                             'serotonin': 'D012701'},\n",
            "             'disease2id': {'hyperprolactinemia': 'D006966'},\n",
            "             'relations': [{'chemical': 'D006220', 'disease': 'D006966'}],\n",
            "             'title': 'Chronic hyperprolactinemia and changes in dopamine '\n",
            "                      'neurons.'},\n",
            " '9132810': {'abstract': 'This report describes unique contrast enhancement of '\n",
            "                         'the white matter on T1-weighted magnetic resonance '\n",
            "                         'images of two patients with disseminated necrotizing '\n",
            "                         'leukoencephalopathy, which developed from acute '\n",
            "                         'lymphoblastic leukemia treated with high-dose '\n",
            "                         'methotrexate. In both patients, the enhancement was '\n",
            "                         'more pronounced near the base of the brain than at '\n",
            "                         'the vertex. Necropsy of the first case revealed loss '\n",
            "                         'of myelination and necrosis of the white matter. '\n",
            "                         'Possible mechanisms causing such a '\n",
            "                         'leukoencephalopathy are discussed.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the white matter enhancement '\n",
            "                         'was not seen in the first case, and that the second '\n",
            "                         'case was a patient with a history of acute '\n",
            "                         'lymphoblastic leukemia who had received high-dose '\n",
            "                         'methotrexate.',\n",
            "             'chemical2id': {'methotrexate': 'D008727'},\n",
            "             'disease2id': {'acute lymphoblastic leukemia': 'D054198',\n",
            "                            'leukoencephalopathy': 'D056784',\n",
            "                            'loss of myelination': 'D003711',\n",
            "                            'necrosis': 'D009336'},\n",
            "             'relations': [{'chemical': 'D008727', 'disease': 'D003711'},\n",
            "                           {'chemical': 'D008727', 'disease': 'D056784'},\n",
            "                           {'chemical': 'D008727', 'disease': 'D009336'}],\n",
            "             'title': 'Treatment-related disseminated necrotizing '\n",
            "                      'leukoencephalopathy with characteristic contrast '\n",
            "                      'enhancement of the white matter.'},\n",
            " '9158667': {'abstract': 'A case of acute renal failure, due to occlusion of '\n",
            "                         'renal vessels in a patient with acute promyelocytic '\n",
            "                         'leukemia (APL) treated with all-trans-retinoic acid '\n",
            "                         '(ATRA) and tranexamic acid has been described '\n",
            "                         'recently. We report a case of acute renal failure in '\n",
            "                         'an APL patient treated with ATRA alone. This case '\n",
            "                         'further supports the concern about thromboembolic '\n",
            "                         'complications associated with ATRA therapy in APL '\n",
            "                         'patients. The patients, a 43-year-old man, presented '\n",
            "                         'all the signs and symptoms of APL and was included '\n",
            "                         'in a treatment protocol with ATRA. After 10 days of '\n",
            "                         'treatment, he developed acute renal failure that was '\n",
            "                         'completely reversible after complete remission of '\n",
            "                         'APL was achieved and therapy discontinued. We '\n",
            "                         'conclude that ATRA is a valid therapeutic choice for '\n",
            "                         'patients with APL, although the procoagulant '\n",
            "                         'tendency is not completely corrected. Thrombotic '\n",
            "                         'events, however, could be avoided by using low-dose '\n",
            "                         'heparin.The important background information needed '\n",
            "                         'to understand this text is  the fact that the use of '\n",
            "                         'ATRA in APL patients is associated with a high risk '\n",
            "                         'of thromboembolic complications.',\n",
            "             'chemical2id': {'all-trans-retinoic acid': 'D014212',\n",
            "                             'atra': 'D014212',\n",
            "                             'heparin': 'D006493',\n",
            "                             'tranexamic acid': 'D014148'},\n",
            "             'disease2id': {'acute promyelocytic leukemia': 'D015473',\n",
            "                            'acute renal failure': 'D058186',\n",
            "                            'apl': 'D015473',\n",
            "                            'occlusion of renal vessels': '-1',\n",
            "                            'thromboembolic': 'D013923',\n",
            "                            'thrombotic': 'D013927'},\n",
            "             'relations': [{'chemical': 'D014212', 'disease': 'D013927'},\n",
            "                           {'chemical': 'D014212', 'disease': 'D058186'}],\n",
            "             'title': 'Thrombotic complications in acute promyelocytic '\n",
            "                      'leukemia during all-trans-retinoic acid therapy.'},\n",
            " '9197951': {'abstract': 'A 30-year-old cocaine-dependent man who was a '\n",
            "                         'subject in a study evaluating the anticraving '\n",
            "                         'efficacy of the stimulant medication diethylpropion '\n",
            "                         '(DEP) became manic during his second week on the '\n",
            "                         'study drug. Pupillometric changes while on DEP, '\n",
            "                         'especially changes in the total power of pupillary '\n",
            "                         'oscillation, were dramatically different than those '\n",
            "                         'observed in the eight other study subjects who did '\n",
            "                         'not become manic. The large changes in total power '\n",
            "                         'of pupillary oscillation occurred a few days before '\n",
            "                         'the patient became fully manic. Such '\n",
            "                         'medication-associated changes in the total power of '\n",
            "                         'pupillary oscillation might be of utility in '\n",
            "                         'identifying persons at risk for manic-like adverse '\n",
            "                         'effects during the medical use of psychomotor '\n",
            "                         'stimulants or sympathomimetic agents.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that the pupil is a highly '\n",
            "                         'sensitive indicator of the effects of drugs on the '\n",
            "                         'central nervous system.',\n",
            "             'chemical2id': {'cocaine': 'D003042',\n",
            "                             'dep': 'D004053',\n",
            "                             'diethylpropion': 'D004053'},\n",
            "             'disease2id': {'mania': 'D001714',\n",
            "                            'manic': 'D001714',\n",
            "                            'pupillary oscillation': 'D011681'},\n",
            "             'relations': [{'chemical': 'D004053', 'disease': 'D001714'}],\n",
            "             'title': 'Pupillary changes associated with the development of '\n",
            "                      'stimulant-induced mania: a case report.'},\n",
            " '920167': {'abstract': 'Two mothers with heart valve prosthesis were treated '\n",
            "                        'with warfarin during pregnancy. In the first case a '\n",
            "                        'caesarean section was done one week after replacement '\n",
            "                        'of warfarin with heparin. The baby died of cerebral '\n",
            "                        'and pulmonary hemorrhage. The second mother had a '\n",
            "                        'male infant by caesarean section. The baby showed '\n",
            "                        'warfarin-induced embryopathy with nasal hypoplasia '\n",
            "                        'and stippled epiphyses (chondrodysplasia punctata). '\n",
            "                        'Nasal hypoplasia with or without stippled epiphyses '\n",
            "                        'has now been reported in 11 infants born to mothers '\n",
            "                        'treated with warfarin during the first trimester, and '\n",
            "                        'a causal association is probable. In view of the '\n",
            "                        'risks to both mother and fetus in women with '\n",
            "                        'prosthetic cardiac valves it is recommended that '\n",
            "                        'therapeutic abortion be advised as the first '\n",
            "                        'alternative.The important background information '\n",
            "                        'needed to understand this text is  that the risk of '\n",
            "                        'warfarin-induced embryopathy is not a '\n",
            "                        'contraindication to pregnancy.',\n",
            "            'chemical2id': {'heparin': 'D006493', 'warfarin': 'D014859'},\n",
            "            'disease2id': {'cerebral hemorrhage': 'D002543',\n",
            "                           'chondrodysplasia punctata': 'D002806',\n",
            "                           'embryopathy': 'D005315',\n",
            "                           'hemorrhage': 'D006470',\n",
            "                           'nasal hypoplasia': '-1',\n",
            "                           'pulmonary hemorrhage': 'D008171',\n",
            "                           'stippled epiphyses': 'D002806'},\n",
            "            'relations': [{'chemical': 'D014859', 'disease': 'D006470'},\n",
            "                          {'chemical': 'D014859', 'disease': 'D008171'},\n",
            "                          {'chemical': 'D014859', 'disease': 'D002543'},\n",
            "                          {'chemical': 'D014859', 'disease': 'D002806'}],\n",
            "            'title': 'Fetal risks due to warfarin therapy during pregnancy.'},\n",
            " '9272404': {'abstract': 'OBJECTIVE: We wanted to test whether assessment of '\n",
            "                         'both a central pain-related signal '\n",
            "                         '(chemo-somatosensory evoked potential, CSSEP) and a '\n",
            "                         'concomitantly recorded peripheral signal (negative '\n",
            "                         'mucosal potential, NMP) allows for separation of '\n",
            "                         'central and peripheral effects of NSAIDs. For this '\n",
            "                         'purpose, experimental conditions were created in '\n",
            "                         'which NSAIDs had previously been observed to produce '\n",
            "                         'effects on phasic and tonic pain by either central '\n",
            "                         'or peripheral mechanisms. METHODS: According to a '\n",
            "                         'double-blind, randomised, controlled, threefold '\n",
            "                         'cross-over design, 18 healthy subjects (11 males, 7 '\n",
            "                         'females; mean age 26 years) received either placebo, '\n",
            "                         '400 mg ibuprofen, or 800 mg ibuprofen. Phasic pain '\n",
            "                         'was applied by means of short pulses of CO2 to the '\n",
            "                         'nasal mucosa (stimulus duration 500 ms, interval '\n",
            "                         'approximately 60 s), and tonic pain was induced in '\n",
            "                         'the nasal cavity by means of dry air of controlled '\n",
            "                         'temperature, humidity and flow rate (22 degrees C, '\n",
            "                         '0% relative humidity, 145 ml.s-1). Both CSSEPs as '\n",
            "                         'central and NMPs as peripheral correlates of pain '\n",
            "                         'were obtained in response to the CO2 stimuli. '\n",
            "                         'Additionally, the subjects rated the intensity of '\n",
            "                         'both phasic and tonic pain by means of visual '\n",
            "                         'analogue scales. RESULTS: As described earlier, '\n",
            "                         'administration of ibuprofen was followed by a '\n",
            "                         'decrease in tonic pain but-relative to placebo-an '\n",
            "                         'increase in correlates of phasic pain, indicating a '\n",
            "                         'specific effect of ibuprofen on the interaction '\n",
            "                         'between the pain stimuli under these special '\n",
            "                         'experimental conditions. Based on the similar '\n",
            "                         'behaviour of CSSEP and NMP, it was concluded that '\n",
            "                         'the pharmacological process underlying this '\n",
            "                         'phenomenon was localised in the periphery. By means '\n",
            "                         'of the simultaneous recording of interrelated '\n",
            "                         'peripheral and central electrophysiologic correlates '\n",
            "                         'of nociception, it was possible to separate central '\n",
            "                         'and peripheral effects of an NSAID. The major '\n",
            "                         'advantage of this pain model is the possibility of '\n",
            "                         'obtaining peripheral pain-related activity directly '\n",
            "                         'using a non-invasive technique in humans.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  that the experimental '\n",
            "                         'conditions were designed to mimic the clinical '\n",
            "                         'situation in which the drug is administered.',\n",
            "             'chemical2id': {'co2': 'D002245', 'ibuprofen': 'D007052'},\n",
            "             'disease2id': {'pain': 'D010146'},\n",
            "             'relations': [{'chemical': 'D007052', 'disease': 'D010146'}],\n",
            "             'title': 'The negative mucosal potential: separating central and '\n",
            "                      'peripheral effects of NSAIDs in man.'},\n",
            " '931801': {'abstract': 'Dehydrated rats regularly develop acute renal failure '\n",
            "                        'following single injection of aminoglycoside '\n",
            "                        'antibiotics combined with dextran or of antibiotics '\n",
            "                        'only. Oral administration of '\n",
            "                        '2,5-di-O-acetyl-D-glucaro-1,4-6,3-dilactone protected '\n",
            "                        'rats against renal failure induced by '\n",
            "                        'kanamycin-dextran. The protective effect was '\n",
            "                        'prevalent among D-glucarates, and also to other '\n",
            "                        'saccharic acid, hexauronic acids and hexaaldonic '\n",
            "                        'acids, although to a lesser degree, but not to a '\n",
            "                        'hexaaldose, sugar alcohols, substances inthe TCA '\n",
            "                        'cycle and other acidic compounds. D-Glucarates were '\n",
            "                        'effective against renal damage induced by peptide '\n",
            "                        'antibiotics as well as various aminoglycoside '\n",
            "                        'antibitocis. Dose-responses were observed in the '\n",
            "                        'protective effect of D-Glucarates. With a D-glucarate '\n",
            "                        'of a fixed size of dose, approximately the same '\n",
            "                        'degree of protection was obtained against renal '\n",
            "                        'damages induced by different basic antibiotics '\n",
            "                        'despite large disparities in administration doses of '\n",
            "                        'different antibiotics. D-Glucarates had the ability '\n",
            "                        'to prevent renal damage but not to cure it. Rats '\n",
            "                        'excreted acidic urine when they were spared from '\n",
            "                        'renal lesions by monosaccharides. The reduction '\n",
            "                        'effect of D-glucarates against nephrotoxicity of '\n",
            "                        'basic antibiotics was discussed.The important '\n",
            "                        'background information needed to understand this text '\n",
            "                        'is  that D-glucarates are not only effective against '\n",
            "                        'renal damage induced by basic antibiotics but also '\n",
            "                        'against renal damage induced by peptide antibiotics.',\n",
            "            'chemical2id': {'2,5-di-o-acetyl-d-glucaro-1,4-6,3-dilactone': 'C038936',\n",
            "                            'aminoglycoside': 'D000617',\n",
            "                            'd-glucarate': 'D005937',\n",
            "                            'd-glucarates': 'D005937',\n",
            "                            'hexaaldonic acids': '-1',\n",
            "                            'hexauronic acids': 'D006603',\n",
            "                            'kanamycin': 'D007612',\n",
            "                            'monosaccharides': 'D009005',\n",
            "                            'saccharic acid': 'D005937',\n",
            "                            'sugar alcohols': 'D013402',\n",
            "                            'tca': 'D002952'},\n",
            "            'disease2id': {'acute renal failure': 'D058186',\n",
            "                           'dehydrated': 'D003681',\n",
            "                           'nephrotoxicity': 'D007674',\n",
            "                           'renal damage': 'D007674',\n",
            "                           'renal damages': 'D007674',\n",
            "                           'renal failure': 'D051437',\n",
            "                           'renal lesions': 'D007674'},\n",
            "            'relations': [{'chemical': 'D000617', 'disease': 'D058186'},\n",
            "                          {'chemical': 'D007612', 'disease': 'D058186'}],\n",
            "            'title': 'Effect of D-Glucarates on basic antibiotic-induced renal '\n",
            "                     'damage in rats.'},\n",
            " '9323412': {'abstract': 'A 41-year-old woman with a strong history of '\n",
            "                         'postoperative nausea and vomiting presented for '\n",
            "                         'abdominal hysterectomy 3 months after a previous '\n",
            "                         'anaesthetic where ondansetron prophylaxis had been '\n",
            "                         'used. She had developed a severe acute major '\n",
            "                         'depression disorder almost immediately thereafter, '\n",
            "                         'possibly related to the use of a serotonin '\n",
            "                         'antagonist. Nine years before she had experienced a '\n",
            "                         'self-limited puerperal depressive episode. '\n",
            "                         'Anaesthesia with a propofol infusion and avoidance '\n",
            "                         'of serotonin antagonists provided a nausea-free '\n",
            "                         'postoperative course without exacerbation of the '\n",
            "                         'depression disorder.The important background '\n",
            "                         'information needed to understand this text is  that '\n",
            "                         'the patient had a history of depression and that she '\n",
            "                         'had been treated with ondansetron for postoperative '\n",
            "                         'nausea and vomiting.',\n",
            "             'chemical2id': {'ondansetron': 'D017294',\n",
            "                             'propofol': 'D015742',\n",
            "                             'serotonin': 'D012701'},\n",
            "             'disease2id': {'depression': 'D003866',\n",
            "                            'depression disorder': 'D003866',\n",
            "                            'depressive episode': 'D003866',\n",
            "                            'major depression disorder': 'D003865',\n",
            "                            'nausea': 'D009325',\n",
            "                            'postoperative nausea and vomiting': 'D020250'},\n",
            "             'relations': [{'chemical': 'D017294', 'disease': 'D003865'}],\n",
            "             'title': 'Acute severe depression following peri-operative '\n",
            "                      'ondansetron.'},\n",
            " '9382023': {'abstract': 'Among 3,129 dobutamine stress echocardiographic '\n",
            "                         'studies, a hypertensive response, defined as '\n",
            "                         'systolic blood pressure (BP) > or = 220 mm Hg and/or '\n",
            "                         'diastolic BP > or = 110 mm Hg, occurred in 30 '\n",
            "                         'patients (1%). Patients with this response more '\n",
            "                         'often had a history of hypertension and had higher '\n",
            "                         'resting systolic and diastolic BP before dobutamine '\n",
            "                         'infusion.The important background information needed '\n",
            "                         'to understand this text is  the fact that the '\n",
            "                         'hypertensive response is a marker of a more severe '\n",
            "                         'coronary artery disease.',\n",
            "             'chemical2id': {'dobutamine': 'D004280'},\n",
            "             'disease2id': {'hypertension': 'D006973',\n",
            "                            'hypertensive': 'D006973'},\n",
            "             'relations': [{'chemical': 'D004280', 'disease': 'D006973'}],\n",
            "             'title': 'Hypertensive response during dobutamine stress '\n",
            "                      'echocardiography.'},\n",
            " '9428298': {'abstract': 'A retrospective, case-controlled analysis comparing '\n",
            "                         'patients admitted to a medical intensive care unit '\n",
            "                         'with severe exacerbations of asthma who received '\n",
            "                         'continuously nebulized albuterol (CNA) versus '\n",
            "                         'intermittent albuterol (INA) treatments is reported. '\n",
            "                         'Forty matched pairs of patients with asthma are '\n",
            "                         'compared. CNA was administered for a mean of 11 +/- '\n",
            "                         '10 hr. The incidence of cardiac dysrhythmias was '\n",
            "                         'similar between groups. Symptomatic hypokalemia did '\n",
            "                         'not occur. CNA patients had higher heart rates '\n",
            "                         'during treatment, which may reflect severity of '\n",
            "                         'illness. The incidence of intubation was similar. We '\n",
            "                         'conclude that CNA and INA demonstrated similar '\n",
            "                         'profiles with regard to safety, morbidity, and '\n",
            "                         'mortality.The important background information '\n",
            "                         'needed to understand this text is  the fact that the '\n",
            "                         'majority of patients with asthma exacerbations are '\n",
            "                         'treated with nebulized albuterol.',\n",
            "             'chemical2id': {'albuterol': 'D000420'},\n",
            "             'disease2id': {'asthma': 'D001249',\n",
            "                            'cardiac dysrhythmias': 'D001145',\n",
            "                            'hypokalemia': 'D007008'},\n",
            "             'relations': [{'chemical': 'D000420', 'disease': 'D001145'}],\n",
            "             'title': 'Continuously nebulized albuterol in severe '\n",
            "                      'exacerbations of asthma in adults: a case-controlled '\n",
            "                      'study.'},\n",
            " '946593': {'abstract': 'A patient who developed paraplegia following the '\n",
            "                        'intrathecal instillation of methotrexate is '\n",
            "                        'discribed. The ten previously reported cases of this '\n",
            "                        'unusual complication are reviewed. The following '\n",
            "                        'factors appear to predispose to the development of '\n",
            "                        'this complication: abnormal cerebrospinal dynamics '\n",
            "                        'related to the presence of central nervous system '\n",
            "                        'leukemia, and epidural cerebrospinal leakage; '\n",
            "                        'elevated cerebrospinal fluid methothexate '\n",
            "                        'concentration related to abnormal cerebrospinal fluid '\n",
            "                        'dynamics and to inappropriately high methotrexate '\n",
            "                        'doses based on body surface area calculations in '\n",
            "                        'older children and adults; the presence of neurotoxic '\n",
            "                        'preservatives in commercially available methotrexate '\n",
            "                        'preparations and diluents; and the use of '\n",
            "                        'methotrexate diluents of unphysiologic pH, ionic '\n",
            "                        'content and osmolarity. The role of methotrexate '\n",
            "                        'contaminants, local folate deficiency, and cranial '\n",
            "                        'irradiation in the pathogenesis of intrathecal '\n",
            "                        'methotrexate toxicity is unclear. The incidence of '\n",
            "                        'neurotoxicity may be reduced by employing lower doses '\n",
            "                        'of methotrexate in the presence of central nervous '\n",
            "                        'system leukemia, in older children and adults, and in '\n",
            "                        'the presence of epidural leakage. Only '\n",
            "                        \"preservative-free methotrexate in Elliott's B \"\n",
            "                        'Solution at a concentration of not more than 1 mg/ml '\n",
            "                        'should be used for intrathecal administration. '\n",
            "                        'Periodic monitoring of cerebruspinal fluid '\n",
            "                        'methotrexate levels may be predictive of the '\n",
            "                        'development of serious neurotoxicity.The important '\n",
            "                        'background information needed to understand this text '\n",
            "                        'is  the fact that the incidence of this complication '\n",
            "                        'is extremely low and that the clinical presentation '\n",
            "                        'is usually mild and self-limited.',\n",
            "            'chemical2id': {'methothexate': 'D008727',\n",
            "                            'methotrexate': 'D008727'},\n",
            "            'disease2id': {'central nervous system leukemia': 'D002493',\n",
            "                           'folate deficiency': 'C536409',\n",
            "                           'neurotoxic': 'D020258',\n",
            "                           'neurotoxicity': 'D020258',\n",
            "                           'paraplegia': 'D010264',\n",
            "                           'toxicity': 'D064420'},\n",
            "            'relations': [{'chemical': 'D008727', 'disease': 'D010264'}],\n",
            "            'title': 'Paraplegia following intrathecal methotrexate: report of '\n",
            "                     'a case and review of the literature.'},\n",
            " '9538487': {'abstract': 'A 45-year-old man, with a 10-year history of manic '\n",
            "                         'depression treated with lithium, was admitted with '\n",
            "                         'hyperosmolar, nonketotic coma. He gave a five-year '\n",
            "                         'history of polyuria and polydipsia, during which '\n",
            "                         'time urinalysis had been negative for glucose. After '\n",
            "                         'recovery from hyperglycaemia, he remained polyuric '\n",
            "                         'despite normal blood glucose concentrations; water '\n",
            "                         'deprivation testing indicated nephrogenic diabetes '\n",
            "                         'insipidus, likely to be lithium-induced. We '\n",
            "                         'hypothesize that when this man developed type 2 '\n",
            "                         'diabetes, chronic polyuria due to nephrogenic '\n",
            "                         'diabetes insipidus was sufficient to precipitate '\n",
            "                         'hyperosmolar dehydration.The important background '\n",
            "                         'information needed to understand this text is  that '\n",
            "                         'lithium-induced nephrogenic diabetes insipidus is a '\n",
            "                         'rare but important complication of lithium therapy.',\n",
            "             'chemical2id': {'glucose': 'D005947', 'lithium': 'D008094'},\n",
            "             'disease2id': {'dehydration': 'D003681',\n",
            "                            'hyperglycaemia': '-1',\n",
            "                            'hyperosmolar nonketotic coma': 'D006944',\n",
            "                            'hyperosmolar, nonketotic coma': 'D006944',\n",
            "                            'manic depression': 'D001714',\n",
            "                            'nephrogenic diabetes insipidus': 'D018500',\n",
            "                            'polydipsia': 'D059606',\n",
            "                            'polyuria': 'D011141',\n",
            "                            'polyuric': 'D011141',\n",
            "                            'type 2 diabetes': 'D003924'},\n",
            "             'relations': [{'chemical': 'D008094', 'disease': 'D011141'},\n",
            "                           {'chemical': 'D008094', 'disease': 'D018500'},\n",
            "                           {'chemical': 'D008094', 'disease': 'D006944'}],\n",
            "             'title': 'Hyperosmolar nonketotic coma precipitated by '\n",
            "                      'lithium-induced nephrogenic diabetes insipidus.'},\n",
            " '9570197': {'abstract': 'BACKGROUND: In dogs, a large amount of intravenous '\n",
            "                         'cocaine causes a profound deterioration of left '\n",
            "                         'ventricular (LV) systolic function and an increase '\n",
            "                         'in LV end-diastolic pressure. This study was done to '\n",
            "                         'assess the influence of a high intracoronary cocaine '\n",
            "                         'concentration on LV systolic and diastolic function '\n",
            "                         'in humans. METHODS AND RESULTS: In 20 patients (14 '\n",
            "                         'men and 6 women aged 39 to 72 years) referred for '\n",
            "                         'cardiac catheterization for the evaluation of chest '\n",
            "                         'pain, we measured heart rate, systemic arterial '\n",
            "                         'pressure, LV pressure and its first derivative '\n",
            "                         '(dP/dt), and LV volumes and ejection fraction before '\n",
            "                         'and during the final 2 to 3 minutes of a 15-minute '\n",
            "                         'intracoronary infusion of saline (n=10, control '\n",
            "                         'subjects) or cocaine hydrochloride 1 mg/min (n=10). '\n",
            "                         'No variable changed with saline. With cocaine, the '\n",
            "                         'drug concentration in blood obtained from the '\n",
            "                         'coronary sinus was 3.0+/-0.4 (mean+/-SD) mg/L, '\n",
            "                         'similar in magnitude to the blood cocaine '\n",
            "                         'concentration reported in abusers dying of cocaine '\n",
            "                         'intoxication. Cocaine induced no significant change '\n",
            "                         'in heart rate, LV dP/dt (positive or negative), or '\n",
            "                         'LV end-diastolic volume, but it caused an increase '\n",
            "                         'in systolic and mean arterial pressures, LV '\n",
            "                         'end-diastolic pressure, and LV end-systolic volume, '\n",
            "                         'as well as a decrease in LV ejection fraction. '\n",
            "                         'CONCLUSIONS: In humans, the intracoronary infusion '\n",
            "                         'of cocaine sufficient in amount to achieve a high '\n",
            "                         'drug concentration in coronary sinus blood causes a '\n",
            "                         'deterioration of LV systolic and diastolic '\n",
            "                         'performance.The important background information '\n",
            "                         'needed to understand this text is  the fact that '\n",
            "                         'cocaine is a potent coronary vasoconstrictor in dogs '\n",
            "                         'and that the coronary vasoconstrictor effect of '\n",
            "                         'cocaine is not mediated by the release of '\n",
            "                         'catecholamines.',\n",
            "             'chemical2id': {'cocaine': 'D003042',\n",
            "                             'cocaine hydrochloride': 'D003042'},\n",
            "             'disease2id': {'chest pain': 'D002637',\n",
            "                            'deterioration of left ventricular (lv) systolic function': 'D018487',\n",
            "                            'deterioration of lv systolic and diastolic performance': 'D018487'},\n",
            "             'relations': [{'chemical': 'D003042', 'disease': 'D018487'}],\n",
            "             'title': 'Effects of the intracoronary infusion of cocaine on '\n",
            "                      'left ventricular systolic and diastolic function in '\n",
            "                      'humans.'},\n",
            " '9578276': {'abstract': 'OBJECTIVE: To determine the maximum tolerated dose '\n",
            "                         '(MTD) of carbetocin (a long-acting synthetic '\n",
            "                         'analogue of oxytocin), when administered immediately '\n",
            "                         'after vaginal delivery at term. MATERIALS AND '\n",
            "                         'METHODS: Carbetocin was given as an intramuscular '\n",
            "                         'injection immediately after the birth of the infant '\n",
            "                         'in 45 healthy women with normal singleton '\n",
            "                         'pregnancies who delivered vaginally at term. Dosage '\n",
            "                         'groups of 15, 30, 50, 75, 100, 125, 150, 175 or 200 '\n",
            "                         'microg carbetocin were assigned to blocks of three '\n",
            "                         'women according to the continual reassessment method '\n",
            "                         '(CRM). RESULTS: All dosage groups consisted of three '\n",
            "                         'women, except those with 100 microg (n=6) and 200 '\n",
            "                         'microg (n=18). Recorded were dose-limiting adverse '\n",
            "                         'events: hyper- or hypotension (three), severe '\n",
            "                         'abdominal pain (0), vomiting (0) and retained '\n",
            "                         'placenta (four). Serious adverse events occurred in '\n",
            "                         'seven women: six cases with blood loss > or = 1000 '\n",
            "                         'ml, four cases of manual placenta removal, five '\n",
            "                         'cases of additional oxytocics administration and '\n",
            "                         'five cases of blood transfusion. Maximum blood loss '\n",
            "                         'was greatest at the upper and lower dose levels, and '\n",
            "                         'lowest in the 70-125 microg dose range. Four out of '\n",
            "                         'six cases with blood loss > or = 1000 ml occurred in '\n",
            "                         'the 200 microg group. The majority of additional '\n",
            "                         'administration of oxytocics (4/5) and blood '\n",
            "                         'transfusion (3/5) occurred in the dose groups of 200 '\n",
            "                         'microg. All retained placentae were found in the '\n",
            "                         'group of 200 microg. CONCLUSION: The MTD was '\n",
            "                         'calculated to be at 200 microg carbetocin.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  the fact that the dose of '\n",
            "                         'carbetocin used in this study was not based on the '\n",
            "                         'results of a phase I study.',\n",
            "             'chemical2id': {'carbetocin': 'C020731', 'oxytocin': 'D010121'},\n",
            "             'disease2id': {'abdominal pain': 'D015746',\n",
            "                            'blood loss': 'D006473',\n",
            "                            'hypertension': 'D006973',\n",
            "                            'hypotension': 'D007022',\n",
            "                            'retained placenta': 'D018457',\n",
            "                            'vomiting': 'D014839'},\n",
            "             'relations': [{'chemical': 'C020731', 'disease': 'D018457'},\n",
            "                           {'chemical': 'C020731', 'disease': 'D014839'},\n",
            "                           {'chemical': 'C020731', 'disease': 'D006473'},\n",
            "                           {'chemical': 'C020731', 'disease': 'D015746'},\n",
            "                           {'chemical': 'C020731', 'disease': 'D006973'},\n",
            "                           {'chemical': 'C020731', 'disease': 'D007022'}],\n",
            "             'title': 'Ascending dose tolerance study of intramuscular '\n",
            "                      'carbetocin administered after normal vaginal birth.'},\n",
            " '9646784': {'abstract': 'Although several new anticoagulant drugs are in '\n",
            "                         'development, heparin remains the drug of choice for '\n",
            "                         'most anticoagulation needs. The clinical effects of '\n",
            "                         'heparin are meritorious, but side effects do exist. '\n",
            "                         'Important untoward effects of heparin therapy '\n",
            "                         'including heparin-induced thrombocytopenia, '\n",
            "                         'heparin-associated osteoporosis, eosinophilia, skin '\n",
            "                         'reactions, allergic reactions other than '\n",
            "                         'thrombocytopenia and alopecia will be discussed in '\n",
            "                         'this article.The important background information '\n",
            "                         'needed to understand this text is  provided in this '\n",
            "                         'article.',\n",
            "             'chemical2id': {'heparin': 'D006493'},\n",
            "             'disease2id': {'allergic reactions': 'D004342',\n",
            "                            'alopecia': 'D000505',\n",
            "                            'eosinophilia': 'D004802',\n",
            "                            'osteoporosis': 'D010024',\n",
            "                            'skin reactions': 'D012871',\n",
            "                            'thrombocytopenia': 'D013921',\n",
            "                            'thromboembolism': 'D013923'},\n",
            "             'relations': [{'chemical': 'D006493', 'disease': 'D000505'},\n",
            "                           {'chemical': 'D006493', 'disease': 'D010024'},\n",
            "                           {'chemical': 'D006493', 'disease': 'D013923'},\n",
            "                           {'chemical': 'D006493', 'disease': 'D013921'},\n",
            "                           {'chemical': 'D006493', 'disease': 'D004342'},\n",
            "                           {'chemical': 'D006493', 'disease': 'D004802'},\n",
            "                           {'chemical': 'D006493', 'disease': 'D012871'}],\n",
            "             'title': 'Heparin-induced thrombocytopenia, paradoxical '\n",
            "                      'thromboembolism, and other side effects of heparin '\n",
            "                      'therapy.'},\n",
            " '9725303': {'abstract': 'OBJECTIVE: We describe the unique CT features of '\n",
            "                         'ureteric calculi in six HIV-infected patients '\n",
            "                         'receiving indinavir, the most commonly used HIV '\n",
            "                         'protease inhibitor, which is associated with an '\n",
            "                         'increased incidence of urolithiasis. CONCLUSION: '\n",
            "                         'Ureteric obstruction caused by precipitated '\n",
            "                         'indinavir crystals may be difficult to diagnose with '\n",
            "                         'unenhanced CT. The calculi are not opaque, and '\n",
            "                         'secondary signs of obstruction may be absent or '\n",
            "                         'minimal and should be sought carefully. Images may '\n",
            "                         'need to be obtained using i.v. contrast material to '\n",
            "                         'enable diagnosis of ureteric stones or obstruction '\n",
            "                         'in patients with HIV infection who receive indinavir '\n",
            "                         'therapy.The important background information needed '\n",
            "                         'to understand this text is  the increased incidence '\n",
            "                         'of urolithiasis in HIV-infected patients receiving '\n",
            "                         'indinavir.',\n",
            "             'chemical2id': {'indinavir': 'D019469'},\n",
            "             'disease2id': {'hiv infection': 'D015658',\n",
            "                            'hiv-infected': 'D015658',\n",
            "                            'ureteric calculi': 'D014514',\n",
            "                            'ureteric obstruction': 'D014517',\n",
            "                            'ureteric stones': 'D014514',\n",
            "                            'urolithiasis': 'D052878'},\n",
            "             'relations': [{'chemical': 'D019469', 'disease': 'D014514'}],\n",
            "             'title': 'Nonopaque crystal deposition causing ureteric '\n",
            "                      'obstruction in patients with HIV undergoing indinavir '\n",
            "                      'therapy.'},\n",
            " '9759693': {'abstract': 'Sumatriptan succinate, a serotonin-1 '\n",
            "                         '(5-hydroxytryptamine-1) receptor agonist, is an '\n",
            "                         'antimigraine drug that is reported to act by '\n",
            "                         'selectively constricting intracranial arteries. '\n",
            "                         'Recently, vasopressor responses that are distinct '\n",
            "                         'from the cranial circulation have been demonstrated '\n",
            "                         'to occur in the systemic, pulmonary, and coronary '\n",
            "                         'circulations. Cases have been published of coronary '\n",
            "                         'vasospasm, myocardial ischemia, and myocardial '\n",
            "                         'infarction occurring after sumatriptan use. We '\n",
            "                         'report on the development of 8 serious cases of '\n",
            "                         'ischemic colitis in patients with migraine treated '\n",
            "                         'with sumatriptan.The important background '\n",
            "                         'information needed to understand this text is  the '\n",
            "                         'fact that the majority of these cases were '\n",
            "                         'associated with the use of sumatriptan succinate.',\n",
            "             'chemical2id': {'5-hydroxytryptamine': 'D012701',\n",
            "                             'serotonin': 'D012701',\n",
            "                             'sumatriptan': 'D018170',\n",
            "                             'sumatriptan succinate': 'D018170'},\n",
            "             'disease2id': {'coronary vasospasm': 'D003329',\n",
            "                            'ischemic colitis': 'D017091',\n",
            "                            'migraine': 'D008881',\n",
            "                            'myocardial infarction': 'D009203',\n",
            "                            'myocardial ischemia': 'D017202'},\n",
            "             'relations': [{'chemical': 'D018170', 'disease': 'D017091'}],\n",
            "             'title': 'Ischemic colitis and sumatriptan use.'},\n",
            " '9782254': {'abstract': \"51 patients with medically refractory Parkinson's \"\n",
            "                         'disease underwent stereotactic posteromedial '\n",
            "                         'pallidotomy between August 1993 and February 1997 '\n",
            "                         'for treatment of bradykinesia, rigidity, and '\n",
            "                         'L-DOPA-induced dyskinesias. In 29 patients, the '\n",
            "                         'pallidotomies were performed with the Leksell Gamma '\n",
            "                         'Knife and in 22 they were performed with the '\n",
            "                         'standard radiofrequency (RF) method. Clinical '\n",
            "                         'assessment as well as blinded ratings of Unified '\n",
            "                         \"Parkinson's Disease Rating Scale (UPDRS) scores were \"\n",
            "                         'carried out pre- and postoperatively. Mean follow-up '\n",
            "                         'time is 20.6 months (range 6-48) and all except 4 '\n",
            "                         'patients have been followed more than one year. 85 '\n",
            "                         'percent of patients with dyskinesias were relieved '\n",
            "                         'of symptoms, regardless of whether the pallidotomies '\n",
            "                         'were performed with the Gamma Knife or '\n",
            "                         'radiofrequency methods. About 2/3 of the patients in '\n",
            "                         'both Gamma Knife and radiofrequency groups showed '\n",
            "                         'improvements in bradykinesia and rigidity, although '\n",
            "                         'when considered as a group neither the Gamma Knife '\n",
            "                         'nor the radiofrequency group showed statistically '\n",
            "                         'significant improvements in UPDRS scores. One '\n",
            "                         'patient in the Gamma Knife group (3.4%) developed a '\n",
            "                         'homonymous hemianopsia 9 months following treatment '\n",
            "                         'and 5 patients (27.7%) in the radiofrequency group '\n",
            "                         'became transiently confused postoperatively. No '\n",
            "                         'other complications were seen. Gamma Knife '\n",
            "                         'pallidotomy is as effective as radiofrequency '\n",
            "                         'pallidotomy in controlling certain of the symptoms '\n",
            "                         \"of Parkinson's disease. It may be the only practical \"\n",
            "                         'technique available in certain patients, such as '\n",
            "                         'those who take anticoagulants, have bleeding '\n",
            "                         'diatheses or serious systemic medical illnesses. It '\n",
            "                         'is a viable option for other patients as well.The '\n",
            "                         'important background information needed to '\n",
            "                         'understand this text is  that the two methods are '\n",
            "                         'not equivalent and that the Gamma Knife is a more '\n",
            "                         'precise and precise method of targeting the globus '\n",
            "                         'pallidus.',\n",
            "             'chemical2id': {'l-dopa': 'D007980'},\n",
            "             'disease2id': {'bleeding': 'D006470',\n",
            "                            'bradykinesia': 'D018476',\n",
            "                            'dyskinesias': 'D004409',\n",
            "                            'homonymous hemianopsia': 'D006423',\n",
            "                            \"parkinson's disease\": 'D010300',\n",
            "                            'rigidity': 'D009127'},\n",
            "             'relations': [{'chemical': 'D007980', 'disease': 'D004409'}],\n",
            "             'title': 'Pallidotomy with the gamma knife: a positive '\n",
            "                      'experience.'},\n",
            " '978847': {'abstract': 'The pressor response to the intracisternal (i.c.) '\n",
            "                        'injection of carbachol (1 mug) in anesthetized rats '\n",
            "                        'was analyzed. This response was significantly reduced '\n",
            "                        'by the intravenous (i.v.) injection of guanethidine '\n",
            "                        '(5 mg), hexamethonium (10 mg) or phentolamine (5 mg), '\n",
            "                        'and conversely, potentiated by i.v. '\n",
            "                        'desmethylimipramine (0.3 mg), while propranolol (0.5 '\n",
            "                        'mg) i.v. selectively inhibited the enlargement of '\n",
            "                        'pulse pressure and the tachycardia following i.c. '\n",
            "                        'carbachol (1 mug). On the other hand, the pressor '\n",
            "                        'response to i.c. carbachol (1 mug) was almost '\n",
            "                        'completely blocked by i.c. atropine (3 mug) or '\n",
            "                        'hexamethonium (500 mug), and significantly reduced by '\n",
            "                        'i.c. chlorpromazine (50 mug) but significantly '\n",
            "                        'potentiated by i.c. desmethylimipramine (30 mug). The '\n",
            "                        'pressor response to i.c. carbachol (1 mug) remained '\n",
            "                        'unchanged after sectioning of the bilateral cervical '\n",
            "                        'vagal nerves but disappeared after sectioning of the '\n",
            "                        'spinal cord (C7-C8). From the above result it is '\n",
            "                        'suggested that the pressor response to i.c. carbachol '\n",
            "                        'ortral and peripheral adrenergic mechanisms, and that '\n",
            "                        'the sympathetic trunk is the main pathway.The '\n",
            "                        'important background information needed to understand '\n",
            "                        'this text is  the fact that the pressor response to '\n",
            "                        'i.c. carbachol (1 mug) was significantly reduced by '\n",
            "                        'the i.c. injection of atropine (3 mug), hexamethonium '\n",
            "                        '(10 mg) or phentolamine (5 mg), but potentiated by '\n",
            "                        'the i.v. injection of desmethylimipramine (0.3 mg), '\n",
            "                        'while the pressor response to i.c. phenylephrine (1 '\n",
            "                        'mug) was not affected by any of the above drugs.',\n",
            "            'chemical2id': {'atropine': 'D001285',\n",
            "                            'carbachol': 'D002217',\n",
            "                            'chlorpromazine': 'D002746',\n",
            "                            'desmethylimipramine': 'D003891',\n",
            "                            'guanethidine': 'D006145',\n",
            "                            'hexamethonium': 'D018738',\n",
            "                            'phentolamine': 'D010646',\n",
            "                            'propranolol': 'D011433'},\n",
            "            'disease2id': {'enlargement of pulse pressure': 'D006973',\n",
            "                           'tachycardia': 'D013610'},\n",
            "            'relations': [{'chemical': 'D002217', 'disease': 'D013610'},\n",
            "                          {'chemical': 'D002217', 'disease': 'D006973'},\n",
            "                          {'chemical': 'D003891', 'disease': 'D006973'}],\n",
            "            'title': 'Centrally mediated cardiovascular effects of '\n",
            "                     'intracisternal application of carbachol in anesthetized '\n",
            "                     'rats.'},\n",
            " '9831002': {'abstract': 'A 1-year-old female presented with neuroleptic '\n",
            "                         'malignant syndrome probably caused by '\n",
            "                         'methylphenidate. She had defects in the '\n",
            "                         'supratentorial brain including the basal ganglia and '\n",
            "                         'the striatum (multicystic encephalomalacia) due to '\n",
            "                         'severe perinatal hypoxic-ischemic encephalopathy, '\n",
            "                         'which was considered to be a possible predisposing '\n",
            "                         'factor causing neuroleptic malignant syndrome. A '\n",
            "                         'dopaminergic blockade mechanism generally is '\n",
            "                         'accepted as the pathogenesis of this syndrome. '\n",
            "                         'However, methylphenidate is a dopamine agonist via '\n",
            "                         'the inhibition of uptake of dopamine, and therefore '\n",
            "                         'dopaminergic systems in the brainstem (mainly the '\n",
            "                         'midbrain) and the spinal cord were unlikely to '\n",
            "                         'participate in the onset of this syndrome. A '\n",
            "                         'relative gamma-aminobutyric acid-ergic deficiency '\n",
            "                         'might occur because diazepam, a gamma-aminobutyric '\n",
            "                         'acid-mimetic agent, was strikingly effective. This '\n",
            "                         'is the first reported patient with neuroleptic '\n",
            "                         'malignant syndrome probably caused by '\n",
            "                         'methylphenidate.The important background information '\n",
            "                         'needed to understand this text is  that the patient '\n",
            "                         'had a history of perinatal hypoxic-ischemic '\n",
            "                         'encephalopathy and methylphenidate was the only drug '\n",
            "                         'administered.',\n",
            "             'chemical2id': {'diazepam': 'D003975',\n",
            "                             'dopamine': 'D004298',\n",
            "                             'gamma-aminobutyric acid': 'D005680',\n",
            "                             'methylphenidate': 'D008774'},\n",
            "             'disease2id': {'hypoxic-ischemic encephalopathy': 'D020925',\n",
            "                            'multicystic encephalomalacia': 'D004678',\n",
            "                            'neuroleptic malignant syndrome': 'D009459'},\n",
            "             'relations': [{'chemical': 'D008774', 'disease': 'D009459'}],\n",
            "             'title': 'Neuroleptic malignant syndrome and methylphenidate.'},\n",
            " '9869655': {'abstract': 'Effects of 17alpha-ethinylestradiol (EE) on the '\n",
            "                         'neutral and acidic biosynthetic pathways of bile '\n",
            "                         'salt (BS) synthesis were evaluated in rats with an '\n",
            "                         'intact enterohepatic circulation and in rats with '\n",
            "                         'long-term bile diversion to induce BS synthesis. For '\n",
            "                         'this purpose, bile salt pool composition, synthesis '\n",
            "                         'of individual BS in vivo, hepatic activities, and '\n",
            "                         'expression levels of cholesterol 7alpha-hydroxylase '\n",
            "                         '(CYP7A), and sterol 27-hydroxylase (CYP27), as well '\n",
            "                         'as of other enzymes involved in BS synthesis, were '\n",
            "                         'analyzed in rats treated with EE (5 mg/kg, 3 days) '\n",
            "                         'or its vehicle. BS pool size was decreased by 27% '\n",
            "                         'but total BS synthesis was not affected by EE in '\n",
            "                         'intact rats. Synthesis of cholate was reduced by 68% '\n",
            "                         'in EE-treated rats, while that of chenodeoxycholate '\n",
            "                         'was increased by 60%. The recently identified '\n",
            "                         'Delta22-isomer of beta-muricholate contributed for '\n",
            "                         '5.4% and 18.3 % (P < 0.01) to the pool in control '\n",
            "                         'and EE-treated rats, respectively, but could not be '\n",
            "                         'detected in bile after exhaustion of the pool. A '\n",
            "                         'clear reduction of BS synthesis was found in '\n",
            "                         'bile-diverted rats treated with EE, yet biliary BS '\n",
            "                         'composition was only minimally affected. Activity of '\n",
            "                         'CYP7A was decreased by EE in both intact and '\n",
            "                         'bile-diverted rats, whereas the activity of the '\n",
            "                         'CYP27 was not affected. Hepatic mRNA levels of CYP7A '\n",
            "                         'were significantly reduced by EE in bile-diverted '\n",
            "                         'rats only; CYP27 mRNA levels were not affected by '\n",
            "                         'EE. In addition, mRNA levels of sterol '\n",
            "                         '12alpha-hydroxylase and lithocholate '\n",
            "                         '6beta-hydroxylase were increased by bile diversion '\n",
            "                         'and suppressed by EE. This study shows that '\n",
            "                         '17alpha-ethinylestradiol (EE)-induced intrahepatic '\n",
            "                         'cholestasis in rats is associated with selective '\n",
            "                         'inhibition of the neutral pathway of bile salt (BS) '\n",
            "                         'synthesis. Simultaneous impairment of other enzymes '\n",
            "                         'in the BS biosynthetic pathways may contribute to '\n",
            "                         'overall effects of EE on BS synthesis.The important '\n",
            "                         'background information needed to understand this '\n",
            "                         'text is  the fact that EE is a potent inhibitor of '\n",
            "                         'CYP7A, a key enzyme in the neutral pathway of BS '\n",
            "                         'synthesis.',\n",
            "             'chemical2id': {'17alpha-ethinylestradiol': 'D004997',\n",
            "                             'bile salt': 'D001647',\n",
            "                             'bs': 'D001647',\n",
            "                             'chenodeoxycholate': 'D002635',\n",
            "                             'cholate': 'D020355',\n",
            "                             'cholesterol': 'D002784',\n",
            "                             'ee': 'D004997',\n",
            "                             'sterol': 'D013261'},\n",
            "             'disease2id': {'intrahepatic cholestasis': 'D002780'},\n",
            "             'relations': [{'chemical': 'D004997', 'disease': 'D002780'}],\n",
            "             'title': 'Differential effects of 17alpha-ethinylestradiol on the '\n",
            "                      'neutral and acidic pathways of bile salt synthesis in '\n",
            "                      'the rat.'},\n",
            " '9881641': {'abstract': 'The effects of helodermin, a basic 35-amino acid '\n",
            "                         'peptide isolated from the venom of a lizard salivary '\n",
            "                         'gland, on arterial blood pressure and heart rate '\n",
            "                         'were examined in the rat, focusing on the '\n",
            "                         'possibility that activation of ATP sensitive K+ '\n",
            "                         '(K(ATP)) channels is involved in the responses. The '\n",
            "                         'results were also compared with those of vasoactive '\n",
            "                         'intestinal polypeptide (VIP). Helodermin produced '\n",
            "                         'hypotension in a dose-dependent manner with '\n",
            "                         'approximately similar potency and duration to VIP. '\n",
            "                         'Hypotension induced by both peptides was '\n",
            "                         'significantly attenuated by glibenclamide, which '\n",
            "                         'abolished a levcromakalim-produced decrease in '\n",
            "                         'arterial blood pressure. Oxyhemoglobin did not '\n",
            "                         'affect helodermin-induced hypotension, whereas it '\n",
            "                         'shortened the duration of acetylcholine '\n",
            "                         '(ACh)-produced hypotension. These findings suggest '\n",
            "                         'that helodermin-produced hypotension is partly '\n",
            "                         'attributable to the activation of '\n",
            "                         'glibenclamide-sensitive K+ channels (K(ATP) '\n",
            "                         'channels), which presumably exist on arterial smooth '\n",
            "                         'muscle cells. EDRF (endothelium-derived relaxing '\n",
            "                         'factor)/nitric oxide does not seem to play an '\n",
            "                         'important role in the peptide-produced '\n",
            "                         'hypotension.The important background information '\n",
            "                         'needed to understand this text is  the fact that '\n",
            "                         'helodermin is a potent vasodilator and that it is a '\n",
            "                         'potent activator of K (ATP) channels.',\n",
            "             'chemical2id': {'acetylcholine': 'D000109',\n",
            "                             'ach': 'D000109',\n",
            "                             'amino acid': 'D000596',\n",
            "                             'atp': 'D000255',\n",
            "                             'glibenclamide': 'D005905',\n",
            "                             'helodermin': 'C040442',\n",
            "                             'k': 'D011188',\n",
            "                             'levcromakalim': 'D019806',\n",
            "                             'nitric oxide': 'D009569'},\n",
            "             'disease2id': {'hypotension': 'D007022'},\n",
            "             'relations': [{'chemical': 'D000109', 'disease': 'D007022'},\n",
            "                           {'chemical': 'D019806', 'disease': 'D007022'},\n",
            "                           {'chemical': 'C040442', 'disease': 'D007022'}],\n",
            "             'title': 'Glibenclamide-sensitive hypotension produced by '\n",
            "                      'helodermin assessed in the rat.'},\n",
            " '9889429': {'abstract': 'Thirteen psoriatic patients with hypertension during '\n",
            "                         'the course of cyclosporin A therapy were treated for '\n",
            "                         '25 months with a calcium channel blocker, '\n",
            "                         'sustained-release nifedipine, to study the clinical '\n",
            "                         'antihypertensive effects and adverse events during '\n",
            "                         'treatment with both drugs. Seven of the 13 patients '\n",
            "                         'had exhibited a subclinical hypertensive state '\n",
            "                         'before cyclosporin A therapy. Both systolic and '\n",
            "                         'diastolic blood pressures of these 13 patients were '\n",
            "                         'decreased significantly after 4 weeks of nifedipine '\n",
            "                         'therapy, and blood pressure was maintained within '\n",
            "                         'the normal range thereafter for 25 months. The '\n",
            "                         'adverse events during combined therapy with '\n",
            "                         'cyclosporin A and nifedipine included an increase in '\n",
            "                         'blood urea nitrogen levels in 9 of the 13 patients '\n",
            "                         'and development of gingival hyperplasia in 2 of the '\n",
            "                         '13 patients. Our findings indicate that '\n",
            "                         'sustained-release nifedipine is useful for '\n",
            "                         'hypertensive psoriatic patients under long-term '\n",
            "                         'treatment with cyclosporin A, but that these '\n",
            "                         'patients should be monitored for gingival '\n",
            "                         'hyperplasia.The important background information '\n",
            "                         'needed to understand this text is  that cyclosporin '\n",
            "                         'A and nifedipine are both effective in controlling '\n",
            "                         'the blood pressure of psoriatic patients, but that '\n",
            "                         'cyclosporin A may cause gingival hyperplasia.',\n",
            "             'chemical2id': {'blood urea nitrogen': 'D001806',\n",
            "                             'calcium': 'D002118',\n",
            "                             'cyclosporin a': 'D016572',\n",
            "                             'nifedipine': 'D009543'},\n",
            "             'disease2id': {'gingival hyperplasia': 'D005885',\n",
            "                            'hypertension': 'D006973',\n",
            "                            'hypertensive': 'D006973',\n",
            "                            'psoriasis': 'D011565',\n",
            "                            'psoriatic': 'D011565'},\n",
            "             'relations': [{'chemical': 'D016572', 'disease': 'D005885'},\n",
            "                           {'chemical': 'D016572', 'disease': 'D006973'},\n",
            "                           {'chemical': 'D009543', 'disease': 'D005885'}],\n",
            "             'title': 'Long-term efficacy and adverse event of nifedipine '\n",
            "                      'sustained-release tablets for cyclosporin A-induced '\n",
            "                      'hypertension in patients with psoriasis.'}}\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "with open(\"test_out.json\", \"w\") as outfile:\n",
        "    json.dump(test, outfile)"
      ],
      "metadata": {
        "id": "WMUIb73xs1Rx"
      },
      "execution_count": 15,
      "outputs": []
    }
  ]
}